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 ABSTRACT 
MicroRNAs are powerful post-transcriptional regulators of gene expression and are 
biomarkers of chronic diseases such as cancer.  This thesis explores the role of 
microRNAs in human cancer cachexia and Type 2 diabetes.  MicroRNA expression was 
measured in skeletal muscle biopsies using RT-qPCR.  In pancreatic cancer cachexia 
patients, expression of microRNA-1, microRNA-133a, microRNA-133b and 
microRNA-206 was negatively related to weight loss.  In Type 2 diabetes skeletal 
muscle, microRNA-133a and microRNA-206 expression was down-regulated, but there 
was no evidence of altered microRNA transcription or processing and target expression 
was unchanged.  Importantly, microRNA-133a expression predicted fasting glucose, 
glucose tolerance and insulin resistance, and therefore may be a biomarker of Type 2 
diabetes.  Experimental validation of microRNA arrays was unsuccessful in identifying 
further novel cancer cachexia and Type 2 diabetes microRNA biomarkers.  MicroRNA 
knockdown validated CDC42 and PTBP1 as microRNA-133a targets in myoblasts.  In 
addition, muscle microRNA expression may be regulated by insulin and TNFα.  In 
conclusion, microRNA-133a may be a skeletal muscle biomarker of Type 2 diabetes 
and cancer cachexia, microRNA-133a responds to extracellular insulin and TNFα, but it 
remains to be established whether microRNA-133a contributes to cancer cachexia or 
Type 2 diabetes pathogenesis. 
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Chapter 1 - Introduction 
Skeletal muscle phenotype and function is determined by the transcription and 
translation of thousands of genes.  Muscle dysfunction is a key player in the 
pathophysiology of Type 2 diabetes (Muoio & Newgard, 2008; Cohen, 2006; Khan & 
Pessin, 2002; Schinner et al. 2005; Zeggini et al. 2008) and wasting conditions such as 
cancer cachexia (Fearon, 1992; Fearon et al. 2006; Stewart et al. 2006; Tan & Fearon, 
2008; Stephens et al. 2008), which are characterised by profound changes in skeletal 
muscle phenotype.  It has been suggested common transcriptional changes in skeletal 
muscle gene expression may occur in many systemic diseases such as diabetes, cancer, 
AIDS and renal failure, but expression of over 90% of genes appear not to change 
(Lecker et al. 2004).  Therefore many genes in these systemic diseases may be regulated 
post-transcriptionally or alternatively changes in 10% of genes determine skeletal 
muscle phenotype in these systemic diseases. 
The human genome contains many genes that do not code for proteins, including genes 
coding for microRNAs, which were first identified almost a decade ago (Lagos-
Quintana et al. 2001; Lau et al. 2001; Lee & Ambros, 2001).  MicroRNAs may regulate 
over one third of protein coding genes post-transcriptionally. Indeed microRNAs have 
challenged our traditional understanding of gene regulation over the past decade (Bartel, 
2004; Bartel, 2009; Ambros, 2004; Kim et al. 2009). 
1.1. MicroRNAs 
MicroRNAs (microRNA) consist of 19-22 nucleotides, which do not code for proteins, 
but regulate gene expression of protein-coding transcripts (Bartel, 2004; Bartel, 2009).  
Understanding of how microRNAs regulate gene expression has advanced significantly 
over the last decade (Lagos-Quintana et al. 2001; Ambros, 2004; Bartel, 2004; Bushati 
& Cohen, 2007; Bartel, 2009).  The most clearly defined mechanism so far involves 
suppression of gene expression post-transcriptionally (Jackson & Standart, 2007).  
MicroRNAs can suppress translation of transcripts by base pairing to the 3’ untranslated 
regions (3’UTRs) of protein coding genes and each microRNA is predicted to target 
>200 gene transcripts (Lall et al. 2006; John et al. 2004; Lewis et al. 2003).  
Overexpression and knockdown of microRNAs have been demonstrated to profoundly 
affect cell phenotype (Bushati & Cohen, 2007; Ambros, 2004).  There is now evidence 
suggesting microRNAs play a fundamental role in many biological pathways, including 
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adipocyte and skeletal muscle differentiation (Chen et al. 2006; Nakajima et al. 2006; 
Boutz et al. 2007; Yuasa et al. 2008; McCarthy et al. 2007; Kim et al. 2006; Rosenberg 
et al. 2006).  Some studies suggest that microRNAs may also play a role in maintaining 
amino acid, lipid and carbohydrate metabolism (Bushati & Cohen, 2007; Ambros, 
2004).  This has led to the intriguing possibility that microRNAs are involved in disease, 
with the majority of studies focused on cancer (Blenkiron et al. 2007; Lu et al. 2005; 
Dixon-McIver et al. 2008; Szafranska et al. 2008). 
1.2. MicroRNAs are biomarkers of many chronic diseases 
The discovery of microRNAs has provided exciting new possibilities for the 
identification of disease biomarkers, thus potentially facilitating earlier disease 
detection and development of new therapeutic agents. There have been many reviews 
suggesting microRNAs may lead to aberrant gene expression in major diseases 
involving skeletal muscle such as Type 2 diabetes (Gauthier & Wollheim, 2006; 
Hennessy & O'Driscoll, 2008; Poy et al. 2007; Tang et al. 2008), cardiac hypertrophy 
(Carè et al. 2007), muscular dystrophy (van Rooij et al. 2008; Chen et al. 2009; Yang & 
Wu, 2007) and HIV/AIDS (Bushati & Cohen, 2007; Couzin, 2008; Perera & Ray, 2007), 
but there have been few clinical studies in patients. 
1.3. MicroRNA changes in skeletal muscle 
There is evidence to suggest microRNAs play an important role in skeletal muscle (van 
Rooij et al. 2008; Chen et al. 2006; Chen et al. 2009; McCarthy & Esser, 2007; 
McCarthy et al. 2007).  Firstly, during differentiation there is a significant increase in 
expression of muscle-specific microRNAs including miR-1, miR-133a and miR-206 
(Chen et al. 2006).  Secondly, microRNAs appear to be modulated during skeletal 
muscle hypertrophy in mice and humans (Drummond et al. 2008; McCarthy & Esser, 
2007).  Thirdly, microRNAs are modulated during skeletal muscle atrophy and wasting, 
for example in response to hind-limb unloading, space flight and muscular dystrophy 
(Allen et al. 2009; Eisenberg et al. 2007; McCarthy et al. 2007; Rosenberg et al. 2006).  
Fourthly, microRNAs in skeletal muscle respond to endurance training in mice and 
humans (Keller et al. 2007; Safdar et al. 2009).  Taken together these studies suggest 
microRNAs may play a role in skeletal muscle dysfunction in chronic diseases such as 
Type 2 diabetes and cancer (Couzin, 2008; Hennessy & O'Driscoll, 2008).  However, 
there have been no previous studies on microRNA function in skeletal muscle in cancer 
or Type 2 diabetes patients. 
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1.4. Cancer cachexia 
Cachexia is a complex syndrome, which is characterised by progressive loss of skeletal 
muscle and is reportedly a significant contributing factor to mortality rates in cancer 
patients (Fearon, 1992).  Skeletal muscle wasting has major implications for quality of 
life and physical function (Stewart et al. 2006).  Some degree of weight loss is 
experienced by about 50% of all cancer patients (DeWys, 1985).  There is no clearly 
defined physiological profile of cancer cachexia patients.  Studies have considered 
many factors including alterations in protein, glucose and fat metabolism; circulating 
cytokines; tumour derived factors; production of acute phase reactants (Skipworth et al. 
2007; Melstrom et al. 2007; Baracos, 2006; Laviano et al. 2005; Rubin, 2003).  
Importantly, there still appears to be no reliable biomarker of cancer cachexia (Tan & 
Fearon, 2008), thus more research is warranted to identify biomarkers, which can detect 
cachexia in its early stages. 
 
It is clear microRNAs are key players in skeletal muscle differentiation and there are 
indications that microRNAs play a role in skeletal muscle remodelling, growth and 
atrophy (Allen et al. 2009; Eisenberg et al. 2007; Keller et al. 2007; McCarthy et al. 
2007; Rosenberg et al. 2006; Safdar et al. 2009). Therefore, it is plausible that 
microRNA expression in muscle may play a role in cancer cachexia development or 
could be a biomarker of cancer cachexia progression.  Previous findings on atrophy-
associated microRNAs have been mixed due to the use of different atrophy models 
(Eisenberg et al. 2007; McCarthy et al. 2007; Rosenberg et al. 2006; Safdar et al. 2009).  
As yet there have been no studies on microRNA expression in skeletal muscle of cancer 
cachexia patients.  
1.5. Type 2 diabetes 
Skeletal muscle sensitivity to insulin is essential to facilitate glucose disposal in 
response to feeding.  Impairment of skeletal muscle insulin sensitivity is a key factor in 
the development of Type 2 diabetes.  However, the mechanisms responsible for the 
development of insulin resistance and the progression to Type 2 diabetes are still not 
fully understood (Muoio & Newgard, 2008; Shoelson et al. 2006).  It is known skeletal 
muscle is the main site for whole-body glucose disposal, and insulin sensitivity is a key 
determinant of muscle glucose uptake.  Decreased insulin sensitivity leads to impaired 
glucose tolerance and elevated plasma glucose concentrations despite normal β-cell 
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function.  Development of Type 2 diabetes is characterised by loss of glycaemic control 
and eventual β-cell failure (Muoio & Newgard, 2008; Shoelson et al. 2006). 
 
To date microarray studies on Type 2 diabetes have been unable to produce convincing 
evidence of a global change in gene expression profile despite the development of an 
insulin resistant muscle phenotype (Frederiksen et al. 2008; Mootha et al. 2003; Patti et 
al. 2003; J. Timmons et al. personal communication).  This raises the intriguing 
possibility that a post-transcriptional mechanism may play a role.  In diabetic rats, 
microRNA array studies have revealed several candidate Type 2 diabetes microRNAs, 
but there is a lack of consistency between studies (He et al. 2007; Huang et al. 2009).  
Importantly, there have been no clinical studies examining changes in microRNA 
expression in skeletal muscle of Type 2 diabetes patients. 
1.6. Approach 
This thesis will focus on determining the role of microRNAs in two chronic diseases 
affecting human skeletal muscle: Type 2 diabetes characterised by skeletal muscle 
insulin resistance (Muoio & Newgard, 2008; Shoelson et al. 2006) and cancer cachexia 
characterised by skeletal muscle wasting (Tisdale, 2005).  The most robust, sensitive 
and practical method for profiling microRNA expression currently appears to be using 
real-time quantitative PCR (RT-qPCR; Ach et al. 2008; Chen et al. 2005), so RT-qPCR 
was the main methodology employed for detection of microRNAs. 
 
In Chapter 3, expression of the muscle specific microRNAs, miR-1, miR-133a, miR-
133b and miR-206 was profiled in human skeletal muscle from cancer patients to 
determine whether these microRNAs may be early biomarkers of cachexia.  In addition, 
the inflammation-associated miR-21 was also measured as a potential mediator of 
protein degradation pathways in cachexia.  MicroRNA array data from cancer-cachexia 
patients (I. Gallagher, personal communication) was subject to experimental validation 
using RT-qPCR to help identify new candidate microRNA biomarkers in cancer 
cachexia.  Bioinformatics was used to examine the biological processes and disease 
associated pathways targeted by the candidate microRNA biomarkers identified.  
Finally, unpublished microarray data (I. Gallagher, personal communication) from 
cancer cachexia patients was used to analyse microRNA target expression to determine 
whether there was evidence of microRNA action on targets in-vivo. 
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In Chapter 4 the thesis focuses on examining the involvement of microRNAs in Type 2 
diabetes.  Expression of muscle-specific microRNAs, miR-1, miR-133a, miR-133b and 
miR-206 was profiled in patients with varying degrees of insulin resistance and glucose 
tolerance.  Then, microRNA transcription and processing were measured to determine 
whether there were any alterations, which may help explain changes in mature 
microRNA expression in Type 2 diabetes.  To establish whether microRNAs may play a 
role in developing insulin resistance and Type 2 diabetes, multiple regression was used 
to determine whether skeletal muscle microRNA expression could predict fasting 
glucose, glucose tolerance and insulin resistance in patients.  A bioinformatics approach 
was used to determine which biological and cellular functions may be affected by 
microRNA changes in Type 2 diabetes and whether these could plausibly contribute to 
insulin resistance and Type 2 diabetes pathogenesis.  Microarray data from Type 2 
diabetes patients (n = 118; J. Timmons, personal communication) was used to determine 
whether there was evidence of microRNA action on targets in-vivo.  Finally, microRNA 
array data from Type 2 diabetes patients (I. Gallagher, personal communication) was 
subject to experimental validation using RT-qPCR to help identify new candidate 
microRNA biomarkers in Type 2 diabetes. 
 
In Chapter 5 a mechanistic approach was taken to validate specific targets of 
microRNAs and to examine possible regulators of microRNAs in Type 2 diabetes and 
cancer cachexia. MicroRNA knockdown experiments were conducted in muscle cells to 
determine the effect on microRNA target proteins including CDC42 and PTBP1.  To 
investigate whether extracellular factors associated with both Type 2 diabetes and 
cancer cachexia could be partly responsible for the changes in microRNA expression 
observed in-vivo, microRNA expression was measured in muscle cells treated with 
insulin or TNFα. 
 
This thesis demonstrates microRNAs may be involved in the development of both Type 
2 diabetes and cancer cachexia and furthermore microRNAs may provide early 
biomarkers of skeletal muscle changes in these chronic diseases therefore facilitating 
earlier intervention.  This thesis is unique as it presents the first evidence of microRNA 
changes in skeletal muscle from Type 2 diabetes and cancer cachexia patients.  The 
microRNAs identified in this thesis may provide important early biomarkers of Type 2 
diabetes and cancer cachexia, thus potentially facilitating earlier intervention and 
treatment before further complications and decreases in quality of life occur. 
 6 
Chapter 2 - Literature review 
MicroRNAs are a class of non-coding RNAs in the human genome, which do not code 
for proteins (Bartel, 2004).  Many thousands of genes are targeted by microRNAs, 
which act post-transcriptionally to regulate cellular protein levels (Bartel, 2009).  In less 
than a decade since the discovery of microRNAs they have been established as global 
regulators of multiple cellular processes (Bartel, 2009; Ambros, 2004; Bushati & Cohen, 
2007).  Distinct microRNA signatures are associated with a wide-range of chronic 
diseases including cancers, cardiovascular disease, HIV/AIDS and muscle wasting 
(Couzin, 2008; Chen et al. 2009; van Rooij et al. 2008; Eisenberg et al. 2007).  In 2008 
alone over 1300 microRNA studies were published.  Due to the rapidly expanding 
interest in microRNA research our understanding of microRNA biogenesis and function 
is constantly evolving with new research challenging existing ideas (Bartel & Chen, 
2004; Kim et al. 2009). 
2.1. Discovery of microRNAs 
Several studies were published simultaneously that reported the identification of a large 
class of small 20-23 nucleotide RNAs (Lagos-Quintana et al. 2001; Lau et al. 2001; Lee 
& Ambros, 2001).  These microRNAs were first identified by cloning in C.elegans and 
Drosophila, but remarkably many appeared to be highly conserved across species.  A 
group of microRNAs found in the Drosophila melanogastor genome was also found in 
human HeLa cells.  Northern blotting of these microRNAs revealed some were present 
only during embryogenesis and not at later stages of development, whereas some 
microRNAs were present at all stages of development.  For example, miR-1 was 
expressed in the musculature of adult flies but was undetectable in HeLa cells (Lagos-
Quintana et al. 2001).  This led to the proposal that microRNAs may play a regulatory 
role in tissue specification.  When some of these microRNAs were verified using 
Northern blot two additional signals were detected around 70 nt and 1000 nt in the case 
of miR-1 (Lagos-Quintana et al. 2001).  These were subsequently classified as precursor 
microRNA (pre-microRNA) and primary microRNA (pri-microRNA) respectively 
(Griffiths-Jones et al. 2006).  At this point it was not clear why microRNAs were 
processed or how they were processed.  But it was clear microRNAs must be 
transcribed as much longer primary transcripts (Lagos-Quintana et al. 2001; Lau et al. 
2001; Lee & Ambros, 2001). 
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2.2. MicroRNA transcription, biogenesis and processing 
Genomic analysis of these new novel microRNAs revealed all were flanked by 
sequences that could form ~70 nt stem-loop structures (Lagos-Quintana et al. 2001).  
Some of these microRNA stem-loop sequences aligned to longer mammalian ESTs 
suggesting that 20-23 nt small RNAs may be derived from longer transcripts.  The 
genomic location of microRNAs suggested they were transcribed in diverse ways.  
Approximately, 30% are located in intronic regions and many are located in intergenic 
regions indicating they are transcribed from their own promoter (Lagos-Quintana et al. 
2001).  Intronic regions are located between exons of protein coding genes and 
intergenic regions are located outside of protein coding sequences.  At this time little 
was known of how microRNAs were processed; comparison of sequencing data with 
genomic and EST data suggested several steps were involved. 
2.2.1 MicroRNA transcription 
Experiments involving chromatin immunoprecipitation analysis demonstrated that the 
polymerase poll II can be physically associated with a microRNA gene (Lee et al. 2004).  
Inhibition of poll II activity by treatment of human cells with alpha-amanitin reduces 
pri-microRNA concentration, which suggested poll II could be the main polymerase for 
microRNA gene transcription (Lee et al. 2004).  A later study found poll III could be 
required for transcription of around 50 microRNA genes (Borchert et al. 2006).  
Chromatin immunoprecipitation data surrounding microRNA genes found 20% of 
intergenic microRNAs have there own promoter, suggesting intergenic microRNAs can 
be transcribed as independent transcriptional units (Corcoran et al. 2009).  In contrast, 
intronic microRNAs appear to be transcribed in unison with their host gene (Rodriguez 
et al. 2004), based primarily on the observation that intronic microRNA expression is 
often correlated with predicted host-gene expression (Wang & Li, 2009; Baskerville & 
Bartel, 2005).   
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Figure  2-1. MicroRNA biogenesis and processing pathway. 
MicroRNAs are transcribed as long pri-microRNA transcripts.  Pri-microRNAs 
are cleaved by a microprocessor complex consisting of DICER/DGCR8/p68/p72.  
Pre-microRNA are exported to the cytoplasm via EXPORTIN5.  Mature 
microRNAs are the result of pre-microRNA cleavage by DICER.  Mature 
microRNAs are incorporated into an RNA-induced silencing complex (RISC) and 
bind AGO/TRBP or associate with P-bodies leading to translational repression or 
mRNA cleavage (Adapted from Kim et al. 2009) 
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Currently, few primary microRNA transcripts have been verified (Griffiths-Jones et al. 
2006; Saini et al. 2007).  Genomic analysis of regions around intergenic microRNAs 
identified putative transcriptional start sites and poly (A) tails (Saini et al. 2007).  It is 
still not clear why the nascent pri-microRNA transcript can be several kilobytes in 
length considering only 80-100 nucleotides are processed further.  It suggests there are 
unknown regulatory elements within the pri-microRNA transcript that influence its 
transcription.  There are numerous predicted regulatory elements located upstream of 
microRNA genes, which may participate in regulating microRNA transcription but 
many remain to be characterised (Lee et al. 2007).  Putative transcriptional start sites 
and transcription factor binding sites have been identified for primary microRNAs but 
many of these remain to be verified (Saini et al. 2007).  Transcriptional factors 
including c-Myb, NF-Y, Sp-1, MTF-1, and AP-2α are potential regulators of 
microRNA transcription.  Interestingly these have been previously associated with 
diseases such as cancer (Lee et al. 2007).  In addition, transcription factors activated by 
extracellular factors such as hormones may in turn activate primary microRNA 
transcription.  For example, let-7 promoters appear to be activated by steroids via action 
on the nuclear receptor DAF12, resulting in down-regulation of let-7 targets (Bethke et 
al. 2009). 
2.2.2  DROSHA and microRNA processing 
Two years following the initial microRNA sequencing studies, several studies reported 
an RNase III enzyme was essential for initiation of microRNA processing (Han et al. 
2004; Lee et al. 2003; Gregory et al. 2004; Denli et al. 2004).  The RNase III enzyme 
DROSHA initiates microRNA processing in the nucleus (Lee et al. 2003). 
 
DROSHA is the catalytic subunit of a large microprocessor complex (Figure 2-1), 
which cleaves pri-microRNAs leaving ~70 nt hairpin pre-microRNAs (Gregory et al. 
2004).  In-vitro microRNA processing reactions demonstrate immunoprecipitated 
DROSHA can cleave pri-microRNA to pre-microRNA (Lee et al. 2003).  Furthermore, 
when DROSHA is blocked using RNAi, both pre- and mature microRNAs decrease but 
pri-microRNAs increase (Lee et al. 2003).  RNAi against DROSHA resulted in down-
regulation of six microRNAs profiled; miR-23a, miR-27b, let-7a-1, miR-16, miR-20 
and miR-21 (Lee et al. 2003), thus establishing DROSHA as a key regulator of 
microRNA maturation.  However, it is unknown whether DROSHA is critical for 
processing of all human microRNAs.  In Drosophila S2 cells depletion of DROSHA 
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mRNA using dsRNA revealed 137 DROSHA regulated RNAs, although surprisingly 
only 11 pri-microRNAs (Kadener et al. 2009). 
 
The RNA binding protein DGCR8 is another important component of the 
microprocessor complex (Figure 2-1), which is required for microRNA biogenesis 
(Gregory et al. 2004) and also helps stabilize the DROSHA protein (Han et al. 2009).  
DGCR8 recognizes pri-microRNA and directs DROSHA to the specific position for 
cleavage to pre-microRNA (Han et al. 2006).  DEAD-box RNA helicase subunits are 
also part of the microprocessor complex (Gregory et al. 2004) and knockout of the 
DEAD-box RNA helicase subunits, p68 and p72 caused early lethality in mice (Fukuda 
et al. 2007).  Interestingly, in p68 (-/-) and p72 (-/-) embryos, only a subset of 
microRNAs were affected, which suggests DEAD-box RNA helicase subunits may be 
involved in the recognition of specific pri-microRNAs for processing by DROSHA 
(Fukuda et al. 2007). 
2.2.3 Nuclear export of pre-microRNAs 
Following processing by DROSHA, pre-microRNAs are rapidly exported from the 
nucleus to the cytoplasm (Figure 2-1) via a GTP dependent nuclear transport protein 
(Bohnsack et al. 2004; Lund et al. 2004).  Inhibition of nuclear transport proteins 
revealed EXPORTIN5 was responsible for the majority of microRNA export (Lund et 
al. 2004).  Despite the prevailing view that microRNAs are actively exported from the 
nucleus, at least one study has demonstrated mature microRNA can be predominantly 
localised in the nucleus (Hwang et al. 2007).  It is currently not clear how many 
microRNAs are predominantly localised in the nucleus or what their function is.  In the 
case of miR-29, this has been shown to function in the cytoplasm leading to suppression 
of mRNA targets associated with myocardial infarction (van Rooij et al. 2008) and also 
linked to insulin resistance in adipocytes (He et al. 2007).  The original experiments 
demonstrating export of microRNA via EXPORTIN5 reported seven individual 
microRNAs required this protein to accumulate in the cytoplasm (Lund et al. 2004).  It 
has since been assumed EXPORTIN5 is responsible for all microRNA export from the 
nucleus as no selective regulation of microRNA export has been reported. 
2.2.4 Pre-microRNA processing by DICER 
Pre-microRNAs in the cytoplasm are processed by DICER (Figure 2-1) to produce 
functional mature microRNAs (Kim et al. 2009).  This was demonstrated by in-vitro 
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experiments involving incubation of 70 nt pre-microRNAs with immunoprecipitated 
DICER.  The result of these in-vitro experiments was that 22 nt mature microRNAs 
accumulated (Ketting et al. 2001).  In addition, introduction of mutations in the DICER 
gene (DCR-1) blocked cleavage of dsRNA (Knight & Bass, 2001).  Furthermore, other 
studies have clearly shown DICER is essential for global microRNA processing.  For 
example, knockout DICER mutants are generally embryonic lethal, or result in severe 
phenotype abnormalities (Bernstein et al. 2003), and in ovarian cancer DICER 
expression levels predict survival (Merritt et al. 2008).  However, changes in microRNA 
biogenesis protein expression are not always accompanied by increased mature 
microRNA expression, which suggests there must be other regulatory steps involved in 
determining mature microRNA expression. 
2.2.5 RNA induced silencing complex (RISC) 
The RISC consists of three main proteins, DICER, TRBP and ARGONAUTE (Kim et 
al. 2009) and their interaction is shown in Figure 2-1.  TRBP is a double stranded RNA 
binding protein, which binds to the microRNA duplex following cleavage of the pre-
microRNA by DICER (Chendrimada et al. 2005).  The microRNA duplex unwinds and 
the guide strand is incorporated into the RISC while the passenger strand is rapidly 
degraded (Hutvágner & Zamore, 2002).  The ARGONAUTE proteins are critical 
players in the formation and function of the RISC complex (Su et al. 2009).  Most 
endogenous microRNAs are reportedly tightly bound to RISC complexes and few 
remain unbound in the cytoplasm (Tang et al. 2008). 
2.2.6 ARGONAUTE proteins 
Immunoprecipitation of AGO2 protein followed by microarray analysis revealed 
hundreds of microRNAs and mRNAs are bound specifically to AGO2 proteins 
(Rehwinkel et al. 2006).  Knockdown of AGO2 protein is reported to up-regulate 
several hundred mRNAs with significant enrichment of mRNAs containing putative 
microRNA binding sites (Rehwinkel et al. 2006).  Transfection of AGO proteins in 
human HEK 293 cells followed by co-immunoprecipitation revealed known proteins 
such as DICER and TRBP bound to AGO, but also proteins containing DEAD box 
motifs, heterogenous nuclear ribonucleoprotein particles, messenger RNA binding 
proteins and proteins involved in RNA metabolism (Höck et al. 2007).  The role of 
many of these AGO-associated proteins in RISC silencing has not yet been established.  
Knockdown of RBM4 protein revealed it was necessary for microRNA-guided gene 
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regulation (Höck et al. 2007).  Recently, IMP8 was identified as another protein 
required for microRNA regulation.  IMP8 interacts with AGO2 proteins and 
knockdown of IMP8 affects AGO2 associated mRNAs (Weinmann et al. 2009). 
2.2.7 P-bodies 
Repressed mRNA and microRNA can collect in cytoplasmic P-bodies (Figure 2-1), 
which contain enzymes involved in mRNA degradation, such as deadenylases and 
decapping enzymes (Liu et al. 2005; Jackson & Standart, 2007).  These enzymes are 
recruited to P-bodies by GW182.  ARGONAUTE proteins contain multiple GW182 
binding sites (Takimoto et al. 2009) and AGO1 can interact with GW182 thus bringing 
microRNA targets into close proximity with mRNA degradation enzymes (Eulalio et al. 
2008).  Repression of microRNA targets in C.elegans is reportedly dependent on 
GW182 proteins.  Furthermore, in Drosphila knockdown of GW182 is reported to 
alleviate microRNA mediated translational repression (Behm-Ansmant et al. 2006).  P-
bodies may also act as temporary storage depots for untranslated mRNA, which would 
explain translational repression in the absence of mRNA cleavage.  However, it is not 
currently clear whether untranslated mRNA localised in P-bodies can be later released 
and translated. 
2.3. Blockage in microRNA processing 
A large-scale profiling study of different tumour and tissue cell lines revealed widely 
differing microRNA processing (Lee et al. 2008).  Some microRNAs were processed 
efficiently, demonstrated by a strong correlation between pre- and mature microRNA 
abundance (Lee et al. 2008).  In contrast there was discordant expression of pre- and 
mature forms for other microRNAs.  For example, there appeared to be an accumulation 
of pre-miR-31 in cancer cells, as mature miR-31 abundance was much lower (Lee et al. 
2008), which suggests microRNA processing may be blocked in cancer cells at least for 
some microRNAs.  A down-regulation of DROSHA and DICER could help explain 
evidence of decreased microRNA processing.  However, any reduction in DROSHA or 
DICER activity would result in a whole-cell reduction in mature microRNA expression, 
which would be expected to lead to fundamental changes in cell phenotype. 
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2.3.1 RNA binding proteins 
Studies published recently have revealed other factors can influence processing of 
individual microRNAs.  For example, NF90 and NF45 proteins appear to function as 
negative regulators of microRNA processing.  NF90 and NF45 are nuclear proteins, 
which bind pri-microRNAs and depletion of NF90 is reported to decrease pri-let-7 but 
increase mature let-7 expression, thus implicating NF90 as a negative regulator of 
microRNA processing (Sakamoto et al. 2009).  Furthermore, recently BMP2 treatment 
was shown to stimulate pri-miR-206 expression but mature miR-206 was decreased 
(Sato et al. 2009), transfection of SMAD1 and SMAD4 both involved in BMP signaling 
also down-regulated miR-206 (Sato et al. 2009), thus suggesting SMAD proteins may 
modulate processing of specific microRNAs. 
 
Several studies have shown RNA-binding proteins can be critical for microRNA 
processing (Kim et al. 2009).  MicroRNAs can bind to hnRNP A1 prior to DROSHA 
processing and depletion of hnRNP A1 in HeLa cells appears to decrease pre-miR-18a 
abundance (Guil & Cáceres, 2007), indicating that pri-microRNA processing may be 
dependent on hnRNP A1.  Intriguingly, it has been reported that 14% of all pri-
microRNAs have highly conserved loops and it is suggested these may act as landing 
pads for RNA-binding proteins (Michlewski et al. 2008), but this remains to be 
experimentally verified.  Another example of an RNA binding protein inhibiting 
microRNA processing is the inhibition of pri-let-7 by LIN28 (Viswanathan et al. 2008).  
In embryonic stem cells, LIN28 binds to a conserved region in the microRNA stem loop 
encoding let-7, which inhibits the activity of DROSHA and DICER, preventing 
embryonic stem cell differentiation (Viswanathan et al. 2008).  RNA binding proteins 
have also been reported to bind to microRNA target sites.  Dead end 1 (Dnd1) protein 
has been shown to bind to mRNA 3’UTRs and block microRNA function in human and 
zebrafish germ cells (Kedde et al. 2007).  Furthermore, SMAD proteins could be 
involved in microRNA maturation, as both TGF-beta and BMP signaling which are 
responsive to SMAD, increased expression of mature miR-21 (Davis et al. 2008).  
MicroRNA processing by DROSHA was reportedly increased via recruitment of TGF-
beta specific SMAD signal transducer proteins to pri-mir-21 (Davis et al. 2008).  Taken 
together these studies suggest that RNA binding proteins may provide an additional 
layer of regulation in the microRNA processing pathway (Kim et al. 2009).  However, 
most of the studies showing RNA-binding proteins influence microRNA processing are 
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based on in-vitro cell models, it remains to be seen if RNA-binding proteins are 
important for microRNA processing in humans in-vivo.  
2.4. Mechanism of microRNA action  
It has been shown that microRNAs can suppress protein levels through several 
mechanisms.  MicroRNAs can bind to mRNA and cause cleavage, destabilisation, 
degradation of target mRNA or act via translation repression (Jackson & Standart, 
2007). 
2.4.1 MicroRNAs can act via target mRNA cleavage 
MicroRNAs cause mRNA cleavage and degradation of target mRNAs based on several 
observations.  In human cell extracts the RISC appears to be capable of multiple rounds 
of RNA cleavage (Hutvágner & Zamore, 2002).  Depletion of microRNA processing 
proteins in human HEK293 cells increases mRNA abundance and many of the up-
regulated mRNAs were reportedly enriched in sequences complementary to microRNA 
seed regions (Schmitter et al. 2006).  Overexpression of specific microRNAs in HeLa 
cells reveals hundreds of transcripts are modulated, but the transcripts that were down-
regulated were more likely to contain conserved microRNA binding sites (Lim et al. 
2005).  However, overexpression of microRNAs is likely to have many indirect effects 
(Bartel, 2009).  For example, 30% of microRNAs are predicted to target transcription 
factors, which would indirectly affect mRNA abundance (John et al. 2004).  Taken 
together these studies indicate microRNAs can cause cleavage or degradation of many 
mRNAs. 
 
The first direct evidence that microRNAs could function by mRNA cleavage was from 
RNA fragments detected in mouse embryos that corresponded to HOXB8 (Yekta et al. 
2004).  The HOX cluster also encodes miR-196 and HOXB8, HOXC8 and HOXD8 all 
contain evolutionary conserved miR-196 sites.  Cell culture experiments demonstrated 
miR-196 knockdown led to a decrease in HOXB8 cleavage fragments (Yekta et al. 
2004), thus indicating miR-196 can promote cleavage of HOXB8 and hence post-
transcriptionally suppress HOXB8 protein.  Furthermore, another example of 
microRNA mediated mRNA degradation has been reported in zebrafish, miR-430 
appears to be responsible for clearance of mRNAs during early embryogenesis 
(Giraldez et al. 2006).  In zebrafish, maternal mRNAs are targeted by miR-430 resulting 
in deadenylation and degradation (Giraldez et al. 2006).  Deadenylation appears to be a 
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widespread mechanism for microRNA mediated target degradation.  A recent study 
compared mRNA profiles from AGO1, CAF1 or NOT1 depleted cells.  CAF1 and 
NOT1 are both proteins required for deadenylation of mRNAs (Eulalio et al. 2009).  
Interestingly, 60% of AGO1 targets were also regulated by CAF1 or NOT1, which 
suggests that many microRNAs may act via deadenylation (Eulalio et al. 2009). 
2.4.2 MicroRNAs can act via translational repression 
In mammalian cells mRNA cleavage requires perfect complementarity between the 
microRNA seed and the mRNA target 3’UTR (Bartel, 2004; Bartel, 2009).  However, 
most microRNA binding sites in humans have imperfect complementarity.  Therefore, 
in mammalian cells translational repression is most likely to be the main mechanism for 
microRNA mediated silencing.  Translation consists of three major steps - initiation, 
elongation and termination - and is the process by which mRNAs are translated into 
proteins.  Translational repression of microRNA targets appears to involve inhibition of 
translation initiation, as in-vitro experiments show let-7 microRNA is able to repress 
translation initiation within 15 min and without mRNA destabilization, by targeting the 
cap-binding complex eIF4F (Mathonnet et al. 2007).  Action of microRNAs by 
translational repression would therefore be undetectable at mRNA level and could only 
be detected at protein level using, for example, Western blotting. 
2.4.3 MicroRNAs can be translational activators 
The prevailing view is that microRNAs act as translational repressors.  However, some 
data suggest microRNAs can be involved in translational activation.  Interaction of an 
AGO2/FXR1 complex with mRNA 3’UTRs leads to up-regulation rather than down-
regulation of translation (Vasudevan et al. 2007), in addition microRNA action appears 
to be dependent on cell cycle.  For example in proliferating mammalian cells, upon cell 
cycle arrest microRNAs which normally repress translation may induce translational 
up-regulation of target mRNAs (Vasudevan et al. 2008).  Currently, there are no other 
reports of microRNAs inducing translational up-regulation of target mRNAs. 
2.5. Methods to quantify microRNA expression 
The huge interest in microRNA regulation of gene expression in diseases such as cancer 
has led to rapid developments in technology to measure microRNA expression (Cissell 
& Deo, 2009).  The earliest studies on microRNA function in C.elegans and Drosophila 
used solely Northern blots (Ambros et al. 2003; Lagos-Quintana et al. 2001).  Northern 
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blots remain the gold standard despite being impractical for use in human samples due 
to the large RNA input required (Válóczi et al. 2004).  Now real-time quantitative PCR 
(RT-qPCR) is commonly used and a range of custom and commercial microRNA arrays 
has been developed (Cissell & Deo, 2009; Li & Ruan, 2009).  However, Northern blots 
do have advantages for detection of different microRNA precursors (Kim, 2004).  
Indeed it was the appearance of an additional signal at ~70 nt that led to speculation that 
mature microRNA were not transcribed as 22 nt sequences, but were processed from 
longer transcripts (Lagos-Quintana et al. 2001).  Northern blot may be limited when 
sensitivity is required to detect small differences between human RNA samples (Cissell 
& Deo, 2009).  Furthermore, Northern blot does not allow high-throughput 
measurement of many microRNAs so is not feasible for global tissue profiling (Cissell 
& Deo, 2009). 
2.5.1 MicroRNA detection using real-time quantitative PCR 
Real-time quantitative PCR (RT-qPCR) does provide the possibility to measure 
microRNA expression with higher sensitivity and higher-throughput than Northern blot 
(Cissell & Deo, 2009).  Due to the small length of microRNAs and to increase 
specificity a two-step RT-qPCR protocol is widely used (Chen et al. 2005), which 
involves an RT step that instead of using random hexamer primers uses stem-loop 
primers specific to mature microRNA sequences (Chen et al. 2005).  The use of 
microRNA specific stem-loop primers facilitates higher amplification efficiency during 
the second RT-qPCR step.  There are several advantages of using RT-qPCR for 
detection of microRNAs.  Firstly, only a small RNA input is required: as low as 2 ng/µl 
compared to 10 µg needed for Northern blots.  Secondly, RT-qPCR is very sensitive to 
differences in microRNA abundance over a wide dynamic range (Chen et al. 2005).  
Thirdly, RT-qPCR is very specific and should be able to differentiate between mature 
microRNAs from the same family differing by a single nucleotide (Chen et al. 2005; 
Cissell & Deo, 2009).  Typically, an endogenous small RNA is used to control 
variations in cDNA synthesis during the RT step, so it is important to determine 
whether the endogenous small RNA used is stably expressed across all experimental 
conditions (Davoren et al. 2008).  RT-qPCR provides a medium-throughput method to 
determine mature microRNA abundance and generally shows good agreement with 
Northern blot (Chen et al. 2005). 
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2.5.2  MicroRNA detection using microarrays 
Rapid developments have been made in designing microarray chips to detect global 
changes in microRNA profiles (Kong et al. 2009; Liu et al. 2008; Cissell & Deo, 2009).  
These chips work on a similar basis as oligonucleotide arrays, except they contain 
probes designed to hybridise to small RNAs.  There are an ever-growing number of 
commercial and custom microRNA arrays that have been used in different studies, 
which makes comparing studies difficult (Sato et al. 2009). Usually studies involving 
microRNA arrays attempt to validate findings using RT-qPCR or Northern blot for 
microRNAs of interest that are differentially expressed (Sato et al. 2009).  Recently, a 
study compared agreement of microRNA array results across five platforms and 
concluded there was a lack of concordance between different platforms (Sato et al. 
2009).  It is largely unknown what effect different RNA sample preparation methods 
may have on microRNA expression profiles (Wang et al. 2008), or the effect of 
different normalization techniques on the subsequent determination of differentially 
expressed microRNAs (Sato et al. 2009), or how sensitive microRNA arrays are to 
small differences in microRNA abundance (Sato et al. 2009).  Recently, the use of 
additional spike-in controls in microRNA chips was suggested to provide a measure of 
chip-to-chip variation (Sarkar et al. 2008).  Unfortunately, microRNA arrays are still a 
relatively expensive technology, which precludes routine use in laboratories or for 
clinical diagnostics (Cissell & Deo, 2009). 
2.6. MicroRNA function and target prediction 
Non-coding microRNAs consist of only 1-2% of the human genome (Lim et al. 2003).  
However, small non-coding RNA molecules may regulate over one third of protein 
coding transcripts.  Identification of mRNAs with conserved binding sites that are 
complementary to microRNA seed sequences revealed over 5000 human genes may 
potentially be regulated by microRNAs (Lewis et al. 2005).  Recently, the regulatory 
impact of microRNAs on the human genome was suggested to be even more 
widespread.  MicroRNA target predictions using a more recent version of the human 
genome with better annotation suggests over 60% of protein coding genes have been 
under evolutionary pressure to maintain microRNA target sites (Friedman et al. 2009).  
Over 45,000 conserved microRNA target sites have now been identified in human 
3’UTRs (Friedman et al. 2009). 
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2.6.1 Tissue-specific microRNAs 
Analysis of mRNA target expression across tissues revealed that when a microRNA is 
highly expressed in a tissue, corresponding targets are expressed at a significantly lower 
level compared to other tissues (Sood et al. 2006).  In contrast, when a microRNA is not 
expressed highly, target mRNAs are significantly more abundant (Sood et al. 2006).  In 
skeletal muscle several microRNAs are highly expressed, including miR-1, miR-206 
and miR-133.  These have previously been shown to regulate skeletal muscle 
proliferation and differentiation (Chen et al. 2006).  Tissue specific microRNAs appear 
to target non-tissue related genes for post-transcriptional repression during development.  
However, the function of tissue-specific microRNAs in adult skeletal muscle is not fully 
understood.  It appears muscle-specific microRNAs are modulated during hypertrophy 
(McCarthy & Esser, 2007) and atrophy (McCarthy et al. 2007).  The functions of 
muscle-specific microRNAs will be discussed further in section 2.11. 
2.6.2 Prediction of microRNA targets 
There are many microRNA target prediction algorithms, which predict microRNA 
targets across different species.  The most established and widely used are TargetScan, 
PicTar and Miranda (Lall et al. 2006; John et al. 2004; Lewis et al. 2003).  Each uses a 
different set of rules to identify and evaluate the efficacy of a microRNA target using a 
unique scoring system (Sethupathy et al. 2006). 
 
Evaluating the utility of each prediction algorithm is difficult as there is no 
comprehensive set of experimentally validated targets (Bartel, 2009).  Each algorithm 
must first identify potential binding sites according to specific base-pair rules. 
TargetScan requires perfect complementarity between 3’UTRs and microRNA seed 
sequences (Lewis et al. 2003), whereas imperfect seed matches are included in PicTar 
(Lall et al. 2006).  The microRNA seed is defined at nucleotide 2-7 of the mature 
microRNA and is the main binding point of targets (Bartel, 2004; Lewis et al. 2003).  It 
has been established that perfect complementarity between microRNA seed sequence 
and 3’UTR increases the likelihood of target repression (Bartel, 2004), but imperfect 
seed matches can also lead to target repression.  Interestingly, the importance of the 
microRNA seed sequence as the main site for microRNA:mRNA target interactions was 
challenged recently.  Bantam microRNA was reported to bind the 3’UTR of hid at 
nucleotide 3-9 in Drosphila S2 cells (Nahvi et al. 2009), which suggests that current 
target predictions may be missing valid microRNA targets.   
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Cross-species conservation is another important criterion for prediction of microRNA 
binding sites (Sethupathy et al. 2006).  Evidence of cross-species conservation suggests 
there may be evolutionary pressure to retain functional microRNA binding sites (Bartel, 
2004).  TargetScan and PicTar both require conservation between at least five species 
(Lewis et al. 2003; Lall et al. 2006) to help limit false-positive predictions.  TarBase 
contains evidence of experimentally validated microRNA targets (Sethupathy et al. 
2006; Papadopoulos et al. 2009).  Interestingly some are non-conserved microRNA 
targets, therefore would not have been predicted using PicTar or TargetScan, which 
suggest non-conserved microRNA binding sites can also be functional.  Recently, 
TargetScan was updated and now provides predictions of non-conserved target sites 
(Friedman et al. 2009).  However, it is not known how important non-conserved 
microRNA targets are to post-transcriptional regulation of human protein levels.  The 
consensus among microRNA researchers is that experimental validation of predicted 
microRNA targets remains necessary to confirm the functional relationship between a 
microRNA and its target mRNA (Bartel, 2009; Ambros, 2004; Bushati & Cohen, 2007). 
2.6.3 Experimental validation of microRNA targets 
There is still no clear consensus on criteria to validate microRNA targets (Kuhn et al. 
2008).  A range of molecular methods have been employed to provide evidence of 
individual microRNA target interactions or less frequently genome-wide microRNA 
target interactions (Bartel, 2009).  Many of the current microRNA target prediction 
algorithms were based on studies of mRNA and microRNA profiling.  For example, 
Lim et al. (2003) presents correlations between microRNA and mRNA expression in 
response to microRNA knockdown as evidence of microRNA mediated target 
suppression.  However, studying microRNA action on mRNA expression assumes 
microRNAs act primarily through mRNA cleavage (Bartel, 2009), but it is now known 
that microRNAs can target mRNAs for translation repression and so mRNA transcripts 
may remain unchanged.  Translation repression is still suggested to be the main 
mechanism of microRNA action in mammalian cells (Kim et al. 2009). 
 
Several experiments can be conducted to show a functional relationship between a 
microRNA and target mRNAs.  It is important to confirm binding of microRNA to 
mRNA (Kuhn et al. 2008).  This can be done by dual transfection of microRNA 
knockdown oligonucleotides and 3’UTR vectors containing the firefly luciferase gene, 
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followed by comparison of luciferase activity between cells transfected with 3’UTR 
vectors or control vectors without putative microRNA binding sites.  Next it is 
important to establish that changing microRNA availability affects protein targets, by 
either microRNA overexpression in cells using synthetic microRNAs, or microRNA 
knockdown using anti-microRNA oligonucleotides and measuring changes in target 
protein level.  Unfortunately, this approach to experimental validation of microRNA 
targets is not useful to assessing multiple targets, hence why so few predicted 
microRNA targets have been experimentally validated. 
 
There are new approaches to identify many functional microRNA targets 
simultaneously based on co-immunoprecipitation of RISC proteins such as AGO2 or 
GW182 (Easow, Teleman, & Cohen, 2007; Zhang et al. 2007).  Global protein profiling 
has been attempted in two recent studies (Baek et al. 2008; Selbach et al. 2008).  In the 
first study, miR-223 was deleted in mice and the effect on protein measured using 
quantitative mass spectrometry in cultured neutrophils (Baek et al. 2008).  Deletion of 
miR-223 in mice revealed hundreds of genes were directly repressed by miR-223, 
although some gene targets were repressed with no change in mRNA abundance.  The 
most significant finding was that microRNAs appear to act as cellular rheostats and 
fine-tune protein levels (Baek et al. 2008).  In the second study stable isotope labeling in 
cell culture was used after microRNA transfection or endogenous microRNA 
knockdown (Selbach et al. 2008).  It was concluded that microRNAs function by tuning 
protein synthesis of thousands of genes (Selbach et al. 2008).  Although these studies 
provide an opportunity to uncover new rules governing microRNA target interaction, 
there are still unanswered questions about the importance of tissue specific microRNA 
expression.  For example, miR-133 is known to regulate SRF in cardiac muscle (Zhao et 
al. 2005), but it is not known if SRF is also regulated by miR-133 in skeletal muscle, 
adipose, brain or nervous tissue.  Therefore, it is important that each microRNA:target 
interaction is validated in different tissues.  Evidence of a microRNA:mRNA interaction 
in the heart may not apply in other tissues, such as adipose, liver or skeletal muscle 
tissue. 
2.7. Skeletal muscle microRNAs 
Human diseases characterised by muscle deterioration or dysfunction have only recently 
been studied at the post-transcriptional level (Eisenberg et al. 2007; Fredriksson et al. 
2008).  Studies within the past five years have rev
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regulators of muscle development (Nguyen & Frasch, 2006) and there is now evidence 
to suggest microRNAs may be involved in many biological processes influencing 
muscle growth (van Rooij et al. 2008), muscle wasting and remodeling (Yang & Wu, 
2007).  However, most of our current knowledge of microRNA function is from model 
organisms or cell lines.  Most studies tend to take a single gene/microRNA approach, 
which fails to appreciate that microRNAs may regulate >200 transcripts and that more 
than one microRNA determines cell phenotype in-vivo (Bartel, 2009).  Studies on 
microRNA function in human skeletal muscle are surprisingly lacking despite their 
known influence in regulating gene expression.  
2.7.1 MicroRNAs are involved in skeletal muscle development 
Skeletal muscle development models have been used to characterise the role of 
microRNAs in proliferation and differentiation.  In skeletal and cardiac muscle, miR-1, 
miR-133 and miR-206 are all highly expressed.  Chen et al. (2006) identified miR-133a 
was able to drive proliferation of murine skeletal muscle C2C12 cells, while miR-1 and 
miR-206 were able to accelerate differentiation. 
 
MicroRNA-1 is highly conserved between nematodes, flies and vertebrates, where it is 
highly expressed in muscle tissue (Lagos-Quintana et al. 2001).  Tissue specific 
expression of a microRNA is generally assumed to indicate it may be important for 
development or maintenance of tissue phenotype (Sood et al. 2006).  Ectopic expression 
of miR-1 in HeLa cells revealed that most of the target genes that were down-regulated 
are usually expressed at low-levels in skeletal muscle (Lim et al. 2005), which suggests 
miR-1 may be important for suppressing non-muscle genes to maintain tissue identity.  
Loss of miR-1 would be expected to lead to impaired muscle function and indeed it has 
been reported that Drosophila miR-1 mutants have severely deformed musculature 
(Sokol & Ambros, 2005).  In cardiac muscle, there is evidence that miR-1 may regulate 
proliferation and differentiation by targeting HAND2 (Mishima et al. 2007), as HAND2 
is a transcription factor essential for proliferation of cardiac cells.  In developing mouse 
hearts, ectopic expression of miR-1 led to down-regulation of HAND2 (Mishima et al. 
2007).  Knockdown of miR-1-2 was reported to have opposite effects, stimulating 
cardiogenesis (Zhao et al. 2007).  However, analysis of different sections of developing 
mouse hearts revealed HAND2 was down-regulated in part of the right ventricle 
whereas miR-1 was highly expressed (Zhao et al. 2007).  These findings highlight that 
even within a single tissue microRNA expression can vary.  It is difficult to extrapolate 
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these findings to skeletal muscle, as HAND2 has not been shown to be an essential 
factor in myogenesis.  It is likely the relationship between a microRNA and a target 
gene is context specific (Bartel, 2009).  For example, microRNA target suppression in 
pancreatic cells may not occur in skeletal muscle even where both microRNA and target 
are expressed. 
 
In C elegans, miR-1 has been shown to regulate the muscle transcription factor MEF2 at 
the neuromuscular junction (Simon et al. 2008).  MEF2 increases during skeletal muscle 
differentiation and it has been demonstrated that MEF2 can activate transcription of the 
primary transcript encoding miR-1-2 and 133a-1 (Zhao et al. 2007; Liu et al. 2007).  
Pri-miR-1-2 and pri-miR-133a-1 increase significantly during muscle differentiation 
(Brzeszczynska et al. under revision; Rao et al. 2006).  Therefore, miR-1 appears to be 
part of a more complex regulatory network, possibly acting as its own negative 
regulator by targeting MEF2.  However, it is unlikely MEF2 is solely responsible for 
determining miR-1 transcription, as additional transcription factor binding sites have 
been identied on the primary transcripts encoding miR-1 (Rao et al. 2006).  MicroRNA-
1 appears to promote mesoderm formation from both mouse and human embryonic 
stem cells in unison with miR-133 under the regulation of serum response factor (Ivey 
et al. 2008).  Interestingly, in later development during differentiation into cardiac 
muscle progenitors these microRNAs are reported to have opposing functions (Ivey et 
al. 2008). 
 
Muscle microRNAs appear to respond to extra-cellular factors, for example oxidative 
stress reportedly increases miR-1 expression in cardiomyocytes, which corresponded to 
suppression of the miR-1 targets HSP60 and HSP70 promoting apoptosis (Xu et al. 
2007).  In contrast, miR-133 was reported to target CASP9 and protect cardiomocyctes 
from apoptosis (Xu et al. 2007).  Interestingly, it has been suggested both miR-1 and 
miR-133 are transcribed in unison from neighbouring transcripts (Chen et al. 2006).  
Evidence of opposing effects on apoptosis raises the question whether miR-1 and miR-
133 are indeed transcribed in unison but processed at different rates.  A similar situation 
arises during skeletal muscle hypertrophy where mature miR-1 and miR-133 are 
differentially expressed despite originating from the same genomic loci (McCarthy & 
Esser, 2007) and recently differential expression of miR-133a and miR-1 has been 
reported after endurance training in rats (Safdar et al. 2009).  It may be worthwhile 
examining the expression of primary microRNAs encoding miR-1 and miR-133 and 
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determining whether these microRNAs with apparently differing functions in skeletal 
muscle are indeed transcribed and processed together.  Taken together these studies 
suggest microRNAs are involved in important biological functions in skeletal muscle 
including proliferation, differentiation and apoptosis.  Furthermore, it suggests the 
highly expressed muscle specific miR-1, miR-133 and miR-206 may play a role in adult 
skeletal muscle possibly in maintaining muscle phenotype but also potentially under 
pathological conditions such as cancer and Type 2 diabetes.  However, studies on the 
role of these microRNAs in human skeletal muscle are lacking. 
2.7.2 MicroRNAs and skeletal muscle adaptation 
In healthy skeletal muscle, remodeling occurs in response to exercise training.  In 
human skeletal muscle over one thousand transcripts were reportedly changed with 
endurance training (Timmons et al. 2005).  Intriguingly, a follow-up study found 
twenty-one microRNAs were differentially expressed in response to endurance training 
(Keller et al. 2007).  The predicted targets of these microRNAs shared similar gene 
ontology groups to those of the ~1000 differentially expressed mRNAs (Keller et al. 
2007).  Gene-set enrichment analysis revealed up-regulation of the transcription factors 
RUNX1, PAX3 and SOX9 appeared to modulate the transcriptome response to training.  
Interestingly, these transcription factors are targets of five microRNAs (miR-101, -144, 
-1, -206 and -92) down-regulated in response to training (Keller et al. 2007).  Based on 
our current understanding of microRNA function, Keller et al. suggest microRNAs may 
play an important role in muscle adaptation to training.  However, recent findings from 
mice following endurance training found miR-1 was down-regulated but miR-133a was 
unchanged (Safdar et al. 2009).  Nevertheless, these studies suggest microRNAs play a 
role in skeletal muscle remodelling in response to training, but more studies are needed 
to determine whether microRNAs are the cause or an effect of the remodelling process. 
2.7.3 MicroRNAs and skeletal muscle hypertrophy 
Given that microRNAs appear to be critical for skeletal muscle differentiation, it is 
possible microRNAs play a role in skeletal muscle hypertrophy.  Signaling pathways 
associated with hypertrophy have already been identified (Bassel-Duby & Olson, 2006).  
For example, it is known that during recovery from resistance exercise, growth 
pathways are activated including mTOR and S6K (Atherton et al. 2005), activation of 
these pathways is associated with an elevation in protein synthesis.  In rodent skeletal 
muscle, expression of mature miR-1 and miR-133a is reportedly down-regulated by 
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~50% following 7 days of functional overload (McCarthy & Esser, 2007).  However, 
expression of the microRNA precursors encoding miR-1, miR-133, and miR-206 were 
all elevated, which suggests some changes in microRNA processing may be occuring.  
Counter-intuitively, DROSHA and EXPORTIN5 transcript levels were significantly 
increased (McCarthy & Esser, 2007), suggesting another factor must be responsible for 
altered microRNA processing.  The change in miR-1 and miR-133a expression in 
response to skeletal muscle hypertrophy conversely raises the question whether 
microRNAs may also play a role during atrophy and skeletal muscle wasting. 
2.7.4 MicroRNAs and skeletal muscle atrophy 
Eisenberg et al. (2007) conducted microRNA profiling in skeletal muscle across a range 
of primary muscular disorders.  Five microRNAs (miR-146b, miR-155, miR-214, miR-
221 and miR-222) were reportedly dysregulated across ten muscular disorders 
(Eisenberg et al. 2007), which suggest microRNAs may play a role in their 
development.  In Duchenne’s Muscular Dystrophy the biological functions targeted by 
the down-regulated mRNAs were reportedly correlated with biological functions of the 
targets containing binding sites for the up-regulated microRNAs (Eisenberg et al. 2007).  
Over fifty microRNA-mRNA interactions were identified in muscular dystrophy, 
including proenkephalin-miR-29c, trophinin-miR-29c, RUNX1-miR-30a-5p and 
PDE4D-miR-199a.  Unfortunately, these predicted microRNA:mRNA interactions have 
not been experimentally validated.  Surprisingly, no significant interactions were found 
between microRNA expression and changes in genes coding proteins such as 
dystrophin, previously identified as a key player in muscular dystrophy (Eisenberg et al. 
2007), which highlights the need to focus on changes in global gene expression rather 
than expression of single genes. 
 
Muscle function is impaired in various chronic diseases characterized by muscle 
wasting and loss of glycaemic control including cancer and Type 2 diabetes.  Despite 
the reported widespread influence of microRNAs on molecular, cellular and biological 
function, the role of microRNAs in skeletal muscle of cancer and Type 2 diabetes 
patients is unknown. 
2.8. Cancer cachexia 
Cachexia is a complex syndrome, which is characterised by progressive losses of both 
skeletal muscle and adipose tissue (Skipworth et al. 2007).  Some degree of weight loss 
Chapter 2 – Literature Review 
25 
is experienced by about 50% of all cancer patients and cachexia has been reported to be 
a significant contributing factor to mortality rates in cancer patients (DeWys, 1985).  
Recently, the SCRINO working group classified cancer patients with <10% weight loss 
as asymptomatic pre-cachexia and patients with >10% weight loss as symptomatic 
cachexia (Bozzetti & Mariani, 2008).  In severe cases cachexia patients have been 
observed to lose 20-30% of initial body weight (Weber et al. 2009).  Advanced cachexia 
is associated with anorexia, early satiety, severe weight loss, weakness, anemia and 
edema (Del Fabbro et al. 2006).  It is common in patients with chronic or end-stage 
diseases such as sepsis, AIDS, congestive heart failure and cancer.  It shares common 
features with diabetes, in that there is gross loss of metabolic control and therefore loss 
of proper insulin action (Rofe et al. 1994).  In addition, cachexia has also been linked to 
a decreased response to chemotherapy treatment (DeWys, 1985). 
 
Muscle wasting in cancer patients has major implications for quality of life and physical 
function (Stewart et al. 2006).  Quality of life measures are reported to decline in 
association with weight loss.  These changes also coincide with decreases in physical 
function (Dahele et al. 2007; Ryan et al. 2007; Fouladiun et al. 2007).  Although, 
muscle wasting is the most identifiable characteristic of cachexia patients, many more 
factors may contribute to the manifestation of clinical symptoms of fatigue (Stewart et 
al. 2006).  There is no clearly defined physiological profile of cancer cachexia patients 
and the pathogenesis of cancer cachexia is still not fully understood.  Studies have 
reported many factors may be associated with cancer cachexia pathogenesis including 
alterations in protein, glucose and fat metabolism; circulating cytokines, tumour derived 
factors, and production of acute phase reactants (Skipworth et al. 2007; Melstrom et al. 
2007; Baracos 2006; Laviano et al. 2005; Rubin, 2003). 
2.8.1 Acute-phase response in cancer cachexia 
An acute phase response is characteristic of many weight-losing cancer patients with 
tumour progression.  The acute phase response represents a global response by the host-
immune system to injury and involves the synthesis of acute phase proteins in 
hepatocytes (Stephens et al. 2008).  C-reactive protein concentration in plasma is often 
used as an indicator of the degree of the acute phase response, for example Fearon et al. 
(1992) reported high C-reactive protein concentrations of 75 ml/l in a sample of colon-
cancer patients.  The degree of the acute phase response at cancer diagnosis has been 
reported to be a strong predictor of 5 year survival in colon cancer patients (Fearon, 
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1992).  Furthermore, in pancreatic cancer patients the presence of an acute-phase 
protein response was found to be a significant independent predictor of survival 
duration (Falconer et al. 1995).  Production of acute-phase reactants requires a supply of 
amino acids.  If dietary intake is low as is often the case in cancer patients (Hutton et al. 
2006) then amino acid requirements must be met by the breakdown of protein from 
other sources such as muscle.  Thus it has been suggested the acute phase response may 
drive the breakdown of skeletal muscle proteins and lead to loss of muscle function 
(Reeds et al. 1994; Skipworth et al. 2007; Stephens et al. 2008).  Nevertheless, the 
development of an acute phase response in cancer patients can not be the sole factor 
determining weight loss, as not all patients with metastatic disease, nor weight-losing 
cancer patients exhibit an acute phase response (Fearon, 1992). 
2.8.2 Cytokines and cancer cachexia 
Several cytokines have been implicated in the acute-phase response. Both in-vitro and 
in-vivo studies have shown IL-1 and TNFα can produce an acute phase response, for 
example infusion of TNFα in cancer patients is reported to elevate serum C-reactive 
protein concentrations (Selby et al. 1987).  Yet in cancer cachexia patients circulating 
TNFα and IL-1 have been reported to be very low or undetectable (Fearon, 1992).  In 
contrast IL-6 concentrations were significantly increased in cancer cachexia patients 
compared to controls.  Unfortunately, there is a lack of consistency between studies on 
cytokine levels in cancer patients, thus cytokines may be of limited use as biomarkers of 
cachexia (Tan & Fearon, 2008). 
 
Cancer patients with cachexia tend to have elevated levels of IL-6 in plasma (Fearon et 
al. 1991).  Infusion of IL-6 into non-tumour bearing mice is reported to affect muscle 
protein levels.  For example, myofibrillar protein was reportedly reduced by 17% over 
14 days due to IL-6 infusion in non-tumour bearing mice (Haddad et al. 2005).  In 
tumour-bearing mice circulating IL-6 has been observed to be increased (Lönnroth et al. 
1990), but in another study no elevation of IL-6 levels was found in tumour-bearing 
mice compared to pair-fed controls (Mulligan et al. 1992).  The inconsistency between 
studies using tumour-bearing mice may be related to the type of tumour used, as 
differential gene expression has been observed in different tumour models (Monitto et 
al. 2001).  In humans, IL-6 levels reportedly do not differ between cachexic and non-
cachexic patients diagnosed with non small cell lung cancer (Kayacan et al. 2006).  
However, a review of clinical studies on targeted anti-IL-6 monoclonal antibody 
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therapy in cancer patients revealed treatment was effective in decreasing CRP and was 
also associated with a decrease in the incidence of cachexia (Trikha et al. 2003).  Taken 
together these studies suggest cytokines may play a role in cachexia pathogenesis, by 
activating an acute phase response or triggering protein breakdown in skeletal muscle. 
2.8.3 Activation of the ubiquitin-proteasome pathway in cancer cachexia 
In atrophy conditions the ubiquitin-proteasome pathway appears to be critical for 
breakdown of myofibrillar proteins.  Indeed, in head trauma, sepsis and AIDS, gene 
expression of the ubiquitin-proteasome pathway is reportedly increased (Mansoor et al. 
1996; Tiao et al. 1997; Llovera et al. 1998; Williams et al. 1999).  The degradation of 
proteins via the ubiquitin-proteasome pathway involves conjugation of ubiquitin to 
individual proteins, which are then selectively degraded in the proteasome. Ubiquitin 
activates an E1 enzyme and activated ubiquitin binds to an E2 enzyme, which allows 
interaction with an E3 enzyme.  The E3 enzyme binds to the protein substrate to be 
degraded and catalyzes the transfer of the activated ubiquitin from the E2 carrier (Kwak 
et al. 2004).  Finally, ubiquitin tagged proteins are targeted to the 26S proteasome where 
degradation occurs.   
 
The ATP-ubiquitin-proteasome pathway is reportedly activated in skeletal muscle of 
cachectic rats bearing a hepatoma (Baracos et al. 1995).  A later study found the 
expression of genes in the ubiquitin-proteasome proteolytic pathway was increased in 
skeletal muscle from patients with cancer (Williams et al. 1999).  The mRNA levels for 
the ubiquitin and 20S proteasome subunits were reported to be 2-4 times higher in 
cancer patients compared to controls, although it is not clear whether gene expression 
was associated with patient status as only 12 patients were sampled.  Only three of these 
patients exhibited weight loss, suggesting ubiquitin genes may be up-regulated prior to 
protein breakdown resulting in loss of muscle mass.  As with all studies measuring 
mRNA levels, it is not clear whether changes in expression are indicative of increased 
transcription or increased mRNA stability.  In addition, changes in mRNA do not 
exclude the possibility of further post-transcriptional regulation of the ubiquitin-
proteosome or other pathways in cancer cachexia. 
 
In atrophying muscle, molecular signaling pathways controlling protein synthesis may 
be dysregulated, but there are only limited data on the activation of molecular growth 
pathways in human cancer cachexia.  Schmitt et al. (2007) examined activation of the 
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Akt pathway in muscle and liver biopsies from patients with pancreatic carcinoma.  In 
skeletal muscle, Akt on Ther308, mTOR and p70S6 kinase protein content was 
significant reduced (Schmitt et al. 2007), which suggests protein synthesis pathways 
may be down-regulated in cancer cachexia and therefore can not compensate for the 
activation of protein degradation via the ubiquitin proteasome pathway. 
2.8.4 Breakdown of myofibrillar proteins in cancer cachexia 
Myofibrillar protein forms a large proportion of skeletal muscle and consists of the 
contractile proteins myosin heavy chain, actin, troponin and tropomyosin (Bassel-Duby 
& Olson, 2006).  In healthy skeletal muscle, expression of genes encoding myofibrillar 
proteins is essential to maintain muscle mass, loss of muscle mass could be explained 
by decreased expression of genes encoding myofibrillar proteins.  For example, 
Acharyya et al. (2004) observed that MyHC was significantly down-regulated as a 
result of muscle wasting in mice implanted with C-26 tumours, but found no changes in 
expression of tropomyosin, troponin, actin, actinin and myosin light chain.  Intriguingly, 
lower MyHC protein expression in C-26 tumour bearing mice was not associated with 
lower MyHC mRNA (Acharyya et al. 2004), which suggests MyHC could be regulated 
post-transcriptionally in cachexia. 
2.8.5 Tumour-derived factor in cancer cachexia 
Proteolysis inducing factor (PIF) is released from some tumours and was first isolated 
from urine of cancer patients with cachexia (Todorov, 1996).  PIF is a sulphated 
glycoprotein, which has been implicated as an important mediator of protein catabolism 
in cancer cachexia.  There are now in-vitro and in-vivo studies supporting the role of 
PIF in cachexia pathogenesis.  Tisdale and colleagues have shown elevation of PIF 
appears to trigger an intracellular signaling cascade resulting in activation of the 
proteasome pathway (Todorov, 1996).  In C2C12 myotubes PIF has been shown to 
increase protein degradation and decrease protein synthesis (Smith et al. 1999).  In-vivo 
studies on rat gastrocnemius have also demonstrated that PIF increases protein 
degradation (Lorite et al. 1997). 
 
Apoptosis activity is reportedly enhanced by PIF in-vitro.  For example, treatment of 
C2C12 myotubes increases the activity of apoptotic initiators caspases-8 and -9 and 
apoptotic effector caspases -2, -3 and -6 (Smith & Tisdale, 2003).  Furthermore, 
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following PIF treatment there was evidence of DNA fragmentation and free nucleasome 
formation indicating cell apoptosis (Smith & Tisdale, 2003).  
 
More recent in-vivo studies on the role of PIF in cancer cachexia patients have produced 
mixed results (Cabal-Manzano et al. 2001; Williams et al. 2004; Wieland et al. 2007).  
A cross-sectional study in gastrointestinal patients observed PIF correlated with weight 
loss (Cabal-Manzano et al. 2001).  A longitudinal study in cancer patients reported a 
positive relationship between urinary PIF pattern and persistent weight loss over time 
(Williams et al. 2004).  However, another more recent study failed to find any 
association between cachexia severity and urinary PIF concentration in patients 
(Wieland et al. 2007).  Therefore the evidence suggests PIF may be of limited clinical 
value despite reports of elevated PIF levels in cachexia patients. 
2.8.6 Biomarkers for early detection of cachexia 
Review of the cachexia literature to date reveals many potential biomarkers including 
tumour-derived factors such as PIF and cytokines involved in the acute phase response.  
However, although these are often observed to be elevated in cachexic patients in cross-
sectional studies, consistent evidence from longitudinal studies directly linking changes 
in these markers to functional deterioration and weight loss in cancer patients is lacking 
(Lelli et al. 2003).  For example, one cross-sectional study evaluated the potential of 
myoglobin in plasma to predict cancer-related muscle wasting.  The study found plasma 
myoglobin was associated with aerobic capacity and muscle cross sectional area (Weber 
et al. 2007).  Lower muscle cross sectional area and aerobic capacity were reported in 
cachexia patients, but muscle wasting was not associated with increases in plasma 
myoglobin (Weber et al. 2007).  Another cross-sectional study attempted to identify a 
bio-humoral profile that can characterise cachexic and non-cachexic cancer patients, it 
was reported lung cancer patients developing cancer cachexia displayed significantly 
increased plasma TNFα and reactive oxygen species levels (Fortunati et al. 2007).  
However, a prospective study would be essential to confirm any proposed biomarker 
could predict weight loss.  There still appears to be no reliable biomarker of cancer 
cachexia (Tan & Fearon, 2008), thus more research is warranted to identify biomarkers 
that can be used to reliabily detect cachexia in its early stages. 
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2.9. MicroRNAs implicated in cancer cachexia 
It is clear microRNAs are important players in skeletal muscle differentiation and there 
are indications that microRNAs play a role in skeletal muscle remodelling, growth and 
atrophy (van Rooij et al. 2008; Chen et al. 2006; Chen et al. 2009; McCarthy & Esser, 
2007; McCarthy et al. 2007).  It is plausible that muscle microRNAs may play a role in 
cancer cachexia development or could be biomarkers of cancer cachexia progression.  
As yet there have been no studies on microRNA expression in skeletal muscle of cancer 
cachexia patients. 
 
Based on microRNA-mRNA interactions reported in muscular dystrophies (Eisenberg 
et al. 2007), it is likely microRNA-mRNA interactions will also be found in cachexic 
muscle.  Of particular interest are the microRNAs predicted to target genes coding 
proteins in the ubiquitin-proteasome pathway that appears to be activated in cachexia 
(Melstrom et al. 2007; Williams et al. 1999).  In immune cells NF-κb activation induces 
miR-146 expression (Taganov et al. 2006), which is interesting as NF-κb is activated in 
cachexia at least in experimental models. 
 
Other important players known to be involved in skeletal muscle atrophy including the 
E3 ligases MAFbx and MURF1 could also be regulated post-transcriptionally (Chen et 
al. 2007).  MAFbx and MURF1 both contain multiple predicted microRNA target sites, 
however none of these have been experimentally validated. 
2.10. Type 2 diabetes 
Type 2 diabetes is characterised by peripheral insulin resistance, hyperglycaemia, 
hyperinsulinaemia and pancreatic β-cell dysfunction (Muoio & Newgard, 2008).  Type 
2 diabetes is distinct from Type 1 diabetes where pancreatic β-cell failure leads to 
uncontrolled hyperglycemia without external administration of insulin.  Both genetic 
and lifestyle factors have been implicated in the development of Type 2 diabetes 
(Muoio & Newgard, 2008). 
2.10.1 Type 2 diabetes susceptibility genes 
Genome-wide association studies have identified several novel candidate genes with 
single nucleotide polymorphisms (SNPs), which increase Type 2 diabetes susceptibility 
(Zeggini et al. 2008).  A large meta-analysis combining gene-association scans from 
over 10,000 individuals of European descent identified a further six previously 
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unknown loci encoding JAZF1, CDC123, TASPAN8, THADA, ADAMTS9 and 
NOTCH2 (Zeggini et al. 2008).  However, most of the variance in Type 2 diabetes 
susceptibility remains to be explained.  Later studies have found these candidate genes 
are also associated with increased susceptibility in other populations in Asia and Africa 
(Takeuchi et al. 2009).  Most of the Type 2 diabetes susceptibility genes identified so 
far are involved in insulin secretion from pancreatic β-cells (Zeggini et al. 2008).  Thus 
individuals with a family history of Type 2 diabetes have a higher susceptibility of 
progressing to Type 2 diabetes due to inherited pancreatic β-cell dysfunction. 
 
It remains to be seen whether these Type 2 diabetes susceptibility genes are associated 
with the development of insulin resistance and impaired glucose tolerance, which also 
play an important role in Type 2 diabetes pathogenesis.  A recent study found only 
IGF2BP2 and SLC30A8 were associated with impaired insulin sensitivity and glucose 
tolerance, but accounted for less than 10% of the variance in insulin sensitivity and 
glucose tolerance (Ruchat et al. 2008).  Furthermore, a meta-analysis of Type 2 diabetes 
risk loci in a pre-diabetic cohort could not find any significant associations between 
Type 2 diabetes susceptibility genes and the pre-diabetic phenotype characterised by 
impaired insulin secretion and insulin resistance (Staiger et al. 2008).  Together these 
studies suggest either more Type 2 diabetes susceptibility genes remain to be discovered, 
or that a large proportion of the pre-diabetic phenotype is determined by other factors. 
2.10.2 Glucose homeostasis and insulin resistance in Type 2 diabetes 
Normally glucose homeostasis is tightly regulated through production of insulin, which 
stimulates glucose uptake in peripheral tissues (Muoio & Newgard, 2008).  Insulin is 
secreted from pancreatic β-cells in response to elevated blood glucose.  In healthy 
skeletal muscle, binding of insulin to the insulin receptor results in the translocation of 
glucose transporters to the cell membrane and increased skeletal muscle glucose uptake 
(Muoio & Newgard, 2008).  However, the development of insulin resistance leads to 
peripheral tissues being less responsive to insulin (Bouzakri et al. 2005).  The pancreatic 
β-cells attempt to compensate for insulin resistance via increased insulin secretion, 
which can be a factor causing hyperinsulinaemia in Type 2 diabetes patients (Muoio & 
Newgard, 2008).  Insulin resistance can be an early indicator of the development of 
Type 2 diabetes.  However, not all insulin resistant individuals will develop 
hyperglycaemia and conversely patients may develop Type 2 diabetes in the absence of 
high insulin resistance due to hereditary pancreatic β-cell failure. 
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Insulin resistance is not only associated with Type 2 diabetes but also obesity (Kahn et 
al. 2006), physical inactivity (Hamburg et al. 2007), muscle-loss (Rofe et al. 1994), 
cancer and aging (Scheen, 2005).  Obesity, ageing and physical inactivity have all been 
identified as risk factors increasing susceptibility to Type 2 diabetes.  Therefore, it is 
important to control for these known risk factors when attempting to understand the 
underlying mechanisms contributing to insulin resistance and Type 2 diabetes.  Current 
understanding of insulin resistance suggests there may be a breakdown in the 
intracellular signaling pathway activated by insulin (Fröjdö et al. 2009). 
Figure  2-2. Insulin signaling pathway leading to skeletal muscle glucose uptake. 
Binding of insulin to the insulin receptor triggers a phosphorylation cascade.  
Activated of IRS1 triggers phosphorylation of PI3K.  Conversion of PIP2 to PIP3 
activates AKT, which in turn activates AS160 and results in translocation of 
GLUT4 to the plasma membrane.  GLUT4 interacts with CDC42 and VAMP 
proteins may lead to increased glucose uptake.  A selection of microRNAs 
predicted to target insulin signaling proteins are indicated. 
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2.10.3 Insulin signaling in skeletal muscle 
Activation of the insulin signaling cascade in skeletal muscle is important to maintain 
normoglycaemia and may be impaired at multiple levels in Type 2 diabetes (Figure 2.2).  
In healthy skeletal muscle, insulin causes autophosphorylation of the insulin receptor 
(Burant et al. 1984).  Docking of the insulin receptor substrate (IRS) proteins to the 
insulin receptor leads to phosphorylation of IRS proteins (Sun et al. 1991).  Thereafter 
phosphorylated IRS proteins associate with phosphatidylinositol 3-kinase (PI3K) at the 
p85 regulatory sub-unit (Myers et al. 1992) and PI3K translocates to the plasma 
membrane.  PI3K catalyses the conversion of phosphatidylinositol-4-5-biphosphate 
(PIP2) to phosphatidylinositol-3,4-5-triphosphate (PIP3), which results in binding, 
activation and co-localisation of phosphoinositide-dependent protein kinase-1 (PDK1), 
PDK2 and Akt (Stephens et al. 1998).  Activated Akt results in phosphorylation of 
glycogen synthase kinase-3 (GSK3) and AS160, a RAB GTPase-activating protein 
(Kane et al. 2002).  AS160 interacts with RAB10, a small GTPase, which facilitates the 
translocation of GLUT4 to the plasma membrane (Larance et al. 2005).  GLUT4 
vesicles are responsible for the majority of glucose uptake into human skeletal muscle.  
There are several negative regulators of insulin signaling, which may lead to decreased 
GLUT4 translocation and impaired insulin-stimulated muscle glucose uptake, thus 
potentially contributing to the development of insulin resistance and Type 2 diabetes. 
2.10.4 Negative regulators of insulin signaling 
Several points have been identified where insulin signaling may be impaired in Type 2 
diabetes (Muoio & Newgard, 2008) and inflammatory cytokines have been shown to 
contribute to insulin resistance.  Chronic systemic inflammation is a characteristic 
commonly associated with Type 2 diabetes and appears to contribute to the 
development of insulin resistance (Shoelson et al. 2006).  For example, acute IL-6 
administration in myotubes and mice has been reported to increase glucose uptake with 
activation of LKB1, PKB and AS160 (Nieto-Vazquez et al. 2008).  However, chronic 
IL-6 administration has been reported to increase insulin resistance via decreased 
GLUT4 translocation and impaired IRS1 phosphorylation (Nieto-Vazquez et al. 2008).  
Furthermore, insulin resistance induced by chronic IL-6 exposure is associated with 
increased PTP1B activity (Nieto-Vazquez et al. 2008).  PTP1B is a protein tyrosine 
phosphatase and can reverse autophosphorylation of the insulin receptor (Figure 2.2).  It 
has been shown that myocytes deficient in PTP1B have increased insulin sensitivity 
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(Nieto-Vazquez et al. 2007), which suggests increases in PTP1B could result in insulin 
resistance. 
 
Suppressor of cytokine signaling (SOCS) proteins can also act as negative regulators of 
insulin receptor tyrosine activity, which could lead to impaired insulin signaling (Krebs 
& Hilton, 2003).  For example, insulin resistance induced by chronic IL-6 exposure is 
reported to activate JNK1/2 and increase SOC3 (Nieto-Vazquez et al. 2008), which may 
impair insulin induced IRS1 activation and hence contribute to insulin resistance. 
 
PTEN is another negative regulator of insulin signaling, increases in PTEN triggers 
conversion of PIP3 to PIP2, which can attenuate insulin induced activation of 
PDK/AKT and reduce glucose uptake (Figure 2.2).  PTEN could be involved in insulin 
resistance and Type 2 diabetes, as deletion of PTEN in muscle as been shown to protect 
mice from developing insulin resistance and Type 2 diabetes (Wijesekara et al. 2005).  
These studies highlight insulin signaling can be impaired at multiple levels leading to 
decreased insulin-stimulated glucose uptake. 
2.11. MicroRNAs implicated in insulin resistance and Type 2 diabetes 
Many insulin signaling genes have multiple microRNA binding sites in their 3’UTRs 
(Figure 2.2).  Therefore microRNAs may regulate many stages in the insulin signaling 
pathway and play a role in the development of insulin resistance and Type 2 diabetes 
(Hennessy & O'Driscoll, 2008).  Each microRNA is able to regulate multiple mRNAs, 
while each mRNA can be regulated by multiple microRNAs (Bartel, 2009).  Despite the 
multiple microRNA binding sites in genes involved insulin-dependent glucose muscle 
uptake which is known to be impaired in Type 2 diabetes (Figure 2.2), to date there 
have been no studies on microRNA function in skeletal muscle of Type 2 diabetes 
patients. 
2.11.1 MicroRNA-278 may contribute to an insulin resistant phenotype 
It appears microRNAs have the potential to act as biomarkers of insulin resistance in 
muscle.  Drosophila miR-278 mutants are reported to have an insulin resistant 
phenotype due to elevated insulin production, lower body mass and hyperglycaemia 
(Teleman et al. 2006).  Although, miR-278 was reportedly expressed only in brain, gut, 
salivary gland and adipose tissue, but not skeletal muscle.  Therefore, it appears miR-
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278 may contribute to insulin resistance but not insulin resistance in skeletal muscle 
which is a characteristic of Type 2 diabetes. 
2.11.2 MicroRNA-208 and microRNA-133 may target GLUT4 
The glucose transporter GLUT4 is a predicted target of miR-208 (Figure 2.2).  In 
response to miR-208 knockdown, if GLUT4 is a bon a fide target of miR-208 then 
GLUT4 protein should increase.  However, in miR-208 knockout mice GLUT4 was 
found to be unchanged in cardiac muscle (van Rooij et al. 2007), although it is not clear 
whether miR-208 is expressed in skeletal muscle.  It is known miR-133 is highly 
expressed in skeletal muscle and overexpression of miR-133 is reported to decrease the 
protein level of transcription factor KLF-15 and its downstream target GLUT4 
(Takahiro, 2009).  Conversely, silencing of miR-133 is reported to increase GLUT4 and 
increase cellular ATP (Takahiro, 2009).  These studies suggest silencing of miR-133 or 
miR-208 could increase muscle glucose uptake and hence may be involved in the 
development of Type 2 diabetes.  However, it would be important to establish miR-208 
or miR-133 is altered in the skeletal muscle of Type 2 diabetes patients. 
2.11.3 MicroRNA-143 targets diabetes associated genes 
Diabetes-associated genes are reported to be inhibited by miR-143, which is expressed 
in both adipose and muscle tissue.  For example, GLUT4 and peroxisome proliferator-
activated receptor (PPAR-2) are reportedly inhibited by knockdown of miR-143 using 
2'-O-methoxy anti-sense RNA oligonucleotides (Esau et al. 2004).  In addition, 
mitogen-activated protein kinase ERK5, which can affect both PPAR-2 and GLUT4, 
was found to be a predicted target of miR-143 (Esau et al. 2004).  It remains to be seen 
whether miR-143 acts on ERK5 in skeletal muscle and whether it is altered in Type 2 
diabetes patients.  ERK may be targeted by multiple microRNAs in Type 2 diabetes, as 
ERK activity appears to be modulated by miR-21 (Thum et al. 2008). 
2.11.4 MicroRNA-21 targets insulin signaling regulators 
MicroRNA-21 has been shown to inhibit ERK activity via suppression of sprouty 
homologue 1 (SPRY1) in heart fibroblasts (Thum et al. 2008).  From a therapeutic 
perspective, administration of a miR-21 antagomir in mice with cardiac disease 
reportedly reduces ERK-MAP kinase activity and inhibits fibrosis (Thum et al. 2008).  
Furthermore, miR-21 is known to target PTEN (Figure 2.2), which regulates 
phosphoinositide 3-kinase signaling (Meng et al. 2007).  Knockdown of miR-21 in 
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hepatocellular cancer cells increased PTEN expression confirming it as a target for 
repression by miR-21 (Meng et al. 2007).  Fatty acids can down-regulate PTEN in 
hepatic tissue via activation of mTOR and NF-κB complex (Vinciguerra et al. 2008), 
interestingly activation of mTOR and NF-κB increases miR-21 promoter activity.  In 
human liver biopsies from obese patients miR-21 was up-regulated (Vinciguerra et al. 
2008), which points to miR-21 as a potential candidate for regulation in Type 2 diabetes.   
The responsiveness of miR-21 expression to extra-cellular events such as elevated free-
fatty acids is particularly interesting as lipid infusion is associated with the development 
of acute insulin resistance.  Furthermore lipid infusion has been reported to decrease 
IκB a known inhibitor of NFκB.  Taken together these studies suggest elevated free-
fatty acids in Type 2 diabetes may activate miR-21 transcription via NF-κB and 
increased miR-21 could suppress PTEN a negative regulator of insulin signaling.  
However, miR-21 is reportedly post-transcriptionally regulated by SMAD proteins, 
which can block maturation of pri-miR-21 (Davis et al. 2008).  Therefore, it is difficult 
to make predictions about the role of miR-21 in Type 2 diabetes without further in-vivo 
evidence from Type 2 diabetes patients. 
2.11.5   MicroRNA-145 targets insulin signaling protein IRS1 
The insulin signaling IRS proteins are also microRNA targets (Figure 2.2) and IRS 
deficient mice reportedly develop insulin resistance (Kadowaki, 2000).  IRS1 protein is 
decreased in response to overexpression of miR-145 in colon cancer cells, with IRS1 
mRNA unchanged, and the direct interaction between miR-145 and IRS1 was 
confirmed using a luciferase reporter assay (Shi et al. 2007).  However, it is not known 
whether miR-145 is a regulator of IRS1 in skeletal muscle and whether knockdown of 
miR-145 could improve glucose uptake. 
2.11.6   MicroRNA-29 regulates insulin signaling pathway proteins 
Goto-Kakizaki (GK) rats have been used as a non-obese model of Type 2 diabetes.  
Comparison of skeletal muscle from GK rats and healthy rats based on microRNA 
arrays identified four up-regulated and eleven down-regulated microRNAs (He et al. 
2007).  Further work confirmed the miR-29 family was up-regulated in muscle, fat and 
liver of diabetic rats.  Overexpression of the miR-29 family repressed insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes.  The miR-29-induced repression of insulin-
stimulated glucose uptake was comparable to that induced by high glucose and insulin 
treatment (He et al. 2007). 
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Overexpression of miR-29 in adipocytes was not reported to affect IR tyrosine 
phosphorylation or cellular content of IRS1.  However IRS1 and Akt phosphorylation 
was decreased in miR-29 expressing adipocytes (He et al. 2007).  Inhibition of miR-29 
using LNA oligonucleotides activated Akt, but had no effect on glucose uptake (He et al. 
2007).  Both INSIG1 and CAV2 were confirmed as miR-29 targets based on luciferase 
assay and Western blots (He et al. 2007), INSIG1 is responsive to insulin and regulates 
SREBP, while CAV2 is not directly involved in the insulin signaling pathway but has 
been previously linked to Type 2 diabetes.  Other potential miR-29 targets associated 
with Type 2 diabetes include Syntaxin-1, which is involved in GLUT4 translocation 
(Cheatham et al. 1996) and transgenic mice over-expressing syntaxin reportedly have 
elevated insulin-stimulated glucose transport (Spurlin et al. 2004).  In the study of He et 
al. the miR-29 overexpression experiments were all conducted in adipocytes, but it is 
unknown whether the microRNA:target effects are similar in skeletal muscle. All 
members of the miR-29 family are highly expressed in muscle, while only miR-29a and 
miR-29b were confirmed as over expressed in adipose tissue from GK rats.  There were 
eleven more microRNAs identified as over expressed in Type 2 diabetes GK rats, but it 
is unknown how many of these influence glucose uptake.  A future screening study 
using a microRNA library of inhibitors could identify candidate microRNAs, which 
regulate muscle glucose uptake.  
2.12. Therapeutic possibilities for microRNAs 
Following identification of disease-linked microRNAs there are several possibilities for 
therapeutic intervention.  The development of therapeutic interventions has mainly been 
restricted to cell and mouse models (Mattes et al. 2008).  The construction of 
microRNA mimics has been the focus of much of this research.  For example, antisense 
microRNA oligonucleotides (ASOs) with chemical modifications to improve their 
stability are reported to reduce liver cholesterol in mice (Krützfeldt et al. 2005).  
Recently, administration of ASOs targeting miR-320 in mice with cardiac 
ischemia/reperfusion injury was shown to reduce the size of infarction compared to 
saline injection (Ren et al. 2009).  Other possibilities include using a viral-based 
approach and infecting a host with a virus containing a microRNA sequence (He et al. 
2007).  Alternatively, targeting microRNA biogenesis proteins using siRNAs could be 
used to reduce or block microRNA maturation.  Another possibility is targeting 
microRNA promoters using siRNAs however very few microRNA promoters have been 
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characterised.  Currently, there have been no studies published on the efficacy of 
microRNA based therapeutic agents in patients, although reportedly clinical trials are 
underway.  However, it is important to firstly understand what microRNAs do and how 
microRNAs work in skeletal muscle during chronic diseases such as cancer and Type 2 
diabetes. 
2.13. Summary of research direction 
Understanding of microRNA biogenesis, processing and function is advancing at a 
remarkable pace (Bartel, 2004; Bartel, 2009; Ambros, 2004; Kim et al. 2009).  It is clear 
these small non-coding RNAs can play important regulatory roles in many biological 
processes (Bushati & Cohen, 2007; Ambros, 2004).  There is now huge interest in the 
role of microRNAs in chronic human diseases including Type 2 diabetes, 
cardiovascular disease and muscular dystrophies (van Rooij et al. 2008; Chen et al. 
2009; Yang & Wu, 2007; Couzin, 2008; Hennessy & O'Driscoll, 2008).   
 
This thesis will focus on determining the role of microRNAs in two chronic diseases 
affecting human skeletal muscle: Type 2 diabetes characterised by skeletal muscle 
insulin resistance and cancer cachexia characterised by skeletal muscle wasting.  In 
Type 2 diabetes there is already evidence from diabetic mice suggesting post-
transcriptional regulation is important for controlling glucose uptake (Hennessy & 
O'Driscoll, 2008; He et al. 2007).  Genome-wide transcriptome data from our laboratory 
intriguingly suggests the development of an insulin resistant phenotype could be largely 
due to post-transcriptional changes (J. Timmons, personal communcation).  Microarray 
profiling of a large Scandinavian Type 2 diabetes cohort (n = 118) found no evidence of 
transcriptional changes in Type 2 diabetes (Timmons et al. unpublished).  Currently, 
there have been no large microarray studies in cancer cachexia patients.  Therefore it is 
unknown whether there are significant global changes in transcription or whether post-
transcriptional regulation is widespread.  Nevertheless, to date there have been no 
studies examining microRNAs in human skeletal muscle from Type 2 diabetes patients 
or cancer cachexia patients. 
 
Several microRNAs are highly expressed in skeletal muscle including miR-1, miR-133a 
and miR-206, which are associated with proliferation and differentiation in muscle cell 
lines (Chen et al. 2006).  In mice these microRNAs are modulated in atrophy and 
hypertrophy models (van Rooij et al. 2008), but it is unknown whether these 
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microRNAs are modulated in human skeletal muscle in-vivo.  In Chapter 3, microRNA 
expression was measured in cancer cachexia patients with varying degrees of weight 
loss to determine whether microRNAs may provide early biomarkers of cachexia.  
 
In Chapter 4 the thesis focuses on examining the involvement of microRNAs in Type 2 
diabetes using a similar approach.  Expression of muscle-specific microRNAs was 
measured in patients with varying degrees of insulin resistance and glucose tolerance.  
To determine whether microRNAs may be involved in the pathogenesis of Type 2 
diabetes, multiple regression was used to examine whether microRNA expression could 
predict clinical markers of glucose homeostasis and insulin resistance.  
 
In Chapter 5 to determine whether extra-cellular factors may play a role in modulating 
the expression of disease associated microRNAs, microRNA expression in myotubes 
was measured in response to insulin and TNFα treatment, which have been previously 
implicated in cancer cachexia and Type 2 diabetes pathogenesis.  In addition, specific 
microRNA targets were validated in microRNA knockdown experiments.  
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Chapter 3 - Skeletal muscle microRNAs in cancer cachexia patients 
3.1. Introduction 
Cachexia has long been recognised as a significant contributing factor to mortality in 
cancer patients (DeWys, 1985) and over 80% of cancer patients develop cachexia 
before death (Bruera, 1997).  Cachexia is characterised by significant weight loss 
including both adipose and skeletal muscle tissue.  Skeletal muscle protein breakdown 
in cancer cachexia patients results in functional consequences of fatigue and decreased 
muscle strength (Bozzetti & Mariani, 2008; Tan & Fearon, 2008).  Past reviews have 
identified systemic inflammation (Durham et al. 2009; McMillan, 2009), plasma 
cytokines (Seruga et al. 2008), elevated basal energy demands, an acute phase response 
(Stephens et al. 2008; Skipworth et al. 2007), alteration of muscle growth associated 
genes, and activation of the ubiquitin-proteolysis pathway in skeletal muscle 
(Hasselgren & Fischer, 2001; Hasselgren & Fischer, 1997) as central features in cancer 
cachexia pathogenesis.  However, there still remains no consensus on biomarkers for 
early identification of cachexia in cancer patients (Tan et al. 2008).  Furthermore, 
current therapeutic approaches are primarily limited to managing symptoms of cachexia 
patients (Bruera, 1997).  
 
The discovery of new biomarkers and understanding the molecular mechanisms 
involved in cancer cachexia is important to aid early identification of cancer patients at 
risk of cachexia and to facilitate the development of new therapeutic drugs to combat 
cachexia (Tan & Fearon, 2008; Tan et al. 2008; Bozzetti & Mariani, 2008).  In an 
attempt to discover new biomarkers and understand the molecular mechanism involved 
in cancer cachexia, past research has identified transcriptional changes in genes 
associated with muscle catabolism pathways with potential to cause muscle wasting in 
animal models (Lecker et al. 2004). 
3.1.1 Transcriptional changes in cancer cachexia 
It has been suggested common transcriptional changes in gene expression may underlie 
skeletal muscle atrophy in many systemic diseases such as diabetes, cancer, AIDS and 
renal failure (Lecker et al. 2004).  Although comparison of mRNA expression in 
skeletal muscle from rats with cancer cachexia, diabetes mellitus, uremia, fasted or 
paired fed controls revealed that over 90% of mRNAs did not change, a group of genes 
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termed atrogins were strongly induced across all conditions (Lecker et al. 2004).  These 
included MAFbx and MuRF-1, which are both involved in protein degradation via the 
ubiquitin-proteasome proteolytic pathway.  Recent evidence shows MAFbx can target 
MyoD for proteolysis during atrophy of myotubes in-vitro, as silencing of MAFbx 
using shRNAi reportedly inhibited MyoD proteolysis (Lagirand-Cantaloube et al. 2009).   
 
The evidence of a common transcriptional program potentially underlying skeletal 
muscle atrophy characteristic of chronic diseases is limited to rat models of chronic 
diseases (Lecker et al. 2004).  An important caveat to keep in mind when reviewing 
existing research on cancer cachexia pathogenesis is whether studies have been 
conducted in cancer cachexia patients or are based on animal cachexia models.  For 
example, FOXO1 has been reported to target MuRF1, MAFbx and myostatin which 
have been shown to induce cachexia in mice (McFarlane et al. 2006; Zimmers et al. 
2002), however there is no supporting evidence of higher FOXO1 in cancer cachexia 
patients (Schmitt et al. 2007). 
 
It remains to be established whether common transcriptional changes occur in cancer 
cachexia patients.  There is evidence of changes in mRNAs involved in the ubiquitin-
proteasome pathway.  For example, significantly higher ubiquitin and 20S proteasome 
subunit mRNA expression is reported in skeletal muscle from cancer patients (Williams 
et al. 1999).  In contrast, a study in a larger group of lung cancer patients reported no 
change in mRNA of ubiquitin-proteasome pathway genes (Jagoe et al. 2002).  Yet in 
gastric cancer patients ubiquitin mRNA expression was found to be higher than in 
control patients (Bossola et al. 2003).  When proteasome sub-unit expression was 
compared in patients with different cachexia severity, there appeared to be no evidence 
of changes in proteasome sub-unit mRNA in patients with less than 10% weight loss 
(Khal et al. 2005).  Taken together these studies suggest ubiquitin-proteasome gene 
expression is higher in cancer cachexia patients, but does not explain early protein 
degradation in cachexia.  Therefore, further studies are needed to identify early 
biomarkers of cachexia onset before >10% weight loss occurs. 
 
Systemic overexpression of myostatin in adult mice via activation of serum myostatin 
has been reported to induce significant muscle and fat loss comparable to human 
cachexia (Zimmers et al. 2002).  Mice injected with a Chinese hamster ovary (CHO) 
cell line with inducible myostatin expression lost on average 33% body weight 
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(Zimmers et al. 2002).  There do not appear to be any studies reporting myostatin 
expression in cancer cachexia patients.  However, patients with atrophy of type 2 non-
oxidative muscle fibres have been shown to have elevated myostatin protein, but 
unchanged myostatin mRNA (Wójcik et al. 2008).  It remains to be seen whether 
myostatin is a biomarker of cachexia.  The lack of correlation between myostatin 
mRNA and protein levels in patients with skeletal muscle atrophy indicates that 
myostatin could be regulated post-transcriptionally.  This is supported by evidence that 
a mutation in the myostatin 3’UTR in TEXEL sheep creates a miR-206 binding site 
which leads to a significant increase in muscularity via post-transcriptional suppression 
of myostatin (Clop et al. 2006).  To date no studies have examined microRNA 
expression in skeletal muscle of cancer cachexia patients, despite microRNAs 
representing an important group of global post-transcriptional gene regulators. 
3.1.2 Possible changes in muscle-specific microRNAs in cancer cachexia 
The muscle-specific microRNAs, miR-1, miR-133a and miR-206 have all been 
hypothesised to play a central role in muscle degeneration (Chen et al. 2006; van Rooij 
et al. 2008; McCarthy et al. 2007; Rosenberg et al. 2006; Kim et al. 2006), but to date 
there is very limited data from skeletal muscle biopsies of patients with muscle 
degeneration.  Early during differentiation of skeletal muscle myoblasts there is 
consistent evidence that miR-1, miR-133a and miR-206 increase dramatically (Chen et 
al. 2006; Kim et al. 2006).  In our laboratory miR-1, miR-133a and miR-206 have been 
observed to continue to increase even after initial formation of myotubes 
(Brzeszczynska et al. under revision).  Furthermore, miR-1, miR-133a and miR-206 are 
potentially regulated by myogenic differentiating factors (Rao et al. 2006; Liu et al. 
2007).  For example, MyoD, Mef2 and SRF binding sites have been identified upstream 
of the genes encoding miR-1, miR-133a and miR-206 (Zhao et al. 2005; Liu et al. 2007; 
Rao et al. 2006; Sweetman et al. 2008).  The presence of common transcription factor 
binding sites suggests that transcription of miR-1, miR-133a and miR-206 genes may be 
activated in unison (Chen et al. 2006; van Rooij et al. 2008; McCarthy, 2008).  The 
evidence showing increased miR-1, miR-133a and miR-206 transcription and mature 
miR-1, miR-133a and miR-206 abundance during skeletal muscle differentiation in-
vitro suggests these microRNAs may also have important regulatory functions in adult 
muscle growth and regeneration in-vivo (Chen et al. 2006; Rao et al. 2006; 
Brzeszczynska et al. under revision). 
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Studies on miR-1, miR-133a and miR-206 during muscle hypertrophy and atrophy have 
been mostly limited to in-vivo mouse models (McCarthy & Esser 2007; McCarthy et al. 
2007; Carè et al. 2007).  In a mouse model of cardiac hypertrophy, down-regulation of 
miR-133a was observed leading to heart failure (Carè et al. 2007).  The cardiac 
hypertrophy occurring in heart failure is associated with an increase in fibrosis and 
extracellular matrix proteins and a decline in contractile function regulated by miR-133a 
down-regulation (Pretorius et al. 2008).  However, it is not known whether miR-133a 
down-regulation in skeletal muscle leads to similar functional changes in fibrosis and 
extracellular matrix proteins.  Counter-intuitively, miR-133a and miR-1 have been 
reported to be down-regulated in skeletal muscle of mice after 7 days of functional 
overload (McCarthy and Esser, 2007).  This suggests miR-133a may be regulating 
positive functional changes in skeletal muscle while regulating negative functional 
changes in cardiac muscle. 
 
Skeletal muscle atrophy induced by unloading during space flight is reported to be 
associated with a significant down-regulation of miR-206 (Allen et al. 2009), although 
no other microRNAs were measured.  Reduced physical activity and unloading during 
bed-rest are associated with later stages of cancer cachexia (Fouladiun et al. 2007; 
Dahele et al. 2007; Moses et al. 2004; Makridis et al. 1997).  Therefore, microRNAs 
modulated during unloading and physical inactivity could be relevant in cancer cachexia.  
However, the evidence of miR-206 expression changes during atrophy appears to be 
conflicting, with reports of both up- and down-regulation of miR-206 (McCarthy, 2008; 
McCarthy et al. 2007; Yuasa et al. 2008; Allen et al. 2009).  In mdx mice, an animal 
model of muscular dystrophy, miR-206 expression is reported to be significantly 
elevated in the diaphragm but not hindlimb muscle (McCarthy et al. 2007).  A later 
study on mdx mice found elevated miR-206 expression in the tibialis anterior muscle, 
while no differences in miR-1 or miR-133a were observed (Yuasa et al. 2008).  There is 
some evidence that dystrophin may be decreased in skeletal muscle from gastro-
intestinal cancer patients similar to mdx mice (Acharyya et al. 2005).  Therefore, 
changes in microRNAs in the mdx mouse could be relevant in cancer cachexia patients, 
although microRNA changes appear to be dependent on the atrophy model used. 
 
The evidence from muscular dystrophy patients does not support the idea of a central 
role of miR-1, miR-133a and miR-206 in muscle atrophy (Eisenberg et al. 2007).  For 
example, in skeletal muscle from patients with a range of muscular dystrophies 
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characterised by reduced muscle mass, miR-1, miR-133a and miR-206 expression was 
unchanged (Eisenberg et al. 2007).  This suggests miR-1, miR-133a and miR-206 may 
not be a central characteristic of muscle wasting associated with muscular dystrophies 
in adult patients.  However, the microRNA arrays used by Eisenberg et al. were custom 
manufactured and there is no published data on the reliability or validity of these 
microRNA arrays (Ach et al. 2008; Liu et al. 2008).  Eisenberg et al. reported 
microRNA array validation data, but there appears to be limited agreement between 
microRNA array and RT-qPCR microRNA expression data, whether this was due to 
variation in the RT-qPCR data or microRNA array data is unknown.  In other studies 
microRNAs have been quantified by RT-qPCR using stem-loop primers, which have 
been subject to extensive validation studies (Chen et al. 2005).  So until more 
microRNA expression data are available from muscular dystrophy patients or the 
microRNA array platform is more widely used such findings must be interpreted 
cautiously. 
3.1.3 Possible changes in miR-21 in cancer cachexia 
The presence of systemic inflammation in cancer cachexia patients suggests 
microRNAs associated with inflammation may also be altered in cachexic muscle 
(McMillan 2009; Skipworth et al. 2007).  Recently it was reported there was a trend for 
an elevation of mature miR-21 expression in skeletal muscle from intensive care unit 
(ICU) patients and microarray data indicated precursor miR-21 was significantly up-
regulated (Fredriksson et al. 2008).  Skeletal muscle loss occurs during sepsis in ICU 
patients with multiple organ failure and the substantial loss of muscle mass can lead to 
prolonged recovery.  Surprisingly, in skeletal muscle from ICU patients, mitochondrial 
protein synthesis was maintained (Fredriksson et al. 2008).  However, ICU patients 
were being treated with insulin, which is known to stimulate protein synthesis 
(Pearlstone et al. 1994; Lundholm et al. 2007).  The predicted targets of miR-21 were 
reported to include genes involved in the ubiquitin-proteolysis pathway and the 
JAK/STAT pathway (Fredriksson et al. 2008).  Evidence from studies on miR-21 in 
cancer tumours, suggests it can regulate cell survival pathways.  However, microRNA 
targeting is reported to be context specific (Bartel, 2009), therefore it is uncertain 
whether miR-21 functions demonstrated in other cell types are relevant to skeletal 
muscle.  In patients with various muscular dystrophies miR-21 was consistently up-
regulated (Eisenberg et al. 2007).  Thus the existing evidence suggests miR-21 may be a 
plausible candidate as an early biomarker of cancer cachexia. 
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3.1.4 Identifying microRNA biomarkers in cancer cachexia 
The advances in microRNA array technology have led to many studies attempting to 
identify potential microRNA biomarkers of disease pathogenesis.  For example, 
microRNA array expression data has been used to classify different tumour types 
(Blenkiron et al. 2007; Lu et al. 2005; Dixon-McIver et al. 2008; Szafranska et al. 2008).  
MicroRNA arrays could potentially be able to identify cancer patients at risk of 
developing cachexia before significant weight loss and deterioration in quality of life.  
MicroRNA arrays are particularly advantageous as expression levels of all known 
microRNAs can be measured simultaneously and thus possible microRNA biomarkers 
to follow-up can be identified rapidly, compared to alternative approaches such as 
Northern blot or RT-qPCR (Clancy et al. 2007; Liu et al. 2008; Chen et al. 2005; 
Válóczi et al. 2004).  However, it remains imperative that microRNA array expression 
data is validated independently using an alternative technology for detection of 
microRNAs (Ach et al. 2008).  
 
The existing evidence strongly suggests microRNAs may contribute to cancer cachexia 
pathogenesis and therefore may represent possible early biomarkers of cachexia in 
cancer patients.  Specific muscle microRNAs, miR-1, miR-133a, miR-133b and miR-
206 are strongly induced during skeletal muscle differentiation, altered during 
hypertrophy and atrophy in mice (Chen et al. 2006; Nakajima et al. 2006; Boutz et al. 
2007; Yuasa et al. 2008; McCarthy et al. 2007; Kim et al. 2006; Rosenberg et al. 2006).  
Recently, miR-21 was identified as a possible modulator of muscle wasting in ICU 
patients and up-regulated in muscular dystrophy patients (Fredriksson et al. 2008; 
Eisenberg et al. 2007).  Therefore, miR-1, miR-133a, miR-133b, miR-206 and miR-21 
were hypothesised to be potential early biomarkers of cachexia.  Further novel 
microRNA biomarkers were identified through experimental validation of microRNA 
array data from cancer cachexia patients.  Evidence supporting the function of candidate 
cachexia microRNA biomarkers was examined using microarray data from cancer 
cachexia patients, to determine whether there were global changes in the expression of 
microRNA targets.  
3.1.5 Aims 
• Identify muscle microRNA biomarkers of cachexia severity in cancer patients. 
• Examine muscle microRNA target expression for evidence of microRNA function 
in cancer cachexia patients. 
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3.2. Methods 
Cancer cachexia patients were recruited as part of a wider cross-sectional study to 
discover new molecular and functional biomarkers associated with cachexia severity in 
collaboration with Prof Fearon and the Cancer cachexia group at Edinburgh University, 
UK.  I was specifically involved in examining the role of microRNAs in cancer 
cachexia. Patients had a diagnosis of upper gastrointestinal cancer (oesophageal, gastric, 
pancreatic) and were undergoing surgery for resection of primary tumour.  Healthy, 
weight stable patients undergoing surgery for benign conditions (e.g. incisional hernia 
repair) were included as controls.  All patients had the study information explained to 
them by a clinician and gave their informed consent before clinical examination.  
Patients’ weight loss was calculated based on measurement of body mass during initial 
clinical examination and patients’ estimated body mass before cancer diagnosis.  In the 
controls body mass was measured during clinical examination and no weight loss was 
reported.  Mid arm muscle circumference (MAMC) and C-reactive protein (CRP) were 
both measured. BMI was calculated as body mass (kg) / body height (m)2 based on 
estimated body mass before cancer diagnosis (pre-BMI) and patients’ body mass at 
clinical examination (post-BMI).  Muscle biopsies were taken from the rectus 
abdominis during surgery, which involved removing a 1 cm3 section of muscle by sharp 
dissection while the rectus abdominis was exposed.  The cross-sectional cancer 
cachexia study received REC approval (06/S1103/75) from the Lothian Regional Ethics 
Committee, Scotland. 
3.2.1 Approach 
Firstly, the focus was on determining whether the muscle specific microRNAs, miR-1, 
miR-133a, miR-133b and miR-206 were differentially expressed in skeletal muscle 
biopsies from control (0% weight loss), pre-cachexia (0-10% weight loss) and cachexia 
(>10% weight loss) patients.  Secondly, following up from previous work by colleagues 
in our laboratory on miR-21 expression in skeletal muscle from ICU patients (J. 
Timmons, personal communication), elevated pri-miR-21 in the ICU patients was 
confirmed, then primary and mature miR-21 expression was measured in the cancer 
cachexia patients.  Thirdly, microarray data from cancer-cachexia patients (I. Gallagher, 
personal communicaton) was used to examine changes in microRNA target expression.  
Fourthly, further potential microRNA biomarkers were measured using RT-qPCR to 
follow-up preliminary findings from microRNA array profiling (I. Gallagher, personal 
communication) as part of experimental validation.  Finally, gene ontology and pathway 
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enrichment analysis were used to explore the function of predicted targets of 
microRNAs changed in cancer cachexia. 
3.2.2 Clinical characteristics of the cancer cachexia patient cohort 
MicroRNA expression was analysed in 58 patients classified into three groups, cachexia 
pre-cachexia or control based on definitions provided by the SCRINO international 
cancer cachexia working group (Bozzetti & Mariani, 2008).  The cachexia group 
included all patients with above 10% weight loss (n = 19; males = 8, females = 11).  
The pre-cachexia group included all patients with between 0-10% weight loss (n = 32; 
males = 24, females = 8).  The control group included patients without cancer and with 
no weight loss (n = 7; males = 5, females = 2).  The patient characteristics for each 
group are shown in Table  3-1.  Age was significantly lower in the control group 
compared to the pre-cachexia and cachexia groups (P < 0.05).  BMI (at resection of 
primary tumour) and %weight loss were significantly lower in cachexia group 
compared to controls (P < 0.05).  Plasma CRP was significantly higher in the cachexia 
group compared to the pre-cachexia group (P < 0.05).  Ten patients were undergoing 
chemotherapy (n = 5 pre-cachexia; n = 5 cachexia). 
 
Table  3-1. Patient characteristics 
Patient 
characteristics 
Control (n=7) 
0% weight loss 
Pre-cachexia (n=32) 
0-10% weight loss 
Cachexia (n=19) 
>10% weight loss 
Age (y) 51 ± 15 67 ± 10* 64 ± 9* 
BMI 30.6 ± 3.4 26.6 ± 2.6 23.6 ± 4.4* 
%Weight loss 0.0 ± 0.0 4.11 ± 2.9 16.22 ± 7.2* † 
CRP (mg/l) 2.4 ± 1.8 8.3 ± 16.2 30.3 ± 43.8 † 
MAMC (cm) 25.9 ± 3.2 24.7 ± 2.6 23.9 ± 3.0 
Data show mean ± SD. * P < 0.05 compared to control. † P < compared to pre-cachexia. 
3.2.3 RNA isolation 
Patient muscle biopsy samples were prepared whilst on liquid nitrogen; 15-20 mg tissue 
was cut from each sample.  Tissue was homogenised in 1 ml of TRIzol for 15 s using a 
mini-beadbeater.  Samples were then incubated for 5 min at 25°C.  200 µl chloroform 
was added, vortexed for 15 s, then incubated for 3 min at 25°C.  Samples were then 
centrifuged at 12000g for 15 min at 4°C.  The aqueous phase was extracted and 500 µl 
isopropanol was added.  Samples were then incubated for 10 min at 25°C and 
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centrifuged at 12000g for 10 min at 4°C.  The suspension was discarded and 1 ml 70% 
EtOH was added, followed by centrifugation at 7500g for 5 min at 4°C.  The suspension 
was again discarded and the pellet air-dried for 2 min.  The RNA pellet was dissolved in 
15 µl DEPC water.  Samples were stored at -80°C prior to further analysis. 
3.2.4 Determination of RNA concentration and quality 
RNA concentration and quality was determined on RNA Nano chips using an Agilent 
2100 Bioanalyser.  The RNA Nano chip uses micro capillary electrophoresis to separate 
samples and RNA is detected via laser-induced fluorescence (Fleige & Pfaffl, 2006).  It 
is advantageous as it is sensitive to RNA concentrations down to 200 pg.  The RNA 
Nano chips were run according to the manufacturer’s instructions.  Firstly, a gel-dye 
mix was prepared using 1 µl RNA 6000 Nano dye and 65 µl Agilent RNA 6000 Nano 
gel matrix.  This was centrifuged for 10 min at 1500g and stored in the dark at 4°C.  
The RNA Nano chip was primed with 9 µl gel-dye mix using a syringe.  Then 5 µl 
RNA 6000 Nano marker was pipette into the sample wells and the ladder well.  RNA 
samples were prepared by heating on a heating block for 2 min at 70°C, cooling on ice 
for 2 min followed by centrifugation at 1000 g for 2 min.  The RNA Nano chip was 
then loaded with 1 µl sample per well and 1 µl RNA 6000 Nano ladder in the ladder 
well.  The RNA Nano chip was vortexed for 60 s at 2400 rpm and then run on the 
Agilent 2100 Bioanalyser.  
 
The Agilent 2100 software determines a RIN score for each sample based on an 
algorithm taking into account the shape of the electropherogram (Fleige & Pfaffl, 2006).  
RIN scores of 10 are optimal and represent high quality RNA with limited RNA 
degradation (Schroeder et al. 2006).  The RNA concentration is determined based on the 
area under the curve for 18S and 28S.  Many of the initial RNA samples had RIN scores 
of less than 7 and the gels showed evidence of RNA degradation (Supplementary Figure 
3-1).  The Agilent Bioanalyser 2100 is reported to be more susceptible to novice 
operator variation compared to other spectrophotometer methods of RNA quantification 
such as the Nanodrop (Ar et al. 2009).  To ensure operator error was not the cause of 
poor RIN scores, samples with poor RIN scores were re-run on the RNA Nanochips.  
There was evidence of RNA degradation in a significant proportion of the samples 
during early RNA isolation (data not shown).  This may have been the result of freezer 
breakdown affecting some muscle biopsy samples, as poor sample handling may lead to 
RNA degradation (Bustin & Nolan, 2004), but there is no data on which samples may 
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have been involved.  Nevertheless, the initial microRNA RT-qPCR analysis was 
conducted on n = 58 patient samples which all had acceptable RIN scores above seven. 
3.2.5 Mature-microRNA reverse transcription 
Reverse transcription (RT) of RNA to cDNA was conducted using the TaqMan® 
MicroRNA Reverse Transcription Kit according to the manufacturer’s instructions.  The 
RT uses microRNA specific stem-loop primers.  These first hybridise at the 3’ end of 
microRNA molecules and are then reverse transcribed using MultiScribe reverse 
transcriptase (Chen et al. 2005).  Therefore closely related microRNAs that differ by a 
single nucleotide can be quantified specifically (Chen et al. 2005).  Each RT reaction 
was set-up to contain between 2-10 ng of total RNA.  Reactants were thawed on ice and 
RT reactions were prepared.  Each RT reaction contained 0.15 µl 100 mM dNTPs, 1 µl 
MultiScribe Reverse Transcriptase [50 U/µl], 1.5 µl Reverse Transcription Buffer, 0.19 
µl RNase Inhibitor [20 U/µl] and 4.16 µl Nuclease-free water.  To each RT reaction 5 µl 
RNA was added, followed by 3 µl of RT primer.  Samples were mixed gently, 
centrifuged ~3 s at 0.5 RPM then incubated on ice for 5 min.  The reverse transcription 
was performed on a thermal cycler programmed to run for 30 min at 16°C, 30 min at 
42°C, 5 min at 85°C then held at 4°C.  cDNA samples were kept at 4°C and analysed 
within 24 h. 
3.2.6 Real-time quantitative PCR of mature-microRNAs 
TaqMan® MicroRNA Assays were used to measure the microRNAs listed in Table  3-2 
according to the manufacturer’s instructions.  Each PCR reaction was calculated to 
contain 1 µl TaqMan MicroRNA Assay [20x], 1.33 µl cDNA, 10 µl Taqman 2 x 
universal PCR master mix [No AmpErase UNG] and 7.67 µl nuclease-free water.  For 
each microRNA all patient PCR reactions were prepared in triplicate on the same 384-
well plate, triplicate no template controls (NTC) were also run.  The plate was sealed 
and spun down at 3000 rcf in a centrifuge at 4°C.  The PCR reaction was run on an 
Applied Biosystems 7300/7500 Fast Real-Time PCR system in 9600 emulation mode.  
The thermal cycling consisted of a 10 min hold at 95°C, then 40 cycles of 15 s at 95°C 
and 60 s at 60°C.  The Ct threshold was manually determined during the exponential 
fluorescence phase.  Ct values for triplicates were averaged, and ∆Ct values computed 
using RNU48, which is a small nucleolar RNA, as the endogenous control.  RNU48 
was found not to vary significantly between cachexia, pre-cachexia and control groups 
(Supplementary Figure  3-3).  Fold change was calculated using the -2∆∆CT method 
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(Schmittgen & Livak, 2008).  Taqman microRNA assays are reported to detect changes 
in microRNA abundance over seven orders of magnitude (Chen et al. 2005).  Standard 
curves were prepared for miR-133a, miR-206 and miR-1 based on five cDNA dilutions 
(data not shown).  The standard curve was linear across the range of cDNA dilutions in 
agreement with previous studies (Chen et al. 2005).  Furthermore, the Taqman 
microRNA assays appeared to specifically detect mature microRNA sequences, as there 
was no evidence of pri-microRNA or pre-microRNA detectable in RT-qPCR products 
run on an agarose gel (Supplementary Figure  3-2). 
 
Table  3-2. Mature microRNA sequences 
MicroRNA miRbase ID Mature microRNA Sequence 
Hsa-miR-1 MIMAT0000465 5’-uggaauguaaagaaguaugua-3’ 
Hsa-miR-133a MIMAT0001475 5’-uugguccccuucaaccagcugu-3’ 
Hsa-miR-133b MIMAT0000770 5’-uugguccccuucaaccagcua-3’ 
Hsa-miR-206 MIMAT0000879 5’-uggaauguaaggaagugugugg-3’ 
Hsa-miR-21 MIMAT0000076 5’-uagcuuaucagacugauguuga-3’ 
RNU48 NR_002745 5’-gaugaccccagguaacucugagugug 
ucgcugaugccaucaccgcagcgcucugacc-3’ 
 
3.2.7 Design and validation of pri-miR-21 primers 
To determine whether pri-miR-21 transcription was regulated in cachexia and to 
confirm pri-miR-21 was regulated in sepsis patients, primers were designed to amplify 
the intronic regions between the pre-microRNA hairpin and the predicted host gene 
(Figure  3-1).  All primers for pri-microRNA transcripts are listed in Table  3-3.  Primers 
were obtained from Invitrogen UK.  Primer efficiency was tested on five serial dilutions 
of cDNA using the RT-qPCR protocol described in section  4.2.7 and is shown in 
Supplementary Figure  3-4. 
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Figure  3-1.  Location of primers designed to amplify pri-miR-21.  Primers were 
also designed to amplify the predicted host gene TMEM49.  Arrows indicate 
location of forward and reverse primers. 
 
Table  3-3. Primer sequences to amplify pri-miR-21. 
Target Identifier  Primers, sequences or probes 
TMEM49 
(host gene) 
ENSG000
00062716 
F1 
R1 
5’- gcagaagccatttcaggagt -3’ (forward) 
5’- tcaaacatccaggacaacca -3’ (reverse) 
TMEM49 – 
Pri-hsa-miR-21 
ENSG000
00199004  
F2 
R2 
5’- gtcagaatagaatagaattggggttc -3’ (forward) 
5’- aaggtggtacagccatggag -3’ (reverse) 
Pri-hsa-miR-21 
–TUB1 
ENSG000
00199004 
F3 
R4 
5’- tgaataaaatccctaagaagactgc -3’ (forward) 
5’- aagaagagacaaagttgtcgatacag -3’ (reverse) 
Primers were obtained from Invitrogen, UK. 
3.2.8 Pri-miR-21 reverse transcription and real-time quantitative PCR 
RNA was reverse transcribed using a high capacity cDNA reverse transcription kit 
(Applied Biosystems, UK) and is described in detail in Chapter 4 in section  4.2.8.  
Following reverse transcription cDNA samples were stored at -20°C until further 
analysis.  SYBR green reagents (Applied Biosystems, UK) were used for RT-qPCR 
reaction to amplify regions spanning pri-miR-21 transcript; the primers used are listed 
in Table  3-3.  The preparation of each RT-qPCR reaction is described in detail in 
Chapter 4 in section  4.2.9.  The PCR reaction was run on an Applied Biosystems 
7300/7500 Fast Real-Time PCR system in standard mode.  Ct values for triplicates were 
averaged, and ∆Ct values computed using 18S as the endogenous control.  Fold change 
was calculated using the -2∆∆CT method (Schmittgen & Livak, 2008). 
3.2.9 MicroRNA array experimental validation 
Cachexia patient RNA samples were prepared as described in section  3.2.3- 3.2.4.  
Following identification of possible phenol contamination in Type 2 diabetes patient 
samples described in section  4.2.5 it was decided to reprecipitate cachexia patient RNA 
samples, thus cachexia patient RNA samples (n = 58) were re-quantified using the 
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Nanodrop spectrophotometer (Thermoscientific, UK).  The procedure for RNA 
quantification using the Nanodrop spectrophotometer is described in section  4.2.5. 
Patient characteristics are shown in Supplementary Table  3-2.  The microRNA arrays 
were conducted by colleagues on pooled cachexia patient RNA and analysed using 
Significance Analysis of Microarray (SAM) in R to determine differentially expressed 
microRNAs (I. Gallagher, personal communication) and hence is not presented herein.  
Experimental validation of the microRNA array data was conducted on 7 up-regulated 
microRNAs (miR-23a, miR-27b, miR-29a, miR-29b, miR-143, miR-195, miR-424) and 
1 down-regulated microRNA (miR-208) using RT-qPCR as described in section  3.2.5 
and  3.2.6.  The mature microRNA sequences are listed in Table  3-4. 
 
Table  3-4. Mature microRNA sequences for microRNA array validation. 
MicroRNA miRbase ID Mature microRNA Sequence 
Hsa-miR-23a MIMAT0000078 5’-aucacauugccagggauuucc-3’ 
Hsa-miR-27b MIMAT0000419 5’-uucacaguggcuaaguucugc-3’ 
Hsa-miR-29a MIMAT0000086 5’-uagcaccaucugaaaucgguua-3’ 
Hsa-miR-29b MIMAT0000100 5’-uagcaccauuugaaaucaguguu-3’ 
Hsa-miR-143 MIMAT0000435 5’-ugagaugaagcacuguagcuc-3’ 
Hsa-miR-195 MIMAT0000461 5’-uagcagcacagaaauauuggc-3’ 
Hsa-miR-424 MIMAT0001341 5’-cagcagcaauucauguuuugaa-3’ 
Hsa-miR-208 MIMAT0000241 5’-auaagacgagcaaaaagcuugu-3’ 
 
3.2.10 MicroRNA target prediction and expression analysis 
The binding of microRNA to target mRNAs occurs between the “seed” region of the 
microRNA (nucleotide 2-7 of the 5`end of the mature microRNA) and the 3`UTRs of 
the mRNAs.  Genes predicted to be regulated by specific microRNAs were obtained 
using TargetScan 4.2 (Lewis et al. 2003).  The mean absolute expression approach 
(Arora and Simpson, 2008) was used to determine whether there were detectable shifts 
in the average expression of microRNA targets in skeletal muscle from cancer cachexia 
patients when in-vivo microRNA expression was changed.  Unpublished microarray 
data were available from our laboratory (I. Gallagher, personal communication; 
Stephens et al. manuscript under revision) from n = 20 cancer cachexia patients 
included in the present study.  R and Bioconducter were used to process the data, CEL 
files were normalized using the MAS 5.0 algorithm with the simplyaffy package in 
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Bioconducter.  Present/absent calls across all chips were computed and absent probes 
were removed.  Using bioMart the present called probes were mapped to HUGO gene 
symbols from Ensembl and average gene expression computed for each patient.  
Microsoft Access database was used to link microRNA targets with gene expression 
data.  For each patient, average expression of targets for each cachexia microRNA 
biomarker was computed.  To determine whether there were any significant detectable 
shifts in microRNA target expression, differences in average microRNA target 
expression between cachexia, pre-cachexia and control groups were analysed using one-
way ANOVA. 
3.2.11 Gene ontology and pathway enrichment analysis 
Gene ontology (GO) analysis (Ashburner et al. 2000) was used to examine the functions 
of microRNA targets.  To determine which GOs may be regulated by microRNAs 
changed in cancer cachexia patients The Expression Analysis Systematic Explorer 
(EASE) (Hosack et al. 2003) was used.  EASE conducts a statistical analysis of GO 
terms associated with a list of genes (i.e. microRNA targets) and determines which GO 
terms are the most over-represented compared to the background of all genes 
represented in the human genome.  The GO analysis was based on GO terms within 
three GO classifications, Molecular Function, Cellular Component and Biological 
Process.  EASE calculates GO terms over-represented using the EASE score, which is a 
modified version of Fishers Exact probability. The Fisher exact probability is calculated 
based on the probability of the “List Hits” in the “List Total” given the frequency of 
“Population Hits” in the Population Total”. The “Population total” refers to all genes 
annotated within the specified GO classification.  “Population hits” refers to the number 
of genes associated with a given GO term in the population of genes annotated within 
the specified GO classification.  “List Hits” refers to the number of genes within the 
gene list (i.e. microRNA target list) that are associated with a given GO term.  The 
EASE score is the upper bound of the distribution of jackknifed Fisher exact 
probabilities based on 500 iterations, which helps adjust the significance of GO terms 
with only a few genes compared to GO terms with many associated genes.  EASE also 
computes an FDR, to indicate the percentage of GO terms enriched by chance.  The 
FDR provides the probability of observing a given enriched GO term from a given gene 
list by chance.  The FDR was computed from multiple iterations (n = 500) on random 
gene lists from the population.  It is important to emphasise that the GO analysis is an 
exploratory tool to discover the underlying biology of a list of genes, therefore there are 
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no specific p-value cut-offs.  Instead the over-representated GO terms were ranked 
based on an FDR of less than 10%.  All GO analysis results are tabulated in the 
appendix. 
 
The pathway analysis was conducted using EASE as described previously to search for 
microRNA targets over represented in pathways based on the Kyoto Encyclopedia of 
Genes and Genomes (KEGG; Kanehisa & Goto, 2000).  The results are graphically 
presented showing the number of microRNA targets enriched or over-represented in a 
given pathway ranked by FDR.  No specific P value cut-offs were specified, but results 
are presented when FDR was less than 10%.  It is important to highlight that the 
pathway analysis is exploratory, to indicate if a microRNA may co-ordinately target 
specific signaling pathways relevant to cancer cachexia.  KEGG pathways are based on 
the current knowledge of genes associated with signaling pathways, therefore 
microRNA targets which may be relevant to disease pathogenesis may not be 
considered if KEGG pathway enrichment is considered alone, hence the approach of 
using both GO and pathway enrichment analysis. 
3.2.12 Statistical Analysis 
Statistical analysis was conducted in Prism v 5.0 (GraphPad).  Expression of mature 
miR-1, miR-133a, miR-133b, miR-206 was compared between cachexia, pre-cachexia 
and control groups (n = 58) using one-way ANOVA assuming equal variances between 
groups based on Bartlett’s test.  In addition, expression of primary and mature miR-21 
was compared in pancreatic cancer cachexia patients, ICU patients and controls using 
one-way ANOVA.   Post-hoc Bonferroni tests were performed where necessary to 
identify inter-group differences.  When the assumption of equal variances was not met 
the non-parametric Kruskal Wallis test was run. 
 
The classification of patients into discrete groups (cachexia, pre-cachexia and control) 
does not take into account that weight loss or cachexia severity is a continuous variable.  
Therefore another approach was taken; linear regression was used to test whether 
individual patient microRNA expression could explain a significant proportion of the 
variance in weight loss.  To eliminate any additional variation associated with cachexia 
development in different cancer types, further linear regression was conducted on the 
pancreatic cancer cachexia patients only (n = 19) to determine whether cancer cachexia 
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severity was associated with microRNA expression specifically in pancreatic cancer 
patients. 
 
The experimental validation of microRNA arrays was conducted on a smaller patient 
cohort (n = 20), differences in expression of miR-23a, miR-27b, miR-29a, miR-29b, 
miR-143, miR-195, miR-208 and miR-424 between cachexia, pre-cachexia and control 
patients were compared using one-way ANOVA.  Data is presented as mean ± SE 
unless otherwise stated.  P <0.05 was considered as significant.   
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3.3. Results 
3.3.1 Muscle microRNA expression in cancer cachexia patients 
Several microRNAs are abundantly expressed during skeletal muscle differentiation, yet 
their role in adult skeletal muscle is unknown.  The expression of mature miR-1, miR-
133a, miR-133b and miR-206 was measured in skeletal muscle biopsies from cancer 
patients with pre-cachexia or cachexia and compared to controls. 
 
Figure  3-2. Fold change in (A) miR-1, (B) miR-206, (C) miR-133a, and (D) miR-
133b expression in skeletal muscle from cachexia patients with >10% weight loss 
(n = 19), pre-cachexia patients with 0-10% weight loss (n = 32), and control 
patients (n = 7).  Data normalised to control and presented as mean ± SE. 
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Figure  3-2 shows the fold change in miR-1, miR-133a, miR-133b and miR-206 
expression in pre-cachexia and cachexia patients compared to controls.  No significant 
differences were detected.  The lack of significant differences in muscle miR-1, miR-
133a, miR-133b and miR-206 expression between controls, pre-cachexia and cachexia 
patients may have been due to the grouping criteria. 
 
To examine this further, miR-1, miR-133a, miR-133b and miR-206 expression was 
plotted against weight loss (Supplementary Figure  3-5).  Bivariate correlations were 
used to examine whether there was evidence of a linear association between patient 
weight loss and miR-1, miR-133a, miR-133b and miR-206 expression.  There appeared 
to be only weak correlations between microRNA expression and %weight loss among 
cancer patients with various tumours including pancreatic, oesphagus, gastric and 
oesophagogastric junction (OGJ) (Supplementary Figure  3-5).  This may have been due 
to variability in microRNA expression among cancer patients with minimal weight loss 
since diagnosis. 
 
An alternative explanation was that different cancer types might influence microRNA 
expression during cachexia development, which would explain the lack of a clear 
association between muscle growth-linked microRNAs and %weight loss.  In the 
present cancer cachexia cohort, around 30% patients had pancreatic tumours 
(Supplementary Table 3-1).  The incidence of cachexia is reported to be higher in 
pancreatic cancer patients (Fearon, 1992), although it has not yet been establish why 
there is a higher incidence of cachexia among pancreatic cancer patients.  Therefore, 
miR-1, miR-133a, miR-133b and miR-206 expression was re-analysed focusing on the 
pancreatic cancer patients only (n = 19; Supplementary Table 3-1). 
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3.3.2 Muscle microRNA expression predicts weight loss in pancreatic cancer 
The association between miR-1, miR-133a, miR-133b, miR-206 and weight loss was 
examined in pancreatic cancer patients (n = 19) with varying weight loss and controls 
with no weight loss (Figure  3-3).  Multiple linear regression was used to examine 
whether there was a significant relationship present.   
 
Table  3-5. Multiple regression model of muscle specific microRNA expression as a 
predictor of weight loss in pancreatic cancer cachexia patients. 
Variable Coefficient T ratio P-value 
Constant 127.4 ± 28.0 4.6 <0.001 
miR-1 -2.9 ± 4.3 0.7 0.52 
miR-206 5.8 ± 3.8 1.5 0.15 
miR-133a 16.7 ± 5.0 3.3 0.005 
miR-133b 1.5 ± 4.5 0.3 0.74 
 
A multiple linear regression model including miR-1, miR-133a, miR-133b and miR-206 
explained 66% of the variance in weight loss (F = 6.7, P = 0.003; Table  3-5).  Thus 
lower miR-1, miR-133a, miR-133b and miR-206 expression was associated with higher 
weight loss in pancreatic cancer patients (Figure  3-3).  The microRNA expression data 
was normally distributed, there was no evidence of multicollinearity (VIF<0.75) and the 
residuals appeared to be randomly distributed (Supplementary Figure  3-6).  However, 
only miR-133a was a significant contributer to the regression model (t = 3.3, P = 0.005), 
which suggest miR-1, miR-206 and miR-133b expression data were not essential and a 
simpler regression model based on miR-133a alone may well predict weight loss. 
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Figure  3-3. (A) miR-1, (B) miR-206, (C) miR-133a and (D) miR-133b expression 
correlates with weight loss in pancreatic cancer patients.  Higher ∆CT indicates 
lower microRNA expression. 
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3.3.3 Expression of microRNA biogenesis genes in cancer cachexia patients 
Regulation of microRNA biogenesis gene and protein expression can lead to global 
effects on mature microRNA expression.  Expression of the microRNA biogenesis 
genes DROSHA, DGCR8, DICER1 and AGO2 was determined from patients’ 
microarray data (n = 20). However, there were no significant differences in DROSHA, 
DGCR8, DICER1 or AGO2 expression between controls, pre-cachexia and cachexia 
patients (Figure  3-4). 
Figure  3-4. Expression of microRNA biogenesis genes in cancer cachexia patients. 
(A) DROSHA, (B) DGCR8, (C) DICER1 and (D) AGO2. Data based on cachexia 
patient’s microarray data and shown as mean ± SE. 
Chapter 3 – Skeletal muscle microRNAs in cancer cachexia patients 
61 
3.3.4 Muscle wasting and growth pathways enriched with microRNA targets 
MicroRNAs may function co-ordinately on molecular pathways.  Pathway enrichment 
analysis can help identify microRNA targets enriched among known pathway genes.  
The KEGG pathway annotations were used to determine pathways enriched with miR-
1/206 and miR-133a/b targets (Figure  3-5).  The false discovery rate was calculated to 
limit identification of spurious pathways.  Pathways significantly enriched with both 
miR-1/206 and miR-133a/b targets that may be regulated in cancer cachexia included 
the MAPK signaling pathway, the insulin signaling pathway, the JAK-STAT pathway, 
and regulation of actin cytoskeleton (Figure  3-5). 
 
Gene ontology enrichment analysis was used to further explore the possible functional 
role of miR-1/206 and miR-133a/b down-regulation in pancreatic cancer cachexia 
patients. GO enrichment analysis was conducted to find GO molecular function terms, 
GO cellular component terms and GO biological process terms significantly enriched 
among miR-1/206 and miR-133a/b targets (Appendix  7-1).  Molecular functions 
significantly enriched among miR-133a/b targets included protein phosphatase activity 
and transcription regulator activity (P <0.01, FDR <10%).  Analysis of microRNA 
target expression found no evidence of miR-1, miR-133a, miR-133b or miR-206 action 
at the mRNA level in cachexia patients with varying weight-loss (Supplementary Figure 
 3-7), but this does not rule out miR-1, miR-133a, miR-133b or miR-206 action at the 
protein level in cachexia which was not measured in the present study. 
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Figure  3-5. KEGG pathways enriched with (A) miR-1/206 and (B) miR-133 
targets.  Data shows number of microRNA targets (black-bars) and false discovery 
rate (grey-line) based on pathway enrichment analysis. 
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3.3.5 Primary and mature miR-21 expression in pancreatic cancer patients 
Chronic inflammation and loss of muscle mass is a characteristic of ICU patients.  
However, it is not known whether the mechanism leading to loss of muscle mass in ICU 
patients also occurs in cancer cachexia patients.  Recently published data from our 
laboratory showed mature miR-21 was unchanged in ICU patients, while Affymetrix 
probe data suggested primary miR-21 was significantly elevated (Fredriksson et al. 
2008).  RT-qPCR was used to confirm whether pri-miR-21 was elevated in the ICU 
patients.  In the ICU patients, pri-miR-21 expression was significantly higher than 
controls (P < 0.01; Figure  3-6). 
 
Figure  3-6.  Fold change in (A) pri-miR-21 and (B) TMEM49 (host) gene 
expression in ICU patients with sepsis compared to control patients. Data shown as 
mean ± SE.  *** P < 0.001 ** P < 0.01. 
 
Furthermore, TMEM49 which is the host gene from which pri-miR-21 is transcribed 
was also significantly higher in the ICU patients (Figure  3-6) compared to the control 
patients (P < 0.001).  The confirmation of large differences between pri-miR-21 and 
mature miR-21 expression in the skeletal muscle of ICU patients led to the hypothesis 
that pri-miR-21 or mature miR-21 could also be dysregulated in the skeletal muscle of 
cancer cachexia patients.  Mature miR-21 expression was measured in pancreatic cancer 
patients classified into two groups either pre-cachexia with less than 10% weight loss (n 
= 10) or cachexia with more than 10% weight loss (n = 9) and compared to controls 
with no weight loss (n = 7).  Mature miR-21 appeared to increase 50% in the pre-
cachexia group and 120% in the cachexia group compared to controls (Figure  3-7).  
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However, the increase in mature miR-21 was not significant (F = 0.8, P > 0.05).  There 
appeared to be a 90% increase in pri-miR-21 expression in the pre-cachexia compared 
to the control (Figure  3-7), but this was not significant (F = 1.1, P > 0.05). 
 
Figure  3-7.  (A) Fold change in mature miR-21 and (B) pri-miR-21 expression
in pancreatic cancer patients with pre-cachexia (0-10% weight loss) or cachexia 
(>10% weight loss) compared to controls.  Data shown as mean ± SE. 
3.3.6 Muscle wasting pathways enriched with miR-21 targets 
Pathway enrichment analysis revealed miR-21 targets may be involved in several 
pathways, including JAK-STAT, MAPK signaling, apoptosis and cytokine-pathways 
(Figure  3-8).  GO enrichment analysis of miR-21 targets associated with GO Molecular 
function, GO Cellular component and GO Biological process terms are summarised in  
Appendix  7-4.  There was a significant enrichment of genes involved in ubiquitin-
protein ligase activity among the miR-21 target genes (P < 0.01, FDR = 0%), including 
FBXO11, HIP2, RNF103, RNF111, TRIM33, UBE2D3, and UBE4A (Appendix 7-4). 
 
There appeared to be no effect of miR-21 on target expression in cachexia patients at 
the mRNA level.  No significant correlation was found between average miR-21 target 
expression and weight loss in patients (Supplementary Figure  3-9).  This suggests any 
potential effect of miR-21 on muscle wasting pathways in cachexia occurs at the protein 
level, although target proteins were not measured in patients in the present study. 
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Figure  3-8. Top ranked KEGG pathways enriched with miR-21 targets.
Data shows the number of miR-21 targets (black-bars) and false discovery rate 
(grey-line) based on pathway enrichment analysis. 
3.3.7 Experimental validation of microRNA arrays 
To search for further potential candidate microRNAs involved in cancer cachexia, 
microRNA arrays were conducted on pooled patient RNA (I. Gallagher, personal 
communication).  Experimental validation was conducted using RT-qPCR based on a 
subset of cancer cachexia patients profiled on microarrays and microRNA arrays (n = 
20; Supplementary Table  3-2) with varying tumour types. 
 
The experimental validation was conducted on 7 microRNAs (Supplementary Table 
 3-3; miR-23a, miR-27b, miR-29a, miR-29b, miR-424, miR-195 and miR-143) 
identified as up-regulated and 1 microRNA (miR-208) identified as down-regulated 
during weight loss based on SAM analysis of microRNA array data. 
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Figure  3-9. Fold change in (A) miR-23a, (B) miR-27b, (C) miR-29a, (D) miR-29b, 
(E) miR-143, (F) miR-195, (G) miR-208 and (H) miR-424 expression in skeletal 
muscle from cachexia patients with >10% weight loss, pre-cachexia patients with 
0-10% weight loss and control patients (n = 20).  Data normalised to control and 
presented as mean ± SE. 
 
Suprisingly, there were no significant differences detected in miR-23a, miR-27b, miR-
29a, miR-29b, miR-143, miR-195, miR-208 and miR-424 expression (Figure  3-9) 
between the cachexia, pre-cachexia and control group.  The lack of any significant 
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dectectable differences may have been due to variation in microRNA expression within 
the patient groups (F = 0.5, P > 0.05). 
 
3.3.8 Muscle wasting and growth pathways targeted by cachexia microRNAs 
The present RT-qPCR results failed to confirm existing microRNA array data (I. 
Gallagher, personal communication).  Nevertheless, pathway enrichment analysis of 
miR-143 and miR-195/424 targets revealed enrichment of pathways previously linked 
to cachexia including the ubiquitin-mediated proteolysis pathway and the apoptosis 
pathway (Supplementary Figure  3-8).  Among the miR-195/424 targets were genes 
involved in the ubiquitin-mediated proteolysis pathway, including BTRC, CDC27, 
CUL2 and FBXW7.  The miR-195/424 targets enriched among the apoptosis pathway 
genes included AKT3, BCL2, CAPN6, PIK3R1, PPP3CB, PRKACA and PRKAR2A.  
Interestingly, the muscle growth linked MAPK pathway was enriched with miR-23a, 
miR-27b, miR-143 and miR-195/424 targets (Figure  3-10; Supplementary Figure  3-8). 
 
Pathway enrichment analysis of miR-23a targets revealed significant enrichment of 
genes involved in MAPK signaling, focal adhesion and ubiquitin-mediated proteolysis 
(Figure  3-10).  The pathway enrichment analysis of miR-27b targets also revealed 
significant enrichment of genes associated with MAPK signaling and focal adhesion 
pathways.  In addition, genes involved in insulin signaling and calcium signaling were 
enriched among miR-27b targets (Figure  3-10). 
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Figure  3-10. KEGG pathways enriched with (A) miR-23a and (B) miR-27b targets.
Data shows number of microRNA targets (black-bars) and false discovery rate 
(grey-line) based on pathway enrichment analysis. 
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3.3.9 Cachexia microRNAs may target muscle wasting gene groups 
GO enrichment analysis of GO Molecular function terms, GO Cellular component 
terms and GO Biological process terms associated with miR-23a, miR-27b, miR-143, 
miR-195/424 targets revealed enrichment of gene functions linked with muscle-wasting 
and muscle growth.  Ubiquitin cycle genes were enriched among miR-27b targets 
(Appendix 7-10), which may contribute muscle protein breakdown via the ubiquitin 
mediated proteolysis pathway.  Muscle myosin genes were found to be miR-23a targets, 
which is in agreement with the decreased myosin expression that has been reported in 
cachexia patients (Ramamoorthy et al. 2009; Schmitt et al. 2007).  Cell proliferation and 
cell cycle genes were also enriched among miR-23a targets (Appendix  7-7).  There was 
enrichment of miR-195/424 targets associated with ubiquitin dependent protein 
catabolism including BTRC, FBXO21, SIAH1, UBE4B, USP14, USP15, USP2, USP25, 
USP6 and USP9X (Appendix 7-22).  Insulin-like growth factor genes and epidermal 
growth factor receptor genes were enriched among miR-143 targets including, ERBB3, 
ERBB4 and IGF1R, CTGF and IGFBF5 (Appendix  7-19). 
3.3.10 Expression of miR-23a and miR-27b targets correlates with weight loss 
MicroRNA target expression was examined to determine whether there was any in-vivo 
evidence of miR-23a, miR-27b, miR-29a, miR-29b, miR-424, miR-195, miR-143 or 
miR-208 action on weight loss in cancer cachexia patients.  There were no correlations 
found between miR-29a, miR-29b, miR-424, miR-195, miR-143 or miR-208 target 
expression and weight loss (Supplementary Figure  3-9).  However, there was a 
significant negative correlation between miR-23a and miR-27b target expression and 
patient weight loss (Figure  3-11; r = -0.56, P <0.01; r = -0.67, P <0.01). 
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Figure  3-11. (A) miR-23a and (B) miR-27b targets correlate with weight loss.
Average microRNA target intensity for each patient was determined from 
cachexia patient microarray data (n = 20). 
 
Furthermore, there was a negative correlation between miR-143 target expression and 
patient weight loss (Supplementary Figure  3-9; r = -0.45, P <0.05).  Interestingly, miR-
23a is predicted to target MAFbx and MuRF1 (two specific muscle wasting associated 
genes).  Evidence of in-vivo target suppression would be indicated by a negative 
correlation between target gene expression and microRNA expression (Bartel, 2009), 
but no correlation was found between miR-23a and MAFbx or MuRF1 expression. 
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3.4. Discussion 
The pathogenesis of cancer cachexia is largely unknown and there are currently no early 
indicators of cachexia susceptibility among cancer patients (Tan & Fearon 2008; 
Bozzetti & Mariani, 2008; Skipworth et al. 2007; Tan et al. 2008).  Yet it is well 
established that cachexia has major implications for quality of life, morbidity and 
mortality in cancer patients (Bruera, 1997).  The focus of the present study was to 
identify potential biomarkers of cancer cachexia.  MicroRNAs have emerged as novel 
biomarkers in several cancers and can be used to classify tumour types (Blenkiron et al. 
2007; Lu et al. 2005; Szafranska et al. 2008), but whether microRNAs could be novel 
biomarkers of skeletal muscle wasting in cancer cachexia is unknown. 
3.4.1 Evidence of muscle microRNAs as biomarkers of cancer cachexia 
In the present study microRNAs known to be highly expressed in skeletal muscle and 
important for myogenesis were examined for association with cancer cachexia severity.  
Despite the significant weight loss in the cachexia group there were no significant 
differences in miR-1, miR-133a, miR-133b or miR-206 expression between cachexic 
patients and controls.  The lack of any significant differences was somewhat surprising 
given the established role of these microRNAs in myogenesis and muscle growth (Kim 
et al. 2006; Nakajima et al. 2006; Chen et al. 2006; Boutz et al. 2007; van Rooij et al. 
2008).  There are other explanations that may explain the lack of differences in muscle 
growth associated microRNAs.  For example, the heterogeneity in miR-1, miR-133a, 
miR-133b and miR-206 expression could be a reflection of the cachexia state.  There 
has been no universal cause for cachexia identified, for some patients microRNA 
expression may be a factor but for others it may not be an important factor. 
 
Alternatively, the classification of patients into pre-cachexia and cachexia groups 
perhaps hides the sensitivity of muscle microRNA expression to small changes in 
muscle mass.  The idea of classifying cancer patients as pre-cachexic or cachexic based 
on below or above 10% weight loss was based on a proprosal by an international cancer 
cachexia working group (Bozzetti & Mariani, 2008).  Instead, the association between 
individual patients’ microRNA expression and weight loss was examined, which 
revealed a modest negative correlation between miR-133a expression and weight loss 
across cancer patients with different tumour types, but it was not possible to determine 
whether miR-133a expression was also affected by weight loss.  The prevalence of 
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cachexia has been reported to be higher among pancreatic cancer patients compared to 
other cancer patients (Fearon, 1992).  Therefore, miR-1, miR-133a, miR-133b and miR-
206 expression was analysed again in the pancreatic cancer patients only.  Interestingly, 
in the pancreatic cancer patients there was a significant association between miR-1, 
miR-133a, miR-133b and miR-206 expression and weight loss, which was not apparent 
when microRNA expression data from the entire cancer cachexia cohort (n = 58) was 
analysed. Although it appeared miR-133a was the strongest predictor of weight loss in 
the pancreatic cancer patients.  Thus this study provides the first evidence that miR-1, 
miR-133a, miR-133b and miR-206 may be potential biomarkers of cancer cachexia and 
could be useful for identifying pancreatic cancer patients with early signs of skeletal 
muscle wasting. 
3.4.2 Functional role of microRNAs in pancreatic cancer cachexia patients 
Next it was important to establish whether these muscle microRNAs are not only 
potential biomarkers of cachexia, but also play a functional role in cachexia 
pathogenesis in pancreatic cancer patients.  Gene ontology (GO) enrichment analysis 
was used to identify functional gene groups, which were targeted by miR-1, miR-133a, 
miR-133b and miR-206.  Both miR-1 and miR-206 have many common targets as they 
are from the same microRNA family and have similar target seed sequences.  Similarly, 
both miR-133a and miR-133b have many common targets, as they are from the same 
microRNA family and only differ by a single nucleotide.  Biological processes enriched 
with over fifty miR-1/206 targets included regulation of cellular physiological process, 
regulation of cellular metabolism and regulation of transcription.  Muscle development 
genes were also significantly enriched with miR-1/206 target sites.  Molecular functions 
enriched among miR-1/206 targets included transcriptional regulator activity, which 
was also enriched among miR-133a/133b targets.  The targeting of transcriptional 
regulators suggests miR-1/206 and miR-133a/133b may have widespread indirect 
effects on gene expression.  The functional role of miR-1/206 and miR-133a/133b in 
cancer cachexia is not clear.  
 
In C2C12 myoblasts miR-1 and miR-206 have both been shown to promote 
differentiation.  The role of miR-133a in developing muscle is equivocal because miR-
133a promotes proliferation in myoblasts (Chen et al. 2006), but it is strongly induced 
during myogenesis and differentiation of myoblasts into myotubes (Boutz et al. 2007; 
Rao et al. 2006).  Conversely, this would suggest that down-regulation of miR-1, miR-
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133a and miR-206 may be necessary for proliferation and stem-cell renewal.  
Previously, it has been suggested cachexia in skeletal muscle may lead to increases in 
muscle stem cells populations in an attempt to maintain the muscle mass (Berardi et al. 
2008).  The finding of elevated CD45 (+) hematopoietic stem cells in the skeletal 
muscle of C-26 tumour-bearing mice supports the idea that muscle regeneration may by 
occurring during cachexia (Berardi et al. 2008). 
 
There are an increasing number of miR-1 (Yu et al. 2008; Vinther et al. 2006; Nakajima 
et al. 2006; Ikeda et al. 2009; Simon et al. 2008; Shan et al. 2009), miR-133a (Shan et al. 
2009; Yin et al. 2008; Duisters et al. 2009; Chen et al. 2006; Boutz et al. 2007; Chen et 
al. 2009) and miR-206 (Anderson et al. 2006; Rosenberg et al. 2006; Kim et al. 2006; 
Boutz et al. 2007) targets which have been experimentally validated in different studies.  
Two studies have shown IGF-1 can be repressed by miR-1/206 in myoblasts (Yu et al. 
2008; Shan et al. 2009).  IGF-1 is a positive regulator of muscle growth and can inhibit 
FOXO1 mediated atrophy (Stitt et al. 2004).  In multiple atrophy-inducing models IGF 
is down-regulated (Lecker et al. 2004).  In colorectal cancer patients with cachexia IGF-
1 is decreased, but in gastric cancer patients with cachexia IGF-1 is elevated (Huang et 
al. 2005).  Therefore, the present data suggest IGF-1 targeting by miR-1/206 may be 
partly compensatory in cancer cachexia patients.   
 
Global protein profiling using SILAC in HeLa cells transfected with a miR-1 mimic 
reported 11 proteins were suppressed and of these 6 were also repressed in a 3’UTR 
reporter assay (Vinther et al. 2006).  These miR-1 targets included ADAR, HNRPU, 
DHX15, G6PD, CAP1 and TPM3.  ADAR is an adenosine deaminase that acts on RNA 
converting adenosines to inosine known as A to I editing.  In the human transcriptome 
widespread A to I editing has been reported (Athanasiadis et al. 2004), furthermore A to 
I editing in humans predominantly occurs in non-coding RNA regions.  Therefore miR-
1 targeting of ADAR could have potentially widespread effects, for example by 
modifying microRNA target sites in 3’UTRs.  However, the function of ADAR in 
human skeletal muscle has not been examined.  HNRPU is a heterogeneous nuclear 
ribonucleoprotein, which is involved in alternative splicing of genes (Castle et al. 2008) 
and has more recently been linked to microRNA processing (Guil & Cáceres, 2007; 
Michlewski et al. 2008).  Both ADAR and HNRPU have not been previously linked to 
muscle wasting in cancer cachexia patients.  MEF2A is a muscle transcription factor, 
reportedly negatively regulated by miR-1 (Ikeda et al. 2009; Simon et al. 2008), 
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although a MEF2 binding site may also regulate transcription of primary transcripts 
encoding miR-1, miR-133 and miR-206 (Liu et al. 2007).  Muscle wasting in cancer 
cachexia patients has not been previously associated with MEF2A. 
 
Targets of miR-133a have been experimentally validated in a variety of cell types, but it 
is unknown how relevant these targets are in skeletal muscle.  Overexpression of miR-
133 in cardiomyocytes decreased CTGF protein and production of collagens (Duisters 
et al. 2009).  Furthermore, miR-133 was shown to target TGIF-β in fibroblasts and 
overexpression of miR-133 increased cellular collagen (Duisters et al. 2009).  TGIF-β 
treatment in nude mice is reported to be associated with interstitial fibrosis and cachexia 
(Zugmaier et al. 1991), but there have been no reports yet of fibrosis occurring in cancer 
cachexia patients.  In addition, TGF-β inhibits myogenesis mediated by CDC42 and 
activation of the JNK pathway (Meriane et al. 2002).  These studies suggest miR-133 
down-regulation may promote fibrosis. 
 
Taken together the evidence from studies experimentally validating miR-1, miR-133 
and miR-206 targets suggest their down-regulation in pancreatic cancer patients with 
cachexia may trigger positive and negative responses in skeletal muscle.  Targeting of 
muscle transcription factors and translational regulators such as HNRNP suggests miR-
1, miR-133 and miR-206 may have widespread indirect effects.  However, a global 
proteomic profiling approach would be required to establish the importance and 
relevance of miR-1, miR-133 and miR-206 regulation in skeletal muscle during cancer 
cachexia pathogenesis in-vivo. 
3.4.3 Evidence of miR-21 as a biomarker of cancer cachexia 
MicroRNA-21 is reported to be up-regulated in cancer (Iorio et al. 2005).  In the present 
study miR-21 expression was measured in cancer cachexia patients to determine 
whether it was a biomarker of cancer cachexia severity.  Increases in pri- and mature 
miR-21 expression were observed in cachexia patients with >10% weight loss, but the 
>100% change was not significant.  The pathway enrichment and GO enrichment 
analysis suggested miR-21 might have a functional role in cancer cachexia.  Targets of 
miR-21 were enriched in the JAK-STAT, MAPK signaling, apoptosis and cytokine-
cytokine pathways.  Furthermore, miR-21 targets were enriched for ubiquitin-protein 
ligase activity and increased ubiquitin-proteosome components have been reported in 
cancer patients.  For example, significantly higher ubiquitin and 20S proteasome 
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subunit mRNA expression was found in skeletal muscle from cancer patients (Williams 
et al. 1999).  In addition, ubiquitin mRNA was found to be higher in gastric cancer 
patients than control patients (Bossola et al. 2003).  However, the increase in miR-21 in 
cancer cachexia patients would suggest miR-21 may be a post-transcriptional activator 
of ubiquitin-protein ligase targets which would be unusual as most microRNAs 
suppress target expression (Bartel, 2009).  On the other hand miR-21 could be up-
regulated in cancer cachexia patients as a compensatory mechanism to reduce ubiquitin-
system activity 
 
Past studies have shown apoptosis genes are targeted by miR-21 in cancer cells.  For 
example, knockdown of miR-21 activates caspases and leads to increased apoptotic cell 
death in glioblastoma cells (Chan et al. 2005).  The pro-inflammatory cytokine IL-6 has 
been shown to induce miR-21 expression in myeloma cells mediated by STAT3 
(Löffler et al. 2007).  Pro-inflammatory cytokines including IL-6 have been associated 
with survival in pancreatic cancer cachexia patients (Moses et al. 2009).  These studies 
suggest IL-6 could be an inducer of miR-21 in cancer cachexia patients.  Recently miR-
21 was shown to target SPRY1 augmenting the MAPK/ERK pathway in fibroblasts 
contributing to myocardial disease (Thum et al. 2008b), which supports the present 
pathway enrichment analysis showing miR-21 targets were significantly enriched 
among the MAPK pathway genes.  Furthermore, activation of MAPK/ERK in skeletal 
muscle has been reported in response to skeletal muscle overload such as resistance 
exercise and promotes skeletal muscle growth (Carlson et al. 2001). 
 
Taken together these studies suggest miR-21 is a negative regulator of cell survival 
triggering apoptosis and ubiquitin-protein ligase activity, which is counterintuitive as 
miR-21 was up-regulated in cancer cachexia patients in the present study.  However, 
miR-21 up-regulation in cachexia may also suppress MAPK pathway genes associated 
with muscle growth.  Importantly, there have been no studies to date validating miR-21 
targets in skeletal muscle.  Therefore, the function of miR-21 in skeletal muscle remains 
largely unknown. 
3.4.4 Experimental validation of microRNA arrays 
To identify further potential microRNA biomarkers of cancer cachexia, RT-qPCR was 
conducted to measure microRNAs indicated as differentially expressed in cachexia 
based on microRNA array data (I. Gallagher, personal communication).  These were 
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miR-23a, miR-27b, miR-29a, miR-29b, miR-143, miR-195, miR-424 indicated as up-
regulated and miR-208 indicated as down-regulated in cachexia by the microRNA 
arrays (I. Gallagher).  However, the RT-qPCR microRNA expression data were 
equivocal, as the significant differential expression of these microRNAs shown by 
microRNA arrays was not observed in the present study when individual patient 
microRNA expression was measured using RT-qPCR.  There appeared to be large 
variability in the RT-qPCR microRNA expression data, thus differences between 
control, pre-cachexia and cachexia groups were not found to be significant.  There 
appeared to be between 30-100% changes in miR-29a, miR-143, miR-195 and miR-424, 
while miR-23a, miR-27b and miR-208 appeared to be reduced by 10-35% in cachexia 
patients. 
 
A possible explanation for the discrepancy between microRNA array data and RT-
qPCR microRNA expression data may be that patient RNA was pooled for the 
microRNA arrays to reduce costs, while microRNA expression was measured using 
RT-qPCR in individual patients.  Pooling patient RNA may have reduced the effects of 
biological variance during the microRNA array analysis, while true biological variance 
in cachexia patients was retained in the analysis of microRNA RT-qPCR expression 
data.  Therefore it would be advisable when attempting to identify novel microRNA 
biomarkers of chronic diseases using microRNA array profiling to use individual patient 
RNA if costs and time allow. 
 
Intriguingly, the pathway enrichment analysis indicated miR-195/424 target genes 
BTRC, CDC27, CUL2 and FBXW7 are involved in ubiquitin-mediated proteolysis.  In 
addition, apoptosis pathway genes were enriched among miR-195/424 targets.  The 
results of the gene ontology enrichment analysis further suggested miR-195/424 
involvement in protein degradation, as miR-195/424 targets were found to be associated 
with ubiquitin dependent protein catabolism and ubiquitin cycle functions.  Conversely, 
positive regulators of muscle anabolism and growth were found enriched among miR-
143 targets, including insulin-like growth factor genes and epidermal growth factor 
receptor genes.  The GO and pathway enrichment analysis also identified ubiquitin 
proteolysis genes as predicted targets of miR-23a and miR-27b, therefore the expression 
of miR-23a and miR-27b targets was examined further. 
Chapter 3 – Skeletal muscle microRNAs in cancer cachexia patients 
77 
3.4.5 Evidence of miR-23a and miR-27b action on targets in cancer cachexia 
Global analysis of microRNA target expression using microarray data can provide 
evidence of microRNA function via mRNA cleavage (Lim et al. 2005; Sood et al. 2006; 
Arora & Simpson, 2008).  Past studies have reported suppression of hundreds of miR-
133 target mRNAs in response to miR-133 overexpression in HeLa cells (Lim et al. 
2005).  In addition, microRNA expression levels have been shown to inversely correlate 
with mRNA target expression in different tissues (Lim et al. 2005; Sood et al. 2006; 
Arora & Simpson 2008).  In skeletal muscle inverse correlations are reported between 
up-regulated microRNAs and down-regulated target mRNAs (Arora & Simpson, 2008).  
It has been suggested that existing patient microarray data can be mined for evidence of 
microRNA regulation (Arora & Simpson, 2008).  Microarray data was available from 
the cancer cachexia patients in the present study.  A microRNA target expression 
signature was determined for each microRNA measured based on averaging the 
expression of all mRNAs with predicted microRNA binding sites for each patient.  
Linear regression was used to determine whether the patient microRNA target 
signatures were associated with cancer cachexia severity.  The miR-23a and miR-27b 
target signatures were negatively associated with weight loss, which suggests miR-23a 
and miR-27b targets may be suppressed in cachexia patients with high weight loss in 
accordance with microRNA array expression data (I. Gallagher, personal 
communication). 
 
Skeletal muscle atrophy has been consistently linked with increased MAFbx and 
MuRF1 expression (Lecker et al. 2004).  Interestingly, both MAFbx and MuRF1 
harbour a miR-23a binding site in their 3’UTRs.  However, there was no significant 
association between miR-23a expression and MAFbx or MuRF1.  This does not 
preclude the possibility that miR-23a may target MAFbx or MuRF1 for translation 
repression without target mRNA degradation. 
3.4.6 MicroRNA processing genes are unchanged in cancer cachexia 
Changes in microRNA processing genes may help explain the down-regulation of miR-
1, miR-133a, miR-133b and miR-206 observed here in skeletal muscle from pancreatic 
cancer patients with higher weight loss.  The main microRNA processing genes that 
have been studied previously are DROSHA, DICER and AGO2 (Murphy et al. 2008).  
In the present study no differences in the expression of the main microRNA processing 
genes were found between control, pre-cachexia and cachexia patients, but this does not 
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preclude that post-transcriptional changes in the expression of microRNA processing 
genes occurred in the cachexia patients.  In ovarian cancer DICER and DROSHA 
mRNA was reported to be down-regulated and higher DROSHA and DICER levels 
were associated with increased patient survival (Merritt et al. 2008).  In contrast, in 
metastatic prostrate adenocarcinoma DROSHA was shown to be up-regulated with 
other microRNA processing genes (Ambs et al. 2008) suggesting that in the spread of 
prostate cancer DROSHA up-regulation may be important.  Together these studies 
suggest microRNA machinery may play a positive or a negative role in different cancers. 
 
In skeletal muscle DROSHA and EXPORTIN5 have been shown to increase during 
hypertrophy (McCarthy & Esser, 2007).  However, microRNA processing genes were 
reported to be unchanged during muscle atrophy (McCarthy et al. 2007).  Evidence 
from DICER mutant mouse embryonic stem cells suggests muscle stem cells lacking 
DICER would have severe defects in differentiation (Kanellopoulou et al. 2005).  
Intriguingly, DICER protein levels are inhibited by multiple cellular stresses such as 
reactive oxygen species and interferons, (Wiesen & Tomasi, 2009). 
 
Cancer cachexia pathogenesis is linked with elevation of pro-inflammatory cytokines, 
which may activate cellular stress pathways in skeletal muscle (Seruga et al. 2008; 
Stephens et al. 2008; Busquets et al. 2007; Moses et al. 2009).  Therefore, microRNA 
processing genes in skeletal muscle may be influenced by pro-inflammatory cytokines 
in cancer cachexia patients.  However, in the present study there was no evidence of 
alteration of DICER gene expression in cancer cachexia patients.  This may be because 
changes in DICER gene expression in response to cellular stress can occur post-
transcriptionally (Wiesen & Tomasi, 2009), so would not be evident from gene 
expression data. 
 
An alternative explanation is that down-regulated mature miR-1, miR-133a, miR-133b 
and miR-206 expression could be due to decreased primary miR-1, miR-133a, miR-
133b and miR-206 transcription.  MyoD binding sites have been identified on the 
primary transcripts encoding miR-1, miR-133a and miR-206 (Liu et al. 2007; Rao et al. 
2006; Kim et al. 2006).  In addition, MyoD protein has been reported to be decreased in 
gastro-intestinal cancer patients with cachexia (Busquets et al. 2007).  However, 
primary microRNA transcription was not measured in the cancer cachexia patients in 
the present study. 
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3.4.7 Limitations in using weight loss as an indicator of cachexia severity 
Weight loss is used as a universal indicator of cancer cachexia severity in clinical 
studies (Fearon, 1992).  In the present study, the severity of cachexia in patients was 
based on weight loss calculated from body mass during clinical examination and patient 
estimates of body mass prior to cancer diagnosis.  Therefore, the reliability of patient 
reported body mass may have influenced the grouping of patients as pre-cachexia or 
cachexia.  Furthermore, defining cachexia severity based on weight loss assumes fat or 
muscle loss has the same functional consequences, but loss of muscle can lead to 
decreased muscle strength and potentially quality of life (Weber et al. 2009). 
 
In addition, it was not considered whether patients’ initial body mass could have 
influenced patient classification into pre-cachexia or cachexia groups.  For example, a 
patient with an initial BMI of 40 before cancer, but during clinical examination has a 
BMI of 30 would be classified with significant cachexia.  However, the large reduction 
in BMI may be mostly due to loss of fat mass, therefore the functional consequences 
would be minimal.  In contrast, a patient with an initial BMI of 25 before cancer 
diagnosis but during clinical examination has a BMI of 20, may be classified as pre-
cachexia, despite most likely greater loss of muscle mass. 
 
In the current study it was not possible to measure change in muscle mass directly.  
Alternative body composition techniques, which could be used in future include under-
water weighing, air displacement plethsmography, DEXA or MRI (Fouladiun et al. 
2005; Woodrow, 2009).  These body composition techniques all provide an estimate of 
muscle and fat mass, thus would provide a better indication of cachexia severity. 
3.4.8 Limitations in the approach to identify microRNA biomarkers 
A cross-sectional study to identify microRNA biomarkers only indicates microRNA 
expression in patients at the time of clinical examination and assumes patient variability 
in microRNA expression is consistently associated with cachexia severity.  The 
variability in microRNA expression in the control patients may have contributed to the 
lack of statistical significance despite the 50-100% changes in microRNA expression. 
Therefore a longitudinal design would have been better to determine whether 
microRNAs are sensitive to the early changes in skeletal muscle occurring in the pre-
cachexia state 
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Other factors that may influence the variability in microRNA expression in skeletal 
muscle independent of cachexia severity include ageing (Drummond et al. 2008) and 
cancer type.  The cachexia patient groups were older than the control group and age is 
reported to affect skeletal muscle microRNA expression (Drummond et al. 2008).   The 
initial analysis of microRNA expression in the entire cachexia cohort (n = 58) included 
patients with different cancer types and suggested miR-1, miR-133a, miR-133b and 
miR-206 were not biomarkers of cachexia.  However, further analysis revealed miR-1, 
miR-133a, miR-133b and miR-206 expression in pancreatic cancer patients was 
significantly associated with cachexia severity.  Therefore, the present findings suggest 
the importance of microRNAs as biomarkers of cachexia may not be universal across 
different cancer types, but may be limited to pancreatic cancer patients, although this 
would need to be examined in a larger patient cohort of different cancer types. 
3.4.9 Limitations in isolation of RNA and determination of RNA quality. 
RNA was isolated from over 120 muscle biopsies from cancer cachexia patients as part 
of this study, although microRNA expression was measured in only 58 patients due to 
poor RNA quality or insufficient RNA.  All RNA was analysed in the same laboratory 
using an identical protocol, but there was degradation evident in some samples. 
 
It is possible RNA degradation occurred prior to isolation, as there may have been a 
time lapse between performing the muscle biopsy in theatre and storing the muscle 
biopsy at -80°C.  In addition, some patient muscle biopsy samples may have been 
defrosted due to a fault in the -80°C freezer at the Royal Infirmary, Edinburgh.  Six 
months after initial RNA isolation and RNA quality determination, RNA was analysed 
using a Nanodrop spectrophotometer for evidence of RNA contamination. 
 
There was a presence of RNA contamination in some patient samples, which may have 
influenced the efficiency of RT-qPCR for the determination of microRNA expression, 
thus all patient samples were reprecipitated in 100% ethanol.  Despite the loss of patient 
samples due to RNA degradation, miR-1, miR-133a, miR-133b and miR-206 
expression was measured in 58 patients, which should have been sufficient to detect 
whether there were significant differences between control, pre-cachexia, and cachexia 
groups or whether microRNAs may be biomarkers of cachexia severity. 
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The pathway enrichment and gene ontology enrichment analysis was useful to provide 
an overview of possible microRNA functions in cancer cachexia.  However, it is based 
on computational predictions of microRNA targets.  Therefore, false positive 
predictions may influence both the pathway and gene ontology enrichment analysis.  
Gene ontology enrichment analysis can be difficult to interpret due to the enrichment of 
large gene groups associated with a global cellular function such as metabolism or 
binding.  Despite this the enrichment analysis did highlight pathways and gene 
ontologies associated with cancer cachexia. 
3.4.10 Future research directions 
MicroRNAs appear to be biomarkers of cancer cachexia severity in pancreatic cancer 
patients.  Therefore, microRNAs may facilitate earlier diagnosis of cachexia before 
substantial muscle loss and decrease in quality of life.  Longitudinal studies are needed 
to determine whether microRNAs are sensitive to the early changes in skeletal muscle 
occurring in the pre-cachexia state compared to other inflammatory biomarkers such as 
CRP and TNFα.  It would be advantageous in future studies to use more sensitive 
indicators of cancer cachexia severity, for example muscle-mass loss determined by 
MRI or DEXA scans.  In addition, it would be useful to examine serum microRNA 
levels, to determine whether serum microRNA levels reflect changes in skeletal muscle 
microRNAs, as muscle biopsies are not ideal for routine clinical testing. 
 
Bioinformatics approaches such as pathway and gene ontology enrichment analysis are 
useful for examining microRNA function in disease.  But further work to refine existing 
microRNA target prediction algorithms to be context specific and experimentally 
validate targets would facilitate interpretation of pathway and gene-ontology enrichment 
analysis.  From the perspective of microRNA function in cachexia, new approaches to 
measure global changes in microRNA targets in patient skeletal muscle would provide 
more robust evidence of the magnitude of microRNA regulation in cancer cachexia 
pathogenesis. 
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3.4.11 Conclusions 
• Potential microRNA biomarkers of cancer cachexia severity were identified in 
pancreatic cancer patients. These included miR-1, miR-133a, miR-133b and miR-
206, which were inversely associated with weight loss and cancer cachexia severity. 
• Experimental validation or microRNA arrays in cancer cachexia patients revealed 
further microRNAs including miR-23a and miR-27b which may be involved in the 
cancer cachexia pathogenesis, but which would require further validation in a larger 
patient cohort. 
• MAFbx and MuRF1, two E3 ligases associated with muscle wasting, are predicted 
targets of miR-23a.  However, there was no evidence of the affect of miR-23a on 
MAFbx or MuRF1 cleavage in patient skeletal muscle 
• Further longitudinal studies are required to determine whether microRNAs play a 
functional role in cancer cachexia pathogenesis or are mainly biomarkers of the 
disease process. 
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3.5. Supplementary Data 
Supplementary Table  3-1.  Individual patient characteristics for all cancer 
cachexia patients used in miR-1, miR-133a, miR-133b and miR-206 analysis (n = 
58). 
Code Classification Age Sex Tumour 
Site 
BMI % weight 
loss 
F113 Control 67 M None 31.5 0.0 
F175 Control 58 M None 35.9 0.0 
F176 Control 28 F None 32.8 0.0 
F30 Control 69 M None 28.5 0.0 
F119 Control 46 F None 31.1 0.0 
F153 Control 48 M None 25.2 0.0 
F33 Control 41 M None 29.3 0.0 
F111 Pre-cachexia 75 M Pancreas 26.1 3.4 
F114 Pre-cachexia 52 M Oesophagus 25.5 4.1 
F122 Pre-cachexia 58 M OGJ 26.3 -0.5 
F132 Pre-cachexia 66 M Oesophagus 30.4 2.4 
F124 Pre-cachexia 65 M Pancreas 28.1 3.2 
F126 Pre-cachexia 65 M Gastric 29.4 0.0 
F28 Pre-cachexia 64 M Gastric 28.1 -0.5 
F134 Pre-cachexia 76 M Gastric 24.1 2.4 
F141 Pre-cachexia 65 F OGJ 31.3 4.9 
F144 Pre-cachexia 76 F Gastric 30.7 2.0 
F150 Pre-cachexia 75 F Gastric 22.9 3.7 
F40 Pre-cachexia 70 M Oesophagus 26.1 3.3 
F167 Pre-cachexia 74 F Duodenum 21.6 5.0 
F169 Pre-cachexia 60 F Pancreas/ 
duodenum 
29.6 0.6 
F171 Pre-cachexia 66 M Pancreas, 
Gallbladder 
29.7 1.7 
F173 Pre-cachexia 83 F Pancreas  4.2 
F182 Pre-cachexia 70 M OGJ 26.8 0.7 
F183 Pre-cachexia 69 M Gastric 26.1 0.0 
F44 Pre-cachexia 83 M Gastric 24.6 2.4 
F32 Pre-cachexia 70 M Oesophagus 25.9 2.5 
F120 Pre-cachexia 79 M CBD 25.1 5.5 
F143 Pre-cachexia 76 F Pancreas 26.9 9.8 
F152 Pre-cachexia 62 F Pancreas 25.2 8.0 
F29 Pre-cachexia 49 M Oesophagus 28.2 5.2 
F136 Pre-cachexia 75 M Oesophagus 24.6 7.1 
F138 Pre-cachexia 70 M Gastric 24.7 5.7 
F155 Pre-cachexia 52 M Pancreas 27.1 7.7 
F163 Pre-cachexia 52 M Pancreas 30.3 6.1 
F168 Pre-cachexia 45 M OGJ 21.4 7.5 
F172 Pre-cachexia 69 M Gastric 26.4 6.4 
F181 Pre-cachexia 65 M Pancreas 24.4 9.5 
F38 Pre-cachexia 69 M Gastric 27.6 7.6 
F129 Cachexia 72 M Pancreas 24.1 13.8 
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F140 Cachexia 75 F Pancreas 20.1 11.1 
F46 Cachexia 63 F Pancreas 23.2 13.5 
F116 Cachexia 50 M OGJ 26.7 13.2 
F145 Cachexia 62 F Gastric 25.2 11.6 
F146 Cachexia 73 M Gastric 21.0 12.8 
F151 Cachexia 55 F Pancreas 20.5 12.8 
F159 Cachexia 62 F Oesophagus 23.1 14.5 
F164 Cachexia 65 M OGJ 26.2 11.7 
F165 Cachexia 54 M OGJ 32.0 14.7 
F27 Cachexia 67 M Gastric 34.4 12.9 
F118 Cachexia 61 M Oesophagus 24.3 16.3 
F121 Cachexia 69 F Pancreas 20.5 17.3 
F156 Cachexia 71 M Small bowel 21.1 17.1 
F148 Cachexia 71 F Pancreas 16.7 16.5 
F162 Cachexia 65 F Gastric 27.1 16.1 
F166 Cachexia 75 F Pancreas 21.4 16.2 
F157 Cachexia 66 F Pancreas 19.1 22.4 
F158 Cachexia 44 F Pancreas 21.7 43.8 
 
Supplementary Table  3-2. Characteristics of patients used for experimental 
validation of microRNA arrays, microRNA processing gene expression analysis 
and microRNA target expression analysis (n = 20). 
Code Classification Age Sex Tumour Site BMI % weight 
loss 
F129 Cachexia 72 M Pancreas 24 13.8 
F140 Cachexia 75 F Pancreas 20 11.1 
F46 Cachexia 63 F Pancreas 23 13.5 
F118 Cachexia 61 M Oesophagus 24 16.3 
F121 Cachexia 69 F Pancreas 21 17.3 
F156 Cachexia 71 M Small bowel 21 17.1 
F157 Cachexia 66 F Pancreas 19 22.4 
F114 Pre-cachexia 52 M Oesophagus 26 4.1 
F122 Pre-cachexia 58 M OGJ 26 -0.5 
F132 Pre-cachexia 66 M Oesophagus 30 2.4 
F28 Pre-cachexia 64 M Gastric 28 -0.5 
F40 Pre-cachexia 70 M Oesophagus 26 3.3 
F44 Pre-cachexia 83 M Gastric 25 2.4 
F120 Pre-cachexia 79 M CBD 25 5.5 
F143 Pre-cachexia 76 F Pancreas 27 9.8 
F152 Pre-cachexia 62 F Pancreas 25 8.0 
F29 Pre-cachexia 49 M Oesophagus 28 5.2 
F119 Control 46 F HC 31 0.0 
F153 Control 48 M HC 25 0.0 
F33 Control 41 M HC 29 0.0 
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Supplementary Table  3-3. Fold change in microRNA probe expression between 
cachexia patients with high weight-loss and controls from microRNA arrays (I. 
Gallagher, personal communication). Experimental validation was performed on 
these microRNAs using RT-qPCR and data is shown in  3.3.7. 
microRNA Fold Change 
hsa-miR-143/mmu-miR-143/rno-miR-143 1.98 
hsa-miR-195/mmu-miR-195/rno-miR-195 1.22 
hsa-miR-23a/mmu-miR-23a/rno-miR-23a 1.32 
hsa-miR-27b/mmu-miR-27b/rno-miR-27b 1.42 
hsa-miR-29a/mmu-miR-29a/rno-miR-29a 1.30 
hsa-miR-29b/mmu-miR-29b/rno-miR-29b 1.69 
hsa-miR-424 1.51 
 
  
Supplementary Figure  3-1. Example of micro-electrophoresis gel showing RNA 
quality from cancer cachexia and control patient RNA samples during early stages 
of RNA isolation for the entire cachexia cohort.  Clear evidence of RNA 
degradation in lane 9-10, with small RNA fragments detected at bottom of 
electrophoresis gels. RIN scores indicating RNA quality were below normal in 
lanes 2, 9-10 and 12. 
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Supplementary Figure  3-2. Agarose gel showing specificity of microRNA Taqman 
assays to detect mature microRNAs.  Mature miR-1, miR-133a, miR-133b, miR-
206 are dectected around 80 bp as during reverse transcription, 60 nt stem-loop 
primers anneal to mature microRNA sequences. 
 
 
Supplementary Figure  3-3. RNU48 expression was not significantly different 
between control patients (0% weight loss), pre-cachexia patients (0-10% weight 
loss) and cachexia patients (>10% weight loss) (n=58). Data presented as CT ± SE. 
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Supplementary Figure  3-4. Efficiency of pri-microRNA primers targeting (A) 
TUB1 to pri-miR-21, (B) TMEM49 to pri-miR-21 and (C)TMEM49 (host gene) 
across a range of cDNA dilutions. 
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Supplementary Figure  3-5. (A) Correlation of miR-1, (B) miR-206, (C) miR-133a 
and (D) miR-133b expression with weight loss in cancer cachexia patients (n=58). 
Light-coloured markers represent healthy controls, dark-coloured markers 
represent cachexia patients.  Regression lines were determined based on cachexia 
patients only, excluding controls. 
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Supplementary Figure  3-6. Residual plots from multiple regression model 
predicting weight loss in pancreatic cancer patients based on (A) miR-1, (B) miR-
206, (C) miR-133a and (D) miR-133b expression. 
 
Supplementary Figure  3-7. Association of (A) miR-133a/miR-133b and (B) miR-
1/miR-206 target expression with weight loss in patients (n = 20). 
 
Chapter 3 – Skeletal muscle microRNAs in cancer cachexia patients 
90 
 
Supplementary Figure  3-8. Top ranked KEGG pathways enriched with (A) miR-
195/424 targets and (B) miR-143 targets. Data shows number of microRNA targets 
(black-bars) and false discovery rate (grey-line) based on pathway enrichment 
analysis. 
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Supplementary Figure  3-9. Association of (A) miR-21, (B) miR-29a/miR-29b, (C) 
miR-143, (D) miR-195/miR-424 and (E) miR-208 target expression with weight loss 
in patients (n = 20). 
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Chapter 4 - Skeletal muscle microRNAs in Type 2 diabetes patients 
4.1. Introduction 
Type 2 diabetes is characterised by skeletal muscle insulin resistance and reduced 
glucose uptake in insulin sensitive tissues leading to hyperglycaemia (Muoio & 
Newgard, 2008).  Type 2 diabetes is a major public health problem as it is estimated to 
affect over 170 million people worldwide (WHO, 2006) and by 2030 diabetes is 
projected to affect 4.4% of the world population (Wild et al. 2004).  Type 2 diabetes is a 
leading cause of death, with over 8% of deaths in the US, Canada and the Middle East 
attributable to diabetes and worldwide it is the fifth leading cause of death (Roglic et al. 
2005).  Unfortunately, Type 2 diabetes can have mild symptoms, thus may only be 
detected several years after onset by which time further complications may have 
occurred (WHO, 2006).  For example, Type 2 diabetes patients are at increased risk of 
microvascular and macrovascular complications including retinopathy, nephropathy, 
heart disease and stroke (WHO, 2006). Currently, impaired fasting glucose and 
impaired glucose tolerance are recognised as significant risk factors in Type 2 diabetes 
(Edelstein et al. 1997).  However, the aetiology of Type 2 diabetes is still not fully 
understood, thus further research is needed to better understand the mechanism 
underlying the development of Type 2 diabetes and to identify early biomarkers of Type 
2 diabetes. 
 
Insulin resistance contributes to impaired glucose tolerance and individuals with 
impaired glucose tolerance (IGT) are at high risk of developing Type 2 diabetes but this 
is not inevitable (Edelstein et al. 1997; Söderberg et al. 2004).  An eleven-year follow-
up of individuals with IGT found only 30% developed Type 2 diabetes, while 30% 
reverted to normal glucose tolerance (NGT) (Söderberg et al. 2004).  Decline in insulin 
secretion is also a well-recognised factor in the development of Type 2 diabetes.  
Pancreatic β-cell failure in Type 2 diabetes may be partly due to genetics, but may also 
precede the development of insulin resistance due to additional stress on the β-cells 
caused by decreased skeletal muscle insulin-stimulated uptake and hyperglycaemia that 
can be associated with insulin resistance (Muoio & Newgard, 2008).  Therefore, 
focusing on understanding the underlying mechanisms of insulin resistance in skeletal 
muscle may help provide useful early biomarkers of T2D.  Other clinical biomarkers 
associated with Type 2 diabetes include plasma TNFα, adiponectin, triacylglycerol and 
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HDL, which are reported to affect muscle insulin sensitivity and glucose uptake (Muoio 
& Newgard, 2008).  However, none of these clinical biomarkers have been included in 
the WHO criteria for Type 2 diabetes diagnosis.  Therefore more work to identify early 
biomarkers of Type 2 diabetes is required.  Insulin signaling is an important modulater 
of muscle insulin sensitivity and defects in the insulin signaling cascade may contribute 
to insulin resistance and the development of Type 2 diabetes. 
4.1.1 Insulin signaling and muscle glucose uptake 
Insulin stimulates muscle glucose uptake by activating the insulin signaling cascade 
(Figure  2-2), which triggers translocation of the glucose transporter GLUT4 to the 
plasma membrane.  Defects in the activation of the insulin signaling cascade may 
decrease insulin-stimulated glucose uptake, resulting in additional stress on the 
pancreatic β-cells to maintain normoglycaemia.  Impairment of insulin signalling at 
multiple points has been reported, including impaired phosphorylation of IRS1, PI3K 
and AS160 (Kim et al. 1999; Kim et al. 2003; Karlsson et al. 2005; Cohen, 2006).  
Therefore, identifying regulators of insulin signaling which control skeletal muscle 
glucose uptake has generated much research interest (Cohen, 2006; Muoio & Newgard, 
2008).  MicroRNAs are post-transcriptional regulators of gene expression and are 
predicted to target genes coding for proteins important for insulin signaling and glucose 
uptake, but the role of microRNAs in Type 2 diabetes patients is largely unknown 
(Gauthier & Wollheim, 2006; Hennessy & O'Driscoll, 2008; Poy et al. 2007; Tang et al. 
2008). 
4.1.2 MicroRNAs target insulin signaling proteins 
Several studies now suggest microRNAs may regulate components of the insulin 
signaling pathway (Figure  2-2) and thus may be important regulators of insulin 
resistance and Type 2 diabetes (Gauthier & Wollheim, 2006; Hennessy & O'Driscoll, 
2008; Poy et al. 2007; Tang et al. 2008).  For example, miR-29 has been shown to be 
elevated in adipose and muscle tissue of diabetic rats (He et al. 2007).  Furthermore, 
overexpression of miR-29 was found to suppress insulin-stimulated glucose uptake in 
adipocytes (He et al. 2007).  The insulin signaling proteins IRS1 and Akt were not 
directly repressed by miR-29, but IRS1 and Akt phosphorylation was reduced (He et al. 
2007).  Hyperglycaemia and hyperinsulinaemia were both reported to mimic miR-29 
suppression of insulin-stimulated glucose uptake (He et al. 2007).  However, it was not 
clear whether miR-29 was a cause or an effect of the hyperglycaemia and 
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hyperinsulinaemia observed in the diabetic mice (Hennessy & O'Driscoll, 2008; He et al. 
2007).  
 
Multiple microRNAs are predicted to target GLUT4 but few have been confirmed.  
Knockdown of miR-143 was found to inhibit expression of GLUT4 and PPAR-2 (Esau 
et al. 2004), yet miR-143 is not predicted to target GLUT4 or PPAR-2 (Lewis et al. 
2003).  Knockdown of miR-143 was associated with elevation in ERK5 protein and 
ERK is part of the MAPK signaling pathway, which is also activated by insulin via 
GRB2, SOS and RAS proteins.  Post-exercise ERK activity is reported to be elevated 
(Yu et al. 2001) and activation of ERK appears to be correlated with in-vitro muscle 
glucose uptake (Babraj et al. 2009).  However, inhibition of ERK was found to have no 
effect on insulin-stimulated glucose uptake (Cusi et al. 2000).  It is not yet clear by 
which mechanism miR-143 affects GLUT4 or whether it is a regulator of muscle 
glucose uptake and involved in Type 2 diabetes. 
 
Other potential microRNA biomarkers in Type 2 diabetes include miR-145.  IRS1 is 
reportedly decreased in response to overexpression of miR-145 (Shi et al. 2007), which 
suggests that elevation of miR-145 could lead to impaired insulin signaling.  However, 
miR-145 has not been confirmed to target IRS1 in skeletal muscle and miR-145 has not 
been previously associated with Type 2 diabetes (Hennessy & O'Driscoll, 2008). 
4.1.3 MicroRNAs may target negative regulators of insulin signaling 
MicroRNAs may also target negative regulators of the insulin signaling pathway.  For 
example, the 3’UTR of protein tyrosine phosphatase PTP1B contains predicted binding 
sites for miR-1, miR-206 and miR-29 (Lewis et al. 2003).  PTP1B is a negative 
regulator of insulin signaling and can reverse phosphorylation of the insulin receptor 
(Galic et al. 2005; Muoio & Newgard, 2008).  In addition, inhibitors of PTP1B can 
increase insulin sensitivity in mice (Erbe et al. 2009).  Furthermore, a report suggests 
Type 2 diabetes susceptibility may be increased by single nucleotide polymorphisms in 
the 3’UTR of PTP1B (Bento et al. 2004).  Taken together these studies suggest 
microRNAs may also target negative regulators of insulin signalling.  Therefore, loss of 
microRNA expression may lead to a decrease in translational repression and inhibition 
of insulin signaling.  However, the predicted microRNA target sites of these negative 
insulin signaling regulators have yet to be confirmed in skeletal muscle. 
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In skeletal muscle, miR-1, miR-206 and miR-133 are highly expressed during 
development and are modulated in response to different cellular stresses (Chen et al. 
2006; van Rooij et al. 2008; Chen et al. 2009).  These microRNAs are modulated during 
hypertrophy, atrophy and during remodelling of skeletal muscle (McCarthy et al. 2007; 
Allen et al. 2009; McCarthy & Esser, 2007; Drummond et al. 2008).  In Chapter 3, 
miR-1, miR-206 and miR-133 appeared to be down-regulated in skeletal muscle from 
pancreatic cancer patients in proportion to weight loss.  Cancer patients are also 
reported to develop skeletal muscle insulin resistance and therefore are at increased risk 
of developing Type 2 diabetes (Rofe et al. 1994; Heber & Tchekmedyian, 1992).  
Unfortunately, it could not be established in Chapter 3 whether miR-1, miR-133 and 
miR-206 down-regulation was directly linked to insulin resistance.  However, pathway 
enrichment analysis of miR-1, miR-133 and miR-206 targets suggested these 
microRNAs might target genes involved in insulin signaling and relevant to Type 2 
diabetes. 
4.1.4 Evidence of transcriptional changes in Type 2 diabetes skeletal muscle 
The evidence suggests microRNAs could be important in the regulation of genes 
involved in insulin resistance and Type 2 diabetes (Hennessy & O'Driscoll, 2008; 
Gauthier & Wollheim, 2006; Poy et al. 2007; He et al. 2007; Tang et al. 2008).  The 
established mechanism of microRNA action is via post-transcriptional mRNA cleavage 
or translational repression (Bartel, 2009).  Previously genome-wide studies of 
transcriptional changes in insulin resistance and Type 2 diabetes suggested down-
regulation of PGC1-α and reduced expression of oxidative phosphorylation may be 
responsible for the insulin resistance in Type 2 diabetes (Mootha et al. 2003; Patti et al. 
2003).  However these studies appear to be confounded by the effect of BMI and 
VO2max on expression of oxidative phosphorylation associated genes.  Both BMI and 
VO2max have been shown to influence PGC-1α and oxidative phosphorylation genes 
(Krämer et al. 2006; Ling et al. 2004; Mathai et al. 2008; Sriwijitkamol et al. 2007; 
Timmons et al. 2006).  A more recent genome-wide transcriptome study found no 
evidence of transcriptional changes in myotubes from Type 2 diabetes patients when 
compared to BMI and physical activity matched controls (Frederiksen et al. 2008).  In 
addition, a study from our laboratory (J. Timmons, personal communication) compared 
genome-wide transcript profiles (n = 118) from skeletal muscle of Type 2 diabetes 
patients, IGT patients and healthy controls matched by age, BMI and VO2max.  There 
was no evidence of any global transcriptional changes between Type 2 diabetes, IGT or 
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healthy skeletal muscle (J. Timmons, personal communication), supporting the view 
that a post-transcriptional mechanism may be involved in the development of insulin 
resistance and the pathogenesis of Type 2 diabetes (Hennessy & O'Driscoll, 2008; Poy 
et al. 2007; Tang et al. 2008).  Therefore, microRNAs are possible post-transcriptional 
regulators of insulin resistance and Type 2 diabetes or alternatively microRNAs may be 
useful early biomarkers of Type 2 diabetes.   
4.1.5 Aims 
• Determine whether skeletal muscle expression of miR-1, miR-133a, miR-133b and 
miR-206 is changed in Type 2 diabetes patients. 
• Determine whether skeletal muscle microRNA transcription or processing is altered 
in Type 2 diabetes patients. 
• Examine whether skeletal muscle expression of predicted microRNA targets 
changes in Type 2 diabetes patients. 
• Identify further microRNAs based on experimental validation of microRNA array 
data, which may be early biomarkers of Type 2 diabetes. 
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4.2. Methods 
4.2.1 Subjects 
Thirty non-obese individuals were selected from a larger Scandinavian Type 2 diabetes 
cohort (n = 215) and assigned into three groups based on glucose tolerance: Type 2 
diabetes (n = 10), impaired glucose tolerance (IGT; n = 10) and controls with normal 
glucose tolerance (NGT, n = 10).  These groups were matched on age, BMI and 
maximal oxygen uptake (VO2max).  Exclusion criteria were as follows: cardiovascular 
disease associated with claudication, cerebrovascular accidence, angina pectoris, prior 
coronary artery bypass graft, prior percutaneous transluminal coronary angioplasty, 
insulin treatment, recent infection and/or history of malignant disease.  Patients received 
information about the experimental procedures before giving their written informed 
consent.  The Type 2 diabetes patients were instructed to stop hypoglycaemic 
medication one week prior to the study. The study was approved by the Ethics 
Committee of Copenhagen and Frederiksberg Council (01-141/04) and the analysis was 
approved by the Ethics committee of the School of Life Sciences, Heriot-Watt 
University, Edinburgh. 
 
Physical characteristics of the patients are summarised in Table  4-1.  These patients 
have been included in a previous larger case-controlled study (Krabbe et al. 2007; 
Plomgaard et al. 2007; Nielsen et al. 2008).  There were no significant differences 
between patients for age, BMI or VO2max (P > 0.05). 
 
Table  4-1. Physical characteristics of patients 
Patient 
characteristics 
Type 2 diabetes 
(n = 10) 
IGT 
(n = 10) 
Controls 
(n = 10) 
Age (y) 60.4 ± 14 60.2 ± 7.1 60.3 ± 7.5 
Weight (kg) 85.6 ± 12.2 81.1 ± 8.2 78.4 ± 8.9 
Height (cm) 179 ± 10 176 ± 6 174 ± 9 
BMI 26.6 ± 1.9 26.3 ± 1.7 25.9 ± 1.9 
VO2max (ml/kg/min) 28.8 ± 8.6 29.4 ± 6.9 28.4 ± 6.0 
Data are presented as mean ± SD. 
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4.2.2 Approach 
Muscle specific mature microRNAs, miR-1, miR-133a, miR-133b and miR-206 were 
profiled in skeletal muscle biopsies from Type 2 diabetes, IGT and control patients 
using RT-qPCR (see section  4.2.6), followed by examination of primary microRNAs 
(see section  4.2.8), precursor microRNAs (see section  4.2.10) and expression of 
microRNA processing genes to identify if there were any alterations in muscle-specific 
microRNA transcription or processing in Type 2 diabetes.  The predictive power of 
patient microRNA expression was tested using a multiple regression approach.  The 
predicted targets of differentially expressed microRNAs were analysed further as a 
group to determine their possible biological, cellular and molecular role in Type 2 
diabetes pathogenesis (see section  4.2.13).  Existing microarray data on mRNA changes 
in response to microRNA overexpression were mined for links to the insulin resistance 
and Type 2 diabetes literature (see section  4.2.11).  To identify further new potential 
Type 2 diabetes candidate microRNAs, microRNA target expression signatures were 
calculated for each patient based on Type 2 diabetes microarray data from our 
laboratory (see section  4.2.12).  These microRNA target expression signatures were 
analysed by SAM to identify microRNA target signatures differentially expressed in 
Type 2 diabetes patients.  Finally, experimental validation of microRNA array data was 
conducted to confirm differential expression of microRNAs using RT-qPCR (see 
section  0). 
4.2.3 Muscle biopsy and clinical examination 
The patients reported to the hospital for a clinical health examination and an oral 
glucose tolerance test between 0800h and 1000h after an overnight fast.  Muscle 
biopsies were obtained from the Vastus lateralis using the Bergstrom needle technique 
with suction under basal condition.  Biopsies were quickly dissected free from visible 
blood and connective tissue, frozen in liquid nitrogen and stored at -80°C until RNA 
extraction.  An oral glucose tolerance test was performed according to World Health 
Organization guidelines (WHO, 2006).  Patients consumed 75 g glucose in 500 ml 
water, blood samples were taken at baseline, 1 and 2 h.  Patients were classified as 
NGT, IGT or Type 2 diabetes based on the WHO criteria (WHO, 2006).  NGT was 
defined as fasting plasma glucose <7.0 and plasma glucose <7.8 mmol/l after OGTT; 
IGT was defined as fasting plasma glucose <7.0 mmol/l and plasma glucose between 
7.8-11.0 mmol/l OGTT; Type 2 diabetes was defined as fasting plasma glucose >6.9 
mmol/l or plasma glucose >11.0 mmol/l after OGTT.  BMI was calculated as body mass 
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(kg) / body height (m)2.  Cardiorespiratory fitness was measured using the Åstrand-
Rhyming indirect test of maximal oxygen uptake (VO2max) (Astrand & Ryhming, 
1954).   
4.2.4 Blood analysis 
Blood samples collected into glass tubes with EDTA were immediately spun at 3500g 
for 15 min at 4°C and plasma was stored at −20°C until further analysis.  Plasma TNF-
α, sTNFR2 and IL-6 were measured by colleagues in duplicate using ELISA (R&D 
Systems, USA) (Plomgaard et al. 2007).  Plasma cholesterol (HDL and LDL), 
triacylglycerol, C-reactive protein (CRP), glucose and insulin were measured using 
routine laboratory methods as previously described (Plomgaard et al. 2007).  Insulin 
resistance was calculated using the homeostasis model assessment of insulin resistance 
(HOMA[IR]; software available at http://www.dtu.ox.ac.uk). 
4.2.5 RNA isolation, quantification and screening for RNA purity 
Muscle biopsies were homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA) using a 
motor-driven homogenizer (Polytron, Kinematica, Newark, NY, USA) and total RNA 
was isolated according to the manufacturer’s protocol.  The size of the tissue samples 
ranged between 10 and 40 mg.  Total RNA was dissolved in 30 µl RNase-free water, 
quantified using a Spectrophotometer (Pharmacia Biotech, NJ, USA) as previously 
described (Plomgaard et al. 2007), then stored at -80°C prior to analysis. 
 
Later all RNA from the whole diabetes cohort (n = 215) was re-quantified using a 
Nanodrop spectrophotometer (Thermoscientific, UK).  The Nanodrop measures 
absorbance in RNA samples (range 200 to 350 nm) and requires <2 µl solution.  RNA 
quantification is based on absorbance at 260 nm.  Additional absorbance around 220-
230 nm indicates presence of contaminants in the samples, including salts such as 
guanidinium isothiocyanate and phenol or proteins.  Phenol contamination can affect 
absorption at 270 nm and therefore can cause spurious RNA quantification.  The 
260/280 ratio should ideally be >2.0 indicating RNA free of contaminants.  The 
260/230 ratio was <2 indicating possible phenol or guanidinium isothiocyanate 
contamination from the RNA isolation procedure.  Phenol contamination can lead to 
underestimation of RNA quantity and affect downstream measurements including RT-
qPCR via inhibition of Taq polymerase and reduced primer efficiency (Fleige & Pfaffl, 
2006).  Unfortunately, although the Nanodrop is useful for RNA quantification and 
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screening for contaminants, it provides no indication of RNA integrity.  To limit 
possible effects a subset of patient RNA samples were re-precipitated at -20°C 
overnight in 2.5 x RNA volume 100% ethanol and 0.5 x RNA volume 7.5 M sodium 
acetate.  Following re-precipitation of a subset of RNA samples the 260/230 ratio 
improved to 1.5-2.0 and increased RNA yield (Supplementary Table  4-3).  Therefore, 
the decision was made to reprecipitate and re-quantify all RNA samples from the Type 
2 diabetes cohort (n = 215) using the Nanodrop spectrophotometer (data not shown).  
Comparison of the inter-laboratory determined RNA concentrations revealed good 
concordance between laboratories despite the use of different spectrophotometers, 
although there was one outlier (Supplementary Figure  4-9).  RNA quality was assessed 
prior to microRNA expression analysis (n = 30) with the Agilent Bioanalyser using the 
procedure described in  3.2.4.  RIN scores >8 indicated RNA quality was high with no 
sign of RNA degradation on the micro-electrophoresis gel (Supplementary Figure  4-8).  
4.2.6 Mature-microRNA reverse transcription and real-time quantitative PCR 
Reverse transcription (RT) of RNA to cDNA was conducted using the TaqMan® 
MicroRNA Reverse Transcription Kit according to the manufacturer’s instructions.  
Each RT reaction was set up to contain between 2-10 ng of total RNA.  The RT reaction 
was prepared as described in section  3.2.5.  TaqMan® MicroRNA Assays were used to 
measure miR-1, miR-133a, miR-133b, miR-206 and RNU48 listed previously in 
Chapter 3, Table  3-2.  Each PCR reaction was prepared as previously described in 
section  3.2.6.  The PCR reaction was run on an Applied Biosystems 7300/7500 Fast 
Real-Time PCR system in 9600 emulation mode.  Ct values for triplicates were 
averaged, and ∆Ct values computed using RNU48 as the endogenous control.  
Comparison of average RNU48 Ct between Type 2 diabetes, IGT and control groups 
indicated RNU48 expression was not significantly difference between groups 
(Supplementary Figure  4-1).  Fold change was calculated using the -2∆∆CT method 
(Schmittgen & Livak, 2008). 
4.2.7 Design and validation of pri-microRNA primers 
To determine whether pri-microRNA transcription was regulated in Type 2 diabetes, 
primers were designed to amplify the intronic region between the pre-microRNA 
hairpin and the predicted host gene (Figure  4-1).  C20orf166 is the predicted host gene 
of pri-miR-1-1 and pri-miR-133a-2, primers were designed to span exon 2-3 of 
C20orf166. ENSESTG00000007014 is located adjacent to pri-miR-133a-1 and pri-miR-
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1-2, primers were designed to amplify exon 2 of ENSESTG00000007014.  All primers 
for pri-microRNA transcripts are listed in Table  4-2.  Primers were obtained from 
Invitrogen UK. 
 
 
Figure  4-1.  Location of primers designed to amplify pri-miR-1 and pri-miR-133a
transcripts.  Primers were also designed to amplify the predicted host genes.  
Arrows indicate location of forward and reverse primers. 
 
Primer efficiency was tested on five serial dilutions of cDNA using the RT-qPCR 
protocol described in section  4.2.9.  Ct values were found to be linear for pri-miR-1-1, 
pri-miR-1-2, pri-miR-133a-1 and pri-miR-133a-2, with the amplification slope between 
3 and 3.2 indicating similar amplification efficiency for these primers (Supplementary 
Figure  4-11).  However, standard curves for the predicted host genes C20orf166 and 
ENSESTG00000007014 values were not linear, so these primers were not used 
(Supplementary Figure  4-11).  In addition, melting curves were examined to determine 
whether a single PCR product was formed (not presented) and PCR products were 
analysed on a 2% agarose gel which was run as follows:  2% agarose (0.8g) was 
dissolved in 0.5% TBE by heating for 2 min and 0.5 µl DNA bromide red dye was 
added.  The gel was poured and left to polymerise for 10 min.  In the 1st well, low 
weight DNA ladder was loaded, 2 µl of PCR product were mixed with 1 µl blue dye and 
loaded on gel.  The gel was run at 100V for ~1 h in a running buffer of 0.5% TBE.  
Afterwards, DNA bands were visualised under UV light to confirm a single PCR 
product. 
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Table  4-2. Primer sequences to amplify pri-miR-1 and pri-miR-133a transcripts. 
Target Identifier Primers, sequences or probes 
Pri-hsa-
miR-1-1 
ENSG00000199017  5’-caggcgctcgagactttct-3’ (forward) 
5’-tcacacactcacacgatcca-3’ (reverse) 
Pri-hsa-
miR-133a-2 
ENSG00000207764  5’-tctatcctatggctcacaaaagc-3’ (forward) 
5’-ctcactcacgggtggaaac-3’ (reverse) 
Pri-hsa-
miR-133a-1 
ENSG00000207786  5’-aaatgtactttctgtgactgaggtgt-3’ (forward) 
5’-ctgtgggcaaaaggagacat-3’ (reverse) 
Pri-hsa-
miR-1-2 
ENSG00000207694 5’-aagttgttagctgtaaaaacatgaaa-3’ (forward) 
5’-ttcgataaattagtctctgcaaatg-3’ (reverse) 
Primers were obtained from Invitrogen, UK. 
4.2.8 Pri-microRNA reverse transcription  
RNA was reverse transcribed using a high capacity cDNA reverse transcription kit 
(Applied Biosystems, UK).  The RT master mix was prepared with 4 µl 10 x RT buffer, 
1.6 µl 25 x dNTP mix (100 mM), 4 µl 10 x RT random primers, 2 µl MultiScribe 
reverse transcriptase, 2 µl RNase inhibitor and 6.4 µl Nuclease-free water.  RNA was 
diluted to 2 µg/µl in 20 µl of Nuclease-free water.  The RT reaction was prepared by 
mixing 20 µl RT mastermix, 20 µl RNA sample and spinning down. The thermal cycler 
was programmed to run at 25°C for 10 min, 37°C for 120 min, 85°C for 5 sec and then 
held at 4°C.  cDNA samples were stored at -20°C until further analysis. 
4.2.9 Pri-microRNA real-time quantitative PCR 
SYBR green reagents (Applied Biosystems, UK) were used for RT-qPCR reaction to 
amplify regions spanning pri-microRNA transcripts; the primers used are listed in Table 
 4-2.  Each RT-qPCR reaction was prepared using 6 µl SYBR green mastermix, 4.6 µl 
Nuclease-free water, 0.10 µl forward primer, 0.10 µl reverse primer and 1.2 µl cDNA 
(1:10 dilution).  For each primary microRNA transcript all patient PCR reactions were 
prepared in triplicate on the same 384 well plate.  Triplicate wells containing no 
template were also prepared as an additional control to indicate if PCR contaminants 
were present (Bustin & Nolan, 2004).  The plate was sealed and spun down at 3000 rcf 
in a centrifuge at 4°C.  The PCR reaction was run on an Applied Biosystems 7300/7500 
Fast Real-Time PCR system in standard mode.  The following thermal cycling 
parameters were applied, 2 min at 50°C, 10 min at 95°C, then 45 cycles consisting of 15 
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s at 95°C and 60 s at 60°C.  Ct values for triplicates were averaged, and ∆Ct values 
computed using 18S as the endogenous control.  Comparison of the average Ct of 18S 
between Type 2 diabetes, IGT and control groups indicated 18S expression was not 
significantly difference between groups (Supplementary Figure  4-3).  Fold change was 
calculated using the -2∆∆CT method (Schmittgen & Livak, 2008). 
4.2.10 Pre-microRNA detection by Northern blot 
Northern blot was performed to determine whether pre-miR-133a was altered in Type 2 
diabetes, IGT and control groups.  RNA (10 ng) was pooled from patients with diabetes, 
impaired glucose tolerance or normal glucose tolerance respectively.  In addition, four 
individual patient samples were used, including two Type 2 diabetes patients and two 
controls.  RNA samples were precipitated overnight in 100% ethanol and then 
centrifuged at 14000rpm for 30 min at 4ºC.  The RNA pellet was washed in 75% 
ethanol and redissolved in 6 µl of 2 x formide loading dye.  A small RNA blot was 
prepared using 15% denaturing gel, consisting of 15 ml SequaFlowGel sequencing 
system concentrate, 7.5 ml SequaFlowGel diluent, 2.5 ml 10 x MOPS buffer, 250 µl 
10% Ammonium persulfate (APS, Sigma) and 25 µl TEMED.  Polymerization was 
completed in 10 min, wells were washed in 1 x MOPS running buffer.  The gel was 
preheated by running at 100V for 30 min in the WB system (Invitrogen), 1 x 
MOPS/NaOH (20mM, pH 7.0) was used as the running buffer.  In the meantime, RNA 
samples were incubated at 95ºC for 2 min and then loaded on to the gel with a Decade 
Marker (AM7778, Applied Biosystems).  The gel was run at 100 V for 3 h and the 
running buffer was changed after 1.5 h. 
 
The RNA was transferred to blot at 400 mA for 1-1.5 h, using a neutral membrane 
(HybondN, Amersham Biosciences) and gel blotting paper.  For chemical cross-linking, 
the blot was incubated at 55ºC for 2 h, the blot was submerged in a cross linking 
reagent consisting of 9 ml RNase free water, 245 µl 1-methylimidazole, 300 µl 1M HCl, 
0.753 g EDC and Milipore water upto 24 ml.  The blot/membrane was incubated at 
37ºC for 1 h in a prehydridisation mix.  This consisted of 12.5 ml formamide, 6.25 ml 
SSPE (20 x), 1.25 ml denhardt (100 x), 1.25 ml 10% SDS and 500 µl hsDNA (2 mg/ml) 
which was denatured at 95ºC for 2 min before adding to the blot/membrane. 
 
A hydridisation mix was prepared separately consisting of 1 µl 50 uM oligonucleotide, 
11 µl nuclease-free water, 2 µl, 10x buffer, 2 µl RNase inhibitor, 2 µl T4 PNK and 2 µl 
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32P-j-ATP.  The hydridisation mix was spun down and then incubated at 37ºC for 1 h.  
After this 20 µl nuclease-free water was added and the hybridisation mix was filtered 
with a G-25 column, which was then transferred to the pre-hybridisation mix.  The blot 
was hybridised over night at 37ºC, washed twice with 2 x SSC and 0.1% SDS for 1.5 h 
at 65ºC.  Exposition was completed overnight.  The membranes were stripped with 1 L 
stripping solution for 10-15 min at 100ºC.  The stripping solution consisted of 10 ml 
1M Tris (pH 8.5), 10 ml 0.5M EDTA and 10 ml 10% SDS, made up to 1L with 
Millipore water.  Blots were reprobed for t-RNA, which was used as a control.  Image J 
was used to analyse blots, signals were background corrected then normalised to t-RNA. 
4.2.11 Analysis of microRNA targets associated with Type 2 diabetes 
Existing microarray data (GSE8501) from HeLa cells 24 h following transfection of 
miR-133a allowed examination of potential miR-133a regulation of diabetes-associated 
targets.  This approach can provide indirect validation of microRNA targets.  In the 
present study miR-133a targets with previous links to the diabetes literature were 
manually curated based on citations in the NCBI database.  Microarray data (GSE8501) 
was retrieved from GEO (NCBI).  The platform used to generate the microarray data 
was a non-commercial glass oligonucleotide array containing probes designed against 
>23000 human genes.  Pre-processed log2 intensity data was available, so the difference 
in log2 intensity between transfected and control cells was calculated.  Analysis of miR-
133a target expression in response to miR-133a transfections was restricted to targets 
with >1 associated diabetes citations in the NCBI database. 
4.2.12 Analysis of microRNA target signatures 
Evidence of microRNA action on target mRNA cleavage was examined based on mean 
absolute microRNA target expression (Arora & Simpson, 2008).  Unpublished 
microarray data was available from our laboratory from a larger Type 2 diabetes cohort 
(n=115), which was MAS 5.0 normalised and absent filtered data (I. Gallagher, personal 
communication).  For each patient, average expression of targets for each of the human 
microRNAs was computed as described in section  3.2.10.  Thus generating a 
microRNA target signature that could help reveal candidate microRNAs involved in 
Type 2 diabetes.  Firstly, the microRNA target signatures for the muscle-specific 
microRNAs were calculated and differences between Type 2 diabetes, IGT and control 
groups were determined using one-way ANOVA. 
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Secondly, a more global approach was taken to find other potential candidate 
microRNAs involved in Type 2 diabetes.  Significance Analysis of Microarrays (SAM) 
was used to identify differences in individual microRNA target signatures between 
groups.  SAM was run using the siggenes package in Biconducter.  SAM computes a 
moderated t-statistic to adjust for multiple testing and calculates a false discovery rate. 
4.2.13 Gene ontology and pathway enrichment analysis  
Gene ontologies (GO) were used to gain an overview of the possible biological, cellular 
and molecular functions of the differentially expressed microRNAs in Type 2 diabetes 
patients.  The Expression Analysis Systematic Explorer (EASE) (Sherman et al. 2007) 
was used to determine which gene ontologies may be regulated by differentially 
expressed Type 2 diabetes microRNAs as described in section  3.2.11. 
4.2.14 MicroRNA array experimental validation 
MicroRNA array data from pooled patient RNA was analysed using Significance of 
Analysis of Microarray (SAM; http://www.stat.standford.edu/~tibs/SAM) to determine 
differentially expressed microRNAs (I. Gallagher, personal communication).  RT-qPCR 
was used to measure the differentially expressed microRNAs including miR-27b, miR-
29a, miR-29b, miR-143, miR-208 and miR-424 as described in section  3.2.6.  The 
mature microRNA sequences and catalogue references are listed in Table  3-4. 
4.2.15 Statistical analysis 
Expression of mature microRNAs, primary microRNAs and microRNA processing 
genes was compared between Type 2 diabetes, IGT and control groups using one-way 
ANOVA assuming equal variances between groups based on Barletts test.  Post-hoc 
Bonferroni tests were performed where necessary to identify inter-group differences.  
When the assumption of equal variances was not met the non-parametric Kruskal Wallis 
test was run. Linear regression was used to test whether individual patient microRNA 
expression could explain a significant proportion of the variance in clinical measures of 
insulin resistance and glucose homeostasis including, fasting glucose, fasting insulin, 2h 
glucose tolerance, HbA1c and HOMA[IR].  SAM was used to identify differentially 
expressed microRNA target signatures as described in  4.2.12.  The Fishers Exact test 
was the basis for the gene ontology and pathway enrichment analysis as described in 
 4.2.13. 
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4.3. Results 
Patients’ glucose tolerance and insulin sensitivity are shown in Table  4-3.  Fasting 
glucose, 2 h glucose tolerance and HbA1c were all significantly higher in the Type 2 
diabetes compared to IGT and control group (P <0.01).  HOMA[IR] was significantly 
higher in Type 2 diabetes compared to controls (P <0.01).  Basal insulin was 
significantly elevated in the Type 2 diabetes patients compared to the healthy controls.  
Patient inflammatory markers are summarised in Supplementary Table 4-1, there were 
no significant differences between groups for CRP, IL-6, IL-15, IL-18, TNFα, and 
TNFαR2. 
Table  4-3. Glucose homeostasis and insulin sensitivity markers. 
Patient 
characteristics 
Type 2 diabetes 
(n=10) 
IGT 
(n=10) 
Control 
(n=10) 
Fasting glucose 
(mmol/L) 
11.3 ± 2.9*** 5.9 ± 0.5 5.0 ± 0.4 
2-h glucose 
(mmol/L) 
21.1 ± 5.1*** 7.5 ± 1.8 5.1 ± 1.6 
HbA1c 
(%) 
8.3 ± 1.3*** 5.8 ± 0.2 5.6 ± 0.3 
Basal insulin 
(µU/ml) 
76  ± 60* 56 ± 22 28 ± 12 
HOMA[IR] 
 
5.8 ± 3.9*** 2.5 ± 0.9 1.0 ± 0.5 
Data are presented as mean ± SD. 
* P < 0.05 when compared with the control group 
** P < 0.01 when compared with the control group 
*** P < 0.0001 when compared with the control group 

 P < 0.05 when compared with the control group 

 P < 0.01 when compared with the control group 

 P < 0.0001 when compared with the control group 
4.3.1 Down-regulated miR-133a and miR-206 expression in Type 2 diabetes 
To determine whether muscle-specific miR-1, miR-133a, miR-133b or miR-206 was 
significantly altered in Type 2 diabetes, the mean fold change of these microRNAs was 
compared between Type 2 diabetes, IGT and control groups.  There was no significant 
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difference in miR-1 expression between the Type 2 diabetes or the IGT group compared 
to the controls (Figure  4-2).  In the Type 2 diabetes group miR-206 was significantly 
lower compared to the IGT (P < 0.01) and healthy control group (P < 0.05; Figure  4-2). 
 
Figure  4-2. Fold change in (A) miR-1 and (B) miR-206 expression in skeletal 
muscle from patients with Type 2 diabetes, IGT compared to controls. Data shown 
as mean ± SE. * P <  0.05 ** P < 0.01 
 
In the Type 2 diabetes patient group there was a significant down-regulation of miR-
133a compared the IGT group (P < 0.05) and the control group (P < 0.001; Figure  4-3), 
but miR-133b remained relatively stable, with no significant differences in miR-133b 
detected between groups (Figure  4-3).  The discordance in miR-133a and miR-133b 
expression raises the question whether there are significant differences in copy number 
of individual microRNA family members in skeletal muscle.  Potentially certain 
microRNA family members could be more important in target repression.  The relative 
abundance of a gene can be compared based on the cycle threshold, providing 
amplification efficiency and PCR reaction conditions are identical.  Comparison of the 
cycle threshold of miR-133b and miR-133a suggested similar abundance in skeletal 
muscle (Supplementary Figure  4-2). 
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Figure  4-3.  Fold change in (A) miR-133a and (B) miR-133b in skeletal muscle 
from patients with Type 2 diabetes, IGT compared to controls. Data shown as 
mean ± SE. *** P < 0.001  * P < 0.05 
4.3.2 Transcription of miR-133a is unchanged in Type 2 diabetes 
The significant down-regulation of mature miR-133a in Type 2 diabetes patients raises 
the question whether this is caused by decreased microRNA transcription or processing 
(see Chapter 2, section  2.2).  To determine whether the mature miR-133a expression 
observed in Type 2 diabetes could be due to changes in microRNA transcription, 
primers were designed against the two known miR-133a transcripts, miR-133a-1 on 
chromosome 18 and miR-133a-2 on chromosome 20 (Figure  4-1).  Both transcripts can 
be processed into identical mature miR-133a sequences, but there were no significant 
differences in pri-miR-133a-1 or pri-miR-133a-2 between the Type 2 diabetes, IGT and 
control group (Figure  4-4).  In addition, there were no significant differences in pri-
miR-1-1 or pri-miR-1-2 between the Type 2 diabetes, IGT and control group (Figure 
 4-4), which indicates a microRNA processing step downstream of primary transcription 
must be responsible for the down-regulation of miR-133a in Type 2 diabetes. 
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Figure  4-4. Expression of pri-microRNA transcripts encoding miR-1 and miR-
133a. (A) Fold change in pri-miR-133a-1 and pri-miR-1-2 encoded together on 
chromosome 18. (B) Fold change in pri-miR-133a-2 and pri-miR-1-1 encoded 
together on chromosome 20 in skeletal muscle from patients with Type 2 diabetes, 
IGT or controls.  Data shown as mean ± SE.  
 
The current literature assumes miR-1 and miR-133a are transcribed together as two 
bicistronic transcripts (Chen et al. 2006).  However, pri-miR-133a-2 had a significantly 
lower Ct compared to pri-miR-1-1 (P < 0.001; Figure  4-5) suggesting they may not be 
transcribed as a bicistronic transcript, or alternatively are processed at different rates. 
The ribosomal 18S gene was run as an endogenous control across Type 2 diabetes, IGT 
and control samples and was stably expressed across the groups (Supplementary Figure 
 4-3).  Therefore the cycle thresholds presented in Figure  4-5 enable comparison of the 
absolute abundance of each of the primary microRNA transcripts.  Pri-miR-133a-2 had 
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a significantly lower Ct than pri-miR-133a-1 (P < 0.001; Figure  4-5) suggesting it was 
more abundant, but this does not indicate whether pri-miR-133a-2 is primarily 
responsible for determining mature miR-133a levels.  In contrast, pri-miR-1-1 and pri-
miR-1-2 had similar cycle thresholds suggesting similar absolute abundance (Figure 
 4-5). 
  
Figure  4-5. Absolute cycle threshold of pri-miR-133a-1, pri-miR-1-2, pri-miR-
133a-2 and pri-miR-1-1 transcripts in skeletal muscle. Lower cycle threshold 
values indicate high transcript abundance.  Data shown as mean ± SE. *** P < 
0.001 
4.3.3 Pre-miR-133a expression in Type 2 diabetes 
The lack of any difference in pri-miR-133a expression between Type 2 diabetes patients 
and controls, despite significant differences in mature miR-133a expression indicates a 
factor downstream of primary miR-133a transcription may be responsible for the 
observed down-regulation of mature miR-133a in Type 2 diabetes patients.  Northern 
blot allows detection of both mature and pre-microRNA.  The Northern showed that 
pre-miR-133a was substantially less abundant than mature miR-133a (Figure  4-6), most 
likely due to rapid processing in the cytoplasm by DICER, which is in accordance with 
previous pre-miR-133 expression data showing pre-miR-133a-1 and pre-miR-133a-2 
were undetectable in skeletal muscle (Lee et al. 2008).  Quantification of mature miR-
133a expression levels from the Northern confirmed miR-133a was significantly down-
regulated in Type 2 diabetes compared to controls (Supplementary Figure  4-4).  The 
Northern appeared not to be as sensitive as RT-qPCR (see section  4.3.1), possibly 
because the probe against miR-133a may not have been able to differentiate between 
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miR-133 family members due to close sequence homology (Supplementary Table  4-2), 
so represents the average expression of miR-133a and miR-133b.  In contrast, RT-qPCR 
appeared to be able to differentiate between miR-133a and miR-133b in the present 
study (Supplementary Figure  4-2). 
 
Figure  4-6. Northern blot of pre- and mature miR-133a expression.  The miR-133a 
precursor is not strongly expressed, or is quickly processed into mature miR-133a.  
In comparison mature miR-133a is abundantly expressed in Type 2 diabetes, IGT 
and Control.  Lanes 1-3, 6-8 and 6-11 are from pooled RNA.  Lanes 4-5 and 12-13 
are from individual patient’s RNA. 
4.3.4 Expression of microRNA processing genes in Type 2 diabetes 
The lack of detectable changes in primary miR-133a transcription and the rapid 
processing of pre-miR-133a suggested some unknown factors are influencing the 
processing of pri-miR-133a-1 and/or pri-miR-133a-2.  Therefore the expression of 
microRNA processing genes was examined for differences between the Type 2 diabetes, 
IGT and control group that may help explain why mature miR-133a and miR-206 were 
less abundant in Type 2 diabetes patients (Figure  4-7).  There was no detectable 
decrease in genes encoding the nuclear primary microRNA processing proteins 
RNASEN (DROSHA) and DGCR8 in the Type 2 diabetes group compared to the IGT 
and control group (Figure  4-7).  The cytoplasmic pre-microRNA processing proteins 
DICER1 and EIFC2C (AGO) were not detectably different between the Type 2 diabetes 
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and the control group (Figure  4-7).  However, there was a significant difference in 
DICER1 detected between the IGT and the control group (P < 0.01). 
 
Figure  4-7. Expression of microRNA processing genes in Type 2 diabetes.
(A) DROSHA, (B) DGCR8, (C) DICER1 and (D) AGO2 expression.  Data is based 
on microarrays of skeletal muscle from Type 2 diabetes, IGT and control patients 
(n = 118). Data shown as mean ± SE.  ** P < 0.01 
4.3.5 Glucose homeostasis and insulin resistance predicted by miR-133a 
Type 2 diabetes pathogenesis is associated with a progressive increase in insulin 
resistance, which puts stress on the pancreatic β-cells to secrete more insulin to 
compensate and maintain glucose homeostasis.  Indicators of glucose homeostasis and 
insulin resistance are useful clinical markers of impaired glucose tolerance and Type 2 
diabetes.  If microRNAs can predict the decline in glucose tolerance they could 
represent novel biomarkers for the early detection of Type 2 diabetes.  To answer this 
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question multiple regression was used to determine whether miR-133a or miR-206 
could explain some of the variance in clinical indicators of insulin resistance and 
glucose homeostasis.  Glucose tolerance, HbA1c, basal insulin and HOMA[IR] 
appeared not to be normally distributed (Supplementary Figure  4-6 and Supplementary 
Figure  4-7), and therefore were log transformed prior to multiple regression analysis.  
Fasting glucose was rank transformed prior to multiple regression analysis. 
 
Figure  4-8.  Association of miR-133a and miR-206 with (A and B) fasting glucose 
(rank transformed) (C and D) log 2 h glucose tolerance (n = 30). 
. 
A multiple linear regression model including miR-133a and miR-206 explained 42% of 
the variance in fasting glucose (F = 9.8, P < 0.001).  Residuals were randomly 
distributed (Supplementary Figure  4-5), there was no evidence of multicollinearity (R2 
= 0.33) and fasting glucose passed the KS normality test following rank transformation. 
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However, only miR-133a made a significant contribution to the model (Table  4-4), 
suggesting miR-133a could predict fasting glucose alone.  A simpler regression model 
that included only miR-133a was found to explain 42% of the variance in fasting 
glucose concentrations (Figure  4-8; F = 20.4, P < 0.0001) based on the equation 
[Fasting glucose (mmol/L)] = 38.1 + 3.6*[miR-133a]. 
 
Table  4-4. Multiple regression model shows miR-133a predicts fasting glucose. 
Variable β coefficient T ratio P value 
Constant 38.1 ± 5.3 7.2 <0.0001*** 
miR-133a 3.5 ± 1.0 3.5 0.001*** 
miR-206 0.1 ± 1.4 0.1 0.90 
Based on rank transformed fasting glucose. *** P < 0.001  ** P < 0.01  ** P < 0.01 
 
The oral glucose tolerance test provides a useful clinical indicator of patients’ whole-
body glucose disposal rate, which will slow down as insulin resistance develops. 
Multiple regression of miR-133a and miR-206 explained 36% of the variance in 2 h 
glucose tolerance (Figure  4-8; F = 7.6, P = 0.002) but miR-206 made no significant 
contribution to the model (Table  4-5).  Residuals were randomly distributed 
(Supplementary Figure  4-5) and 2 h glucose tolerance passed the KS normality test 
following log transformation.  However, a simpler regression model that included only 
miR-133a explained 36% of the variance in 2 h glucose tolerance (Figure  4-8; F = 15.6, 
P < 0.001) based on the regression model [2 h glucose tolerance] = 1.65 + 0.11*[miR-
133a] 
 
Table  4-5. Multiple regression model shows miR-133a predicts glucose tolerance. 
Variable β coefficient T ratio P value 
Constant 1.65 ± 0.18 8.89 <0.0001*** 
miR-133a 0.11 ± 0.03 3.04 0.005** 
miR-206 0.01 ± 0.05 0.23 0.81 
Based on log transformed glucose tolerance data *** P < 0.001 ** P < 0.01 ** P < 0.01 
 
HbA1c is an indicator of longer-term hyperglycaemia. HbA1c accumulates during 
prolonged hyperglycaemia when glucose binds to haemoglobin. Healthy HbA1c is 
below 7% and higher HbA1c is associated with increased susceptibility to Type 2 
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diabetes complications.  A multiple regression model including miR-133a and miR-206 
explained 31% of the variance in HbA1c (F = 6.0, P = 0.006), but only miR-133a made 
a significant contribution to the model (Table  4-6).  Residuals were randomly 
distributed (Supplementary Figure  4-5) and HbA1c passed the KS normality test 
following log transformation (Figure  4-9).  Although, a simpler regression model with 
only miR-133a predicted 30% of the variance in HbA1c (Figure  4-9); F = 12.3, P = 
0.002) based on the regression model; [HbA1c] = 1.00 + 0.03*[miR-133a]. 
 
Figure  4-9. Association of miR-133a and miR-206 with (A and B) log HbA1c (C 
and D) HOMA[IR] (n = 30). 
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Table  4-6. Multiple regression model shows miR-133a predicts HbA1c. 
Variable β coefficient T ratio P value 
Constant 1.00 ± 0.05 17.3 <0.0001*** 
miR-133a 0.02 ± 0.01 2.6 0.01** 
miR-206 0.006 ± 0.01 0.4 0.68 
Based on log transformed HbA1c data. *** P < 0.001 ** P < 0.01 ** P < 0.01 
 
Basal insulin which is primarily determined by insulin secretion from pancreatic β-cells 
was not found to be correlated with skeletal muscle miR-133a or miR-206 expression 
(Supplementary Figure  4-7).  However, HOMA[IR] which is an indicator of insulin 
resistance was predicted by a multiple regression model including miR-133a and miR-
206 explained 31% of the variance in HOMA[IR] (Figure  4-9; F = 6.1, P = 0.01). 
HOMA[IR] passed the KS normality test after log transformation. 
 
Table  4-7. Multiple regression model shows miR-133a and miR-206 can predict 
insulin resistance (HOMA[IR]). 
Variable β coefficient T ratio P value 
Constant 2.00 ± 0.23 4.6 <0.0001*** 
miR-133a 0.07 ± 0.04 1.6 0.11 
miR-206 0.10 ± 0.06 1.5 0.13 
Based on log transformed HOMA[IR] data. *** P < 0.001 ** P < 0.01 ** P < 0.01 
4.3.6 Overexpression of miR-133a targets diabetes associated genes 
To demonstrate miR-133a may have a functional role in Type 2 diabetes it is important 
to experimentally validate miR-133a targets.  Microarray data from HeLa cells 24 h 
following transfection of a miR-133a duplex designed to mimic endogenous miR-133a 
was retrieved from GEO (Grimson et al. 2007).  Target expression was mapped to 
manually curated literature citations associated with diabetes.  Forty-two miR-133a 
targets were identified with >1 diabetes associated citations in the NCBI database 
(Supplementary Figure  4-10).  Based on the difference in log2 intensity between 
transfected and control cells the majority of diabetes linked miR-133a targets were 
suppressed.  The largest decrease in a diabetes associated miR-133a target was for 
CDC42 which has been linked with GLUT4 trafficking (Nevins & Thurmond, 2005; 
Usui et al. 2003; Ishikura & Klip, 2008). 
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4.3.7  Evidence of microRNA action on target signatures in Type 2 diabetes 
If miR-133a acts primarily through mRNA cleavage and degradation this would be 
reflected by an increase in miR-133a target abundance in Type 2 diabetes patients.  In 
skeletal muscle, miR-1, miR-133a, miR-133b and miR-206 targets were significantly 
suppressed at mRNA level compared to miR-29a and miR-34a targets (Figure  4-10), 
which is in agreement with previous data showing microRNAs repress targets when 
highly expressed in a specific tissue. 
 
However, there was no evidence of a decrease in miR-133a action on mRNA cleavage 
in Type 2 diabetes patients.  The miR-133a target expression signature did not differ 
between patient groups (Figure  4-10), suggesting that miR-133a targets may be subject 
to translational repression rather than mRNA cleavage. Alternatively, the target 
expression signature is not sufficiently sensitive to detect differences in microRNA 
targets between the Type 2 diabetes, IGT and control groups. 
 
The target expression signature of miR-1 and miR-206 was significantly increased in 
the Type 2 diabetes group compared to the control group (Figure  4-10; P <0.05).  Both 
miR-206 and miR-1 are from the same family, with similar seed sequences 
(Supplementary Table  4-2. miR-1/206 and miR-133 family sequence homology), and 
therefore share common targets.  The reduced miR-206 target suppression was in 
agreement with the down-regulation of miR-206 observed in Type 2 diabetes patients 
(Figure  4-2). 
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Figure  4-10. miR-1/miR-206 target expression signatures in Type 2 diabetes.
(A) Target suppression by microRNAs with high copy number (miR-1, 206, 133a) 
compared to microRNAs with low copy number (miR-29a, miR-34a) in healthy 
skeletal muscle.  Points represent mean microRNA target expression for individual 
patients.  (B) miR-133a (C) miR-206 (D) miR-1 target expression in Type 2 
diabetes, IGT and control patients. * P < 0.05 
4.3.8 Gene ontology enrichment analysis 
To examine the potential function of miR-133a in Type 2 diabetes, gene ontology 
enrichment analysis was conducted.  Gene ontology (GO) enrichment analysis finds 
genes with similar biological function based on gene ontology terms as described in 
section  4.2.13.  To limit the identification of spurious biological functions, only gene 
ontology term enrichment with a false discovery rate <10% were considered. 
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There was significant enrichment of GO terms associated with intracellular organelles 
and protein binding among miR-133a targets.  Glucose uptake involves the intracellular 
trafficking of GLUT4 to the plasma membrane, which requires the intracellular 
organelle network (Bryant et al. 2002).  The GO terms, Intracellular membrane-bound 
organelle, Clathrin-coated vesicle and Protein binding were significantly enriched with 
miR-133a targets.  These included SVOP, AFTPH, AP2M1, CLTA, FURIN, VAT1, 
EGFR, LDLRAP1, SYT1 and VAMP2.  It has been reported VAMP2 and VAMP3 are 
associated with SNARE interactions and vesicle transport (Bryant et al. 2002; 
Cheatham et al. 1996; Nevins & Thurmond, 2005), thus may be involved in GLUT4 
trafficking.  Furthermore, there was also significant enrichment of actin-associated GO 
terms including; Cytoskeletal protein binding, Actin cytoskeleton, Actin cytoskeleton 
organization and biogenesis.  Reorganisation of the actin cytoskeleton may be required 
for movement of GLUT4 and insulin signaling proteins, although there have been few 
studies on the role of the actin cytoskeleton in Type 2 diabetes (Eyster & Olson, 2009).   
 
Gene ontology terms linked to negative regulation of insulin signaling were also found.  
For example, miR-133a targets were significantly enriched with the GO term Protein 
phosphatase type 2A complex; miR-133a targets a group of protein phosphatase 
subunits including PPP2CB, PPP2R5D, PPP2R5E and PPP2R4.  Protein phosphatase 2 
(PPP2CB) inhibits insulin signaling via PI-3K (Begum & Ragolia, 1999).  Impairment 
of PPP2CB down-regulation in response to insulin is reported in Type 2 diabetes 
patients (Højlund et al. 2002) and diabetic GK rats (Begum & Ragolia, 1999).  Down-
regulation of miR-133a is consistent with its potential action on protein phosphatase 
type 2A complex, which is a negative regulator of insulin signaling. 
 
Finally, significant enrichment of GO terms linked to transcription were found, 
including Transcription from RNA polymerase II promoter, Transcription factor activity 
and Negative regulation of transcription, indicating that miR-133a targets transcription 
regulators and could have widespread indirect effects via regulation of transcriptional 
factor activity. 
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4.3.9 Identifying Type 2 diabetes biomarkers from microRNA target signatures 
Patients’ microRNA target expression signatures were analysed using Statistical 
Analysis of Microarrays (SAM) to identify further potential microRNA biomarkers in 
Type 2 diabetes.  SAM provides control for multiple testing errors and calculates a false 
discovery rate for the differentially expressed microRNA target signatures.  Based on a 
0.02 FDR and a 1.8 delta cut-off, 248 microRNA target expression signatures were 
identified as differentially expressed between Type 2 diabetes and control patients 
which equates to ~15 false calls (Figure  4-11).  Among these were the microRNA target 
expression signatures for miR-1 and miR-206 in agreement with the ANOVA results 
(section  4.3.7).  The list of 248 microRNAs with differentially expressed target 
signatures is shown in Supplementary Table  4-4.  However, the microRNA target 
signature for miR-133 was not identified using SAM.  Further work should clarify 
whether microRNA target expression signatures correlate with microRNA expression. 
 
Figure  4-11. SAM analysis of microRNA target expression signatures may identify 
possible microRNA biomarkers of Type 2 diabetes.  248 microRNA target 
expression signatures were differentially expressed, with an estimates 15 false calls. 
Grey circles indicate differentially expressed microRNA target expression 
signatures in Type 2 diabetes patients. 
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4.3.10 Experimental validation of microRNA arrays 
Experimental validation of microRNA arrays found no significant difference in miR-
27b, miR-143, miR-208 or miR-424 expression between Type 2 diabetes, IGT and 
control groups (Figure  4-12). The fold change in miR-27b, miR-143, miR-208 and miR-
424 expression detected from microRNA arrays on pooled RNA from Type 2 diabetes 
and control patients is shown in Supplementary Table  4-5.  In the Type 2 diabetes group 
miR-143 appeared to be increased 200%, but variability in miR-143 expression within 
the Type 2 diabetes group may have contributed to the lack of significance (Figure 
 4-12).   
 
Figure  4-12. Fold change in (A) miR-27b, (B) miR-143, (C) miR-208 and (D) miR-
424 expression in skeletal muscle from Type 2 diabetes, IGT and control patients. 
Data shown as mean ± SE. 
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The expression of miR-29a was significantly increased in the Type 2 diabetes compared 
to the control group (P < 0.05), but there was no significant difference in miR-29b 
expression between the Type 2 diabetes, IGT and control groups (Figure  4-13). 
 
Figure  4-13. Fold change in (A) miR-29a and (B) miR-29b expression in skeletal 
muscle from patients with Type 2 diabetes, IGT and controls.  Data shown as mean 
± SE. * P <  0.05 
 
Given that miR-29a expression appeared to be elevated in Type 2 diabetes, the next 
question was whether miR-29a had any detectable effect on target expression in Type 2 
diabetes, IGT and control groups in-vivo.  SAM analysis of all microRNA target 
expression signatures differentially expressed between the Type 2 diabetes and control 
group did not identify the miR-29a target expression signature (Supplementary Table 
 4-4).  Furthermore, comparison of miR-29a target expression signature between the 
Type 2 diabetes, IGT and control groups showed no significant differences (Figure 
 4-14).  The pathway enrichment analysis of miR-29a targets identified several pathways 
associated with Type 2 diabetes including insulin signaling, JAK/STAT, MAPK and 
regulation of the actin cytoskeleton (Figure  4-14). 
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Figure  4-14. (A) No change in miR-29a target expression signature in Type 2 
diabetes. (B) Top ranked KEGG Pathways enrichment with miR-29a targets. 
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4.4. Discussion 
The main findings of this study were that in skeletal muscle from Type 2 diabetes 
patients, miR-133a and miR-206 expression are both significantly lower compared to 
IGT and controls, whereas miR-1 and miR-133b expression is similar.  However, there 
was no change in miR-133a transcription and pre-miR-133a appeared to be rapidly 
processed, thus altered transcription appeared not to explain the changes in mature miR-
133a in Type 2 diabetes. 
 
Clinical indicators of glucose homeostasis and insulin resistance were predicted by 
miR-133a and miR-206 expression, but miR-133a appeared to be the strongest predictor.  
Furthermore, analysis of microarray data from HeLa cells after miR-133a 
overexpression showed miR-133a targets include diabetes-associated genes leading to 
mRNA cleavage.  However, if miR-133a plays a role in skeletal muscle during Type 2 
diabetes pathogenesis it appears miR-133a acts primarily via translation repression 
rather than mRNA cleavage, as no differences were found in miR-133a target 
expression in Type 2 diabetes patients.  Interestingly, genes involved in protein 
phosphatase activity and intracellular transport were significantly enriched with 
predicted miR-133a binding sites, which suggests miR-133a could play a regulatory 
role in Type 2 diabetes pathogenesis.  Alternatively miR-133a could be a promising 
candidate for use as a biomarker of dysregulated glucose homeostasis due to insulin 
resistance or pancreatic β-cell failure in Type 2 diabetes. 
4.4.1 Down-regulation of miR-133a and miR-206 in Type 2 diabetes 
The role of microRNAs during Type 2 diabetes development has not been studied 
previously in human skeletal muscle, although it is becoming clear that microRNAs 
play regulatory roles in numerous human diseases (Bushati & Cohen, 2007; Couzin, 
2008; Perera & Ray, 2007).  In the present study expression of two muscle-specific 
microRNAs, miR-133a and miR-206 was significantly lower in Type 2 diabetes patients 
compared to IGT and controls, which suggests they could play a regulatory role in Type 
2 diabetes pathogenesis or alternatively may be a secondary effect in response to other 
physiological changes such as elevated glucose or insulin. 
 
In diabetic GK rats with low glucose tolerance and Type 2 diabetes, miR-133a 
expression was not significantly different compared to healthy rats (He et al. 2007).  Re-
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analysis of the microRNA array data from that study using SAM with less stringent cut-
offs still failed to identify miR-133a as differentially expressed (data not shown).  This 
may have been due to limitations in the sensitivity of the microRNA array or may be 
due to fundamental differences in Type 2 diabetes pathogenesis between the diabetic rat 
model and human Type 2 diabetes. 
 
Previous studies on the role of miR-133a in skeletal muscle development suggest that it 
is a regulator of proliferation (Chen et al. 2006).  Overexpression of miR-133a in 
C2C12 myoblasts promotes proliferation and delays differentiation (Chen et al. 2006), 
although during skeletal muscle differentiation miR-133a expression is strongly induced 
together with miR-1 and miR-206 (Chen et al. 2006; Kim et al. 2006; Boutz et al. 
2007).  The role of miR-1, miR-133a and miR-206 in adult skeletal muscle is less clear 
and is unlikely to reflect only alterations in cell differentiation and proliferation.  For 
example, miR-1, miR-133a and miR-206 were all found to be down-regulated in 
pancreatic cancer patients with cachexia (Chapter 3).  However, miR-133a has also 
been reported to be down-regulated in a mouse skeletal muscle hypertrophy model 
(McCarthy & Esser, 2007).  In addition, miR-133a is reported to be down-regulated in 
response to endurance exercise training in both mice and humans (Keller et al. 2007; 
Safdar et al. 2009).  Furthermore, miR-133a has been shown to be down-regulated in 
regenerating zebrafish muscle (Yin et al. 2008).  Taken together these studies suggest 
miR-133a and miR-206 may be down-regulated when tissue remodelling is required.  
Therefore, in Type 2 diabetes the decrease in skeletal muscle miR-133a and miR-206 
expression may be a reflection of remodelling occurring. 
 
Hyperglycaemia or hyperinsulinaemia may both contribute to modulating microRNA 
expression levels in Type 2 diabetes skeletal muscle, but there have been no studies 
examining microRNA expression in response to extracellular factors in human skeletal 
muscle.  The stepwise decline in miR-133a expression between normal glucose 
tolerance, impaired glucose tolerance and Type 2 diabetes patients suggests miR-133a 
might be affected or may contribute to the development of hyperglycaemia or 
hyperinsulinaemia in Type 2 diabetes linked to insulin resistance and β-cell dysfunction.  
For example, in adipocytes it is reported miR-29 is responsive to extracellular glucose 
levels (He et al. 2007).  In addition, miR-375 is responsive to extracellular glucose in 
pancreatic β-cells (El Ouaamari et al. 2008).  Furthermore, a screen for glucose-
regulated microRNAs identified 61 microRNAs out of 108 microRNAs were regulated 
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by glucose, but neither miR-133a nor miR-206 were detected in pancreatic β-cells 
(Tang et al. 2009).  Taken together these studies suggest a screening approach could be 
useful in skeletal muscle to identify glucose-regulated microRNAs.  It remains to be 
seen whether miR-133a or miR-206 expression is affected by extracellular glucose or 
insulin. 
4.4.2 Transcription of miR-133a is unaltered in Type 2 diabetes 
To determine whether the down-regulation of mature miR-133a in Type 2 diabetes was 
due to alteration in the transcription or processing of miR-133a, the expression of 
primary miR-133a transcripts and pre-miR-133a were measured.  There was no 
evidence of an alteration in pri-miR-133a-1 or pri-miR-133a-2 expression in Type 2 
diabetes or impaired glucose tolerance.  The current literature assumes miR-1 and miR-
133a are transcribed in unison from two independent bicistronic transcripts (Chen et al. 
2006).  In a mouse model of cardiac hypertrophy miR-1 and miR-133a expression are 
reported to change in a similar manner (Carè et al. 2007) supporting the assumption that 
they are transcribed together as a bicistronic transcript.  The present findings suggest 
this may not be the case because mature miR-1 was unchanged while miR-133a was 
down-regulated in Type 2 diabetes, and pri-miR-1-2 appeared to be more abundant than 
its downstream neighbour pri-miR-133a-1 on chromosome 18.  Several studies have 
reported discordant expression of mature miR-1 and miR-133a and their primary 
transcripts in agreement with the present data (Drummond et al. 2008; McCarthy et al. 
2007).  Taken together these findings indicate that changes in pri-microRNA transcripts 
do not always affect mature microRNA levels.  Interestingly, pri-miR-133a-2 appears to 
be more abundant than pri-miR-133a-1, thus may be primarily responsible for 
determining mature miR-133a expression levels.  In contrast, pri-miR-1-1 and pri-miR-
1-2 appear to be expressed at similar absolute levels, suggesting they would contribute 
equally to determining mature miR-1 levels, but this could not be confirmed in the 
present study. 
4.4.3 No evidence of altered processing of miR-133a in Type 2 diabetes 
Pre-miR-133a expression indicated it must be rapidly processed into mature miR-133a, 
which is in agreement with a previous study indicating pre-miR-133a was present at 
very low levels in skeletal muscle (Lee et al. 2008).  No differences in pre-miR-133a 
expression could be detected between Type 2 diabetes, impaired glucose tolerance or 
normal glucose tolerance suggesting pre-miR-133a processing was not responsible for 
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the down-regulation of mature miR-133a.  In addition, the expression of microRNA 
processing proteins, DROSHA, DCGR8, AGO2 and DICER was similar between Type 
2 diabetes, impaired glucose tolerance and normal glucose tolerance.  Taken together 
these findings suggest there must be other regulatory steps after initial microRNA 
transcription that determines mature microRNA levels. 
4.4.4 Glucose homeostasis and insulin resistance predicted by miR-133a 
Multiple regression modelling was used to examine whether miR-133a and miR-206 
expression were predictors of fasting glucose, basal insulin, HbA1c, HOMA[IR] or 2 h 
glucose tolerance.  The relative expression of miR-133a and miR-206 was able to 
predict 30-40% of the variance in fasting glucose, HbA1c, 2 h glucose tolerance and 
HOMA[IR], but not basal insulin using the multiple regression approach.  Further 
analysis using only miR-133a expression as a predictor of fasting glucose, HbA1c, 2 h 
glucose tolerance and HOMA[IR] found miR-133a alone was able to explain between 
30-40% of the variance in these clinical measures of glucose homeostasis and insulin 
resistance.  However, other factors also influence fasting glucose, HbA1c and 2 h 
glucose tolerance, which were not considered in this study.  For example HbA1c, 
fasting glucose and 2 h glucose tolerance are strongly influenced by insulin secretion.  
However, miR-133a is not highly expressed in the pancreas and has not been linked to 
insulin secretion (Tang et al. 2009), which suggests that miR-133a most likely affects 
insulin resistance in Type 2 diabetes leading to secondary stress on β-cell function. 
 
It is important to emphasise that the multiple regression models with miR-133a and 
miR-206 as predictors explained less than half of the variance in glucose homeostasis 
and insulin resistance indicators.  The least squares regression approach assumes a 
linear relationship between microRNA expression and clinical variables, however 
fasting glucose, 2 h glucose tolerance, HbA1c, basal insulin and HOMA[IR] all showed 
greater variance in the Type 2 diabetes patients, although this was reduced by log 
transformation.  Of the muscle-specific microRNAs profiled miR-133a appeared to be 
the best predictor of fasting glucose and 2 h glucose tolerance, which are both part of 
the current Type 2 diabetes diagnosis criteria and therefore could represent an early 
biomarker of Type 2 diabetes pathogenesis prior to β-cell failure.  However, whether 
miR-133a expression could be a useful biomarker of impaired glucose tolerance and 
Type 2 diabetes would need to be established in a larger prospective study. 
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4.4.5 Potential regulatory role of miR-133a in Type 2 diabetes 
MicroRNAs have been shown to play a regulatory role in diverse diseases, regulating 
differentiation, proliferation, apoptosis, and insulin secretion (Couzin, 2008).  If miR-
133a does play a regulatory role in Type 2 diabetes then examination of miR-133a 
target genes should reveal a group of genes that could contribute to the impaired 
glucose tolerance and insulin resistance in skeletal muscle. 
 
The predicted targets of miR-133a were mined for significantly enriched gene 
ontologies using the bioinformatics functional classification tools available through 
NCBI/DAVID (Sherman et al. 2007).  The calculation of enrichment was based on a 
modified Fischer test, which tests whether the microRNA target list contains a 
significant number of genes belonging to the same ontology group compared to the total 
number of genes in the human genome associated with the same ontology group.  For 
example, genes involved in intracellular transport and protein dephosphorylation were 
significantly enriched among miR-133a targets.  Enrichment of a gene ontology in a 
microRNA target list means that the microRNA may co-ordinately regulate a group of 
genes with similar functions (John et al. 2004).  The data suggests the functional 
consequences of miR-133a in adult skeletal muscle may be partly through repression of 
intracellular transport proteins and protein phosphatases. 
4.4.6 Protein phosphatases are predicted targets of miR-133a 
In particular, genes associated with phosphoprotein phosphatase activity and 
membrane-bound organelles are of interest to Type 2 diabetes as these are involved in 
insulin-stimulated glucose uptake and hence have the potential to modulate glucose 
homeostasis.  The miR-133a targets significantly enriched for phosphoprotein 
phosphatase activity and protein amino acid dephosphorylation ontologies included 
several protein-tyrosine phosphatases. 
 
Protein-tyrosine phosphatases (PTPs) can reduce insulin receptor kinase activity by 
dephosphorylation of the insulin receptor (Youngren et al. 2007).  In-vivo 
overexpression of PTP-1B in mice reduces insulin receptor autophosphorylation leading 
to insulin resistance (Zabolotny et al. 2004), whereas PTP-1B knockout mice have 
enhanced insulin receptor autophosphorylation and insulin sensitivity (Elchebly et al. 
1999).  In Type 2 diabetes patients, activity of PTPs appear to be elevated (Worm et al. 
1996).  The PTPs targeted by miR-133a include PTPN12, PTPRD, PTPRZ1 and protein 
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phosphatase subunits.  Protein phosphatase 2 (PPP2CB) has been previously linked to 
Type 2 diabetes as it can inhibit insulin signaling through PI3K (Begum & Ragolia, 
1999).  In addition, PPP2CB down-regulation in response to insulin has been reported 
to be impaired in Type 2 diabetes patients (Højlund et al. 2002).  Therefore, down-
regulation of miR-133a in Type 2 diabetes may increase protein levels of protein 
phosphatases, which can impair insulin signaling. 
 
In addition to identifying groups of genes that miR-133a may target co-ordinately in 
Type 2 diabetes, each target was examined independently for literature associations 
with diabetes.  This revealed over 15 predicted miR-133a targets with previously 
established links to diabetes providing support for the regulatory role of miR-133a in 
Type 2 diabetes.  However, only CDC42 has been previously experimentally validated 
as a miR-133a target in cardiomyocytes (Carè et al. 2007). 
4.4.7 CDC42 and GLUT4 trafficking proteins are predicted targets of miR-133a 
CDC42 is a small GTP binding protein that contains a highly conserved miR-133a 
target site.  CDC42 has been confirmed as a miR-133a target based on a luciferase 
reporter assay in cardiomyocytes (Carè et al. 2007).  The analysis of existing microarray 
data in HeLa cells from miR-133a transfections (Grimson et al. 2007) showed CDC42 
and other genes down-regulated in response to miR-133a overexpression, thus 
providing further evidence supporting a regulatory role for miR-133a in Type 2 
diabetes.   
 
CDC42 can mediate insulin-stimulated GLUT4 transport and stimulate glucose uptake 
in 3T3-L1 adipocytes (Usui et al. 2003).  In response to extracellular glucose CDC42 
interacts with vesicle-associated membrane protein 2 (VAMP2) and relocates to the 
plasma membrane (Nevins & Thurmond, 2005).  VAMP2 contains a predicted miR-
133a binding site, therefore could also be regulated by miR-133a.  Furthermore, 
diabetes-associated miR-133a targets included RAB14, which is a substrate of the Rab-
GTPase activating protein AS160 and insulin-stimulated GLUT4 translocation is 
reported to require AS160 phosphorylation (Larance et al. 2005).  In addition, 
knockdown of RAB14 in muscle cells has been shown to inhibit insulin-induced 
GLUT4 translocation (Ishikura & Klip, 2008).  Taken together these studies suggest 
miR-133a may co-ordinately target GLUT4 trafficking proteins and therefore help 
regulate insulin-stimulated glucose uptake. 
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4.4.8 SOCS proteins are predicted targets of miR-133a 
The suppressor of cytokine signaling (SOCS) was also found to be a miR-133a target 
previously associated with Type 2 diabetes.  It has already been reported SOCS proteins 
can be regulated post-transcriptionally by microRNAs (Pichiorri et al. 2008).  For 
example, in multiple myeloma the miR-19 family was shown to target SOCS-1, which 
is frequently silenced in multiple myeloma (Pichiorri et al. 2008).  The re-analysis of 
microarray data in HeLa cells following overexpression of miR-133a showed SOCS 
might be regulated mainly through translational repression. 
 
The SOCS family act as negative regulators of JAK/STAT mediated cytokine signaling 
(Balasubramanyam et al. 2005).  SOCS proteins have distinct binding sites for IRS and 
elongin BC ubiquitin-ligase (Rui et al. 2002).  Binding of SOCS1 and 3 to the insulin 
receptor can lead to degradation of insulin receptor substrates, IRS-1 and IRS-2 
(Balasubramanyam et al. 2005).  Thus SOCS proteins can suppress insulin signaling 
downstream of IRS, although the action of miR-133a on SOCS in human skeletal 
muscle has not yet been confirmed.  
4.4.9 MicroRNA target signatures reveal novel Type 2 diabetes microRNAs 
It has been shown that microRNA target signatures can be detected in microarray data 
from different tissues (Sood et al. 2006).  Furthermore, microRNA target signatures in 
tissues can be detected based on the mean absolute expression of microRNA targets 
(Arora & Simpson, 2008).  Thus existing microarray datasets could be mined for 
microRNA target signatures, which is potentially useful for identifying novel candidate 
microRNAs (Arora & Simpson, 2008). 
 
SAM analysis identified the microRNA target signature of miR-206 as significantly 
different in the Type 2 diabetes compared to the control group.  However, the 
microRNA target signatures of miR-133a and miR-29a were not found to be 
significantly different between Type 2 diabetes and controls, which suggests that using 
SAM analysis to find differentially expressed microRNA target signatures between 
disease groups requires further optimisation.  For example, microRNA target signatures 
could be limited to microRNA targets with 8mer site matches only, as 8mer sites are 
suggested to be more effective at target suppression than 7mer-8 and 7mer sites 
(Grimson et al. 2007; Baek et al. 2008; Bartel, 2009).  There are currently no examples 
of microRNAs where all targets have been experimentally validated.  Therefore, it is 
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difficult to directly test the utility of using microRNA target signatures to identify 
possible disease linked microRNAs. 
 
It will be important to experimentally validate miR-133a targets potentially associated 
with Type 2 diabetes or insulin resistance in a muscle cell model, as this will provide 
further evidence to show whether miR-133a is a post-transcriptional regulater of insulin 
resistance and Type 2 diabetes.  It remains to be seen whether microarray data can be 
mined for disease specific microRNA signatures based on comparing the expression of 
a group of microRNA targets for diseased and healthy tissue.  Until then microRNA 
arrays remain the only way to identify many potential disease biomarkers 
simultaneously. 
4.4.10 MicroRNA array validation confirms miR-29a up-regulation 
The experimental validation of microRNA array using RT-qPCR confirmed miR-29a 
was up-regulated in Type 2 diabetes patients, which was in agreement with microRNA 
array and Northern data from GK diabetic rats showing miR-29a up-regulation in 
adipose and muscle tissue (He et al. 2007).  However, in contrast despite being 
identified as differentially expressed based on microRNA arrays, miR-27b, miR-29b, 
miR-143, miR-208 and miR-424 were not found to be differentially expressed using 
RT-qPCR.  It is difficult to explain the lack of agreement between the microRNA array 
data and the RT-qPCR validation data presented here as the microRNA arrays were 
conducted independently (I. Gallagher, personal communication).  However, pooling 
patient RNA for the microRNA arrays is likely to have obscured some of the individual 
variance in microRNA expression preserved during the RT-qPCR validation.  In the 
case of miR-143, variation in miR-143 expression in the Type 2 diabetes patients most 
likely explains the lack of significant differences between Type 2 diabetes patients and 
controls.  Therefore, in future studies microRNA arrays should ideally be conducted on 
individual patients rather than pooled patient RNA. 
 
Comparison of the present results from human Type 2 diabetes with microRNA array 
data from GK rats reveals little concordance between studies.  For example recent 
microRNA array data from diabetic GK rats failed to show miR-29a was over expressed 
in Type 2 diabetes skeletal muscle (Huang et al. 2009).  In this study miR-24, miR-126, 
miR-424, miR-23a, miR-450 and miR-130 were reported to be >2-fold down regulated, 
while miR-301 and let-7f were over 2-fold up-regulated (Huang et al. 2009).  Previously 
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in diabetic GK rats miR-29a, miR-29b, miR-29c and miR-150 were reported to be up-
regulated (He et al. 2007), while miR-379, miR-127, miR-299, miR-434, miR-335, 
miR-130, miR-19b, miR-451, miR-148, miR-199 and miR-152 were reported to be 
down-regulated (He et al. 2007).  Therefore, care should be taken when interpreting 
microRNA studies based on murine Type 2 diabetes models, as they may not represent 
human Type 2 diabetes. 
 
The lack of concordance between two microRNA array studies conducted in diabetic 
GK mice may have been due to the use of different custom microarray platforms 
(Huang et al. 2009; He et al. 2007).  A recent study compared five commercial 
microRNA array platforms for agreement and reported a lack of agreement between 
some platforms (Sato et al. 2009).  The finding that miR-29a was up-regulated in Type 
2 diabetes following microRNA array validation work using RT-qPCR suggests it may 
be worth following up in a future study to determine its role in Type 2 diabetes.  
Knockdown of miR-29 in adipocytes suggests it may influence insulin-stimulated 
glucose uptake via impairment of Akt phosphorylation, but this has not been confirmed 
in skeletal muscle (He et al. 2007).  Therefore, miR-29a appears to have the potential to 
modulate glucose homeostasis in Type 2 diabetes. 
4.4.11 Limitations 
Evaluating the predictive power of individual microRNA expression to explain clinical 
indicators of glucose tolerance and insulin resistance is reliant on accurate diagnosis.  
Ideally, a hyperinsulinaemic-euglycaemic clamp should be used, but this was not 
practical in the present study.  Glucose tolerance is a dynamic response, which will be 
susceptible to biological variation.  Even using the gold standard hyperinsulinemic 
clamp the within subject coefficient of variation (CV) is reported to be around 12%.  To 
minimise biological variation the oral glucose tolerance test was conducted at the same 
time of day for all patients, although the WHO recommends two independent tests 
before any diagnosis to improve reliability (WHO, 2006). 
 
The clinical diagnosis of impaired glucose tolerance and Type 2 diabetes is categorical 
based on oral glucose tolerance, but glycaemia control is a continuous variable thus 
patients close to clinical cut-off criteria may be incorrectly classified.  This was 
highlighted a decade ago when the WHO followed the ADA and lowered the glycaemic 
threshold for identifying impaired glucose tolerance (WHO, 2006; Shaw et al. 2000).  
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Nevertheless, it is important that any microRNA expression profile can distinguish 
between IGT and healthy patients, because it is well established that IGT is a risk factor 
for cardiovascular disease and a predictor of all cause mortality (Balkau et al. 1999; 
Brunner et al. 2006; DECODE STUDY GROUP, 1999; Saydah et al. 2001). 
 
Comparing patients’ microRNA or microRNA target signatures is dependent on well-
defined patient groups with similar characteristics, and while every effort was made to 
control for known confounders such as age, BMI and VO2max, the IGT group included 
individuals with varying levels of glucose tolerance which would influence the power of 
any predictive model based on microRNA expression.  Furthermore, although miR-
133a predicted around ~40% of variation in glucose homeostasis indicators, a single 
microRNA is unlikely to explain the complex disease process. 
 
Both miR-133a and miR-206 are predicted to target between 200-300 genes. The 
identification of microRNA targets is important in determining the function of these 
small molecules in healthy and insulin resistant muscle.  There are an ever-growing 
number of prediction algorithms for determining functional microRNA:mRNA target 
interactions, for example TargetScan, PicTar and Miranda (Lall et al. 2006; John et al. 
2004; Lewis et al. 2003).  These algorithms vary in the rules they apply to determine 
functional targets (Sethupathy et al. 2006).  For the analysis of miR-133a targets the 
TargetScan algorithm was used.  This has been shown to be more sensitive than many 
other algorithms, meaning it can identify ~60% of functional targets (Sethupathy et al. 
2006).  However, potentially important non-conserved sites will not be considered when 
using TargetScan, as it relies on conservation of microRNA:mRNA interactions across 
species.  During preparation of this thesis TargetScan was updated and now includes 
non-conserved microRNA target predictions (Friedman et al. 2009).  It is uncertain how 
effective non-conserved microRNA target sites are in post-transcriptional repression, as 
they have not been widely studied.  Another issue is most algorithms provide global 
microRNA target lists, thus targets could be ranked as important even when microRNA 
or mRNA are not expressed in a tissue. 
  
In the future a global profiling approach to identify insulin resistance and Type 2 
diabetes associated microRNAs, mRNA and proteins would be useful, as this has 
proved successful in other chronic diseases such as cancer.  For example unique 
microRNA signatures have been identified in lung cancer, which can predict patient 
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survival and relapse.  There are limitations in using microRNA signatures to identify 
regulatory microRNAs in Type 2 diabetes because there are no simultaneous mRNA 
and microRNA profiles available for Type 2 diabetes.  Therefore, the effectiveness of 
microRNA signatures in identifying relevant microRNAs could not be evaluated and 
can only be used as a guide to potential microRNAs, which may be dysregulated in 
disease.  Finally the identification of a disease microRNA signature does not confirm 
whether microRNA dysregulation is the main cause of disease or only a biomarker of 
disease pathogenesis. 
4.4.12 Future Directions 
Global microRNA profiling in Type 2 diabetes will undoubtedly provide a new insight 
into post-transcriptional regulation in Type 2 diabetes pathogenesis.  This is an 
especially powerful approach to use when combined with global mRNA and proteomic 
profiling (Baek et al. 2008; Selbach et al. 2008).  However, the range of proteins 
detectable using current methods is limited compared to coverage of the human genome 
on Affymetrix microarrays.  Based on the findings from the present study with the time 
and resources currently available it was important to identify and experimentally 
validate miR-133a and miR-206 targets (Chapter 5), which may contribute to Type 2 
diabetes pathogenesis.  This should provide additional evidence to show microRNAs 
are potentially influential post-transcriptional regulators in Type 2 diabetes 
pathogenesis.  This will require a muscle-cell model, which can be transfected with 
microRNA knockdown oligonucleotides.  Western analysis can be used to identify any 
shift in target protein expression following microRNA knockdown. 
 
In addition, to establish whether these muscle-specific microRNAs are possible 
regulators of insulin resistance another patient cohort characterised by insulin resistance 
could be used such as aging, physical inactivity or obesity.  Identifying post-
transcriptional regulators of skeletal muscle phenotype in Type 2 diabetes is important 
given the central role of muscle insulin resistance in Type 2 diabetes pathogenesis 
(Mootha et al. 2003; Muoio & Newgard, 2008).  In addition identification of novel 
microRNA biomarkers could eventually help facilitate earlier diagnosis of Type 2 
diabetes, which would significantly improve morbidity and mortality rates (Roglic et al. 
2005; Shaw et al. 2000; Wild et al. 2004; WHO, 2006; Zimmet et al. 2001).  Only small 
amounts of RNA are required for microRNA analysis by RT-qPCR, which in addition is 
relatively quick compared to other methods such as Northern blot (Cissell & Deo, 2009; 
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Chen et al. 2005).  It would be particularly useful to determine whether microRNA 
changes in serum correspond to microRNA changes in skeletal muscle, as a blood based 
biomarker would be more practical for clinical use. 
4.4.13 Conclusions 
• Muscle-specific miR-133a and miR-206 are down-regulated in Type 2 diabetes.  
Fasting blood glucose and 2 h glucose tolerance, part of the current Type 2 diabetes 
diagnostic criteria (WHO, 2006) can be partly predicted from miR-133a expression. 
• Transcription of miR-133a is unaltered in Type 2 diabetes, there appears to be a 
post-transcription blockage in miR-133a processing.  However, the expression of 
microRNA biogenesis proteins is unaltered in Type 2 diabetes. 
• MicroRNA-133a is predicted to target diabetes associated genes including protein 
tyrosine phosphatases and vesicle transport proteins. 
• MicroRNA target signatures can be used to mine existing microarray data for novel 
candidate Type 2 diabetes microRNAs. 
• MicroRNA-29a was found to be up-regulated in human Type 2 diabetes in 
agreement with studies in diabetic rats. 
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4.5. Supplementary Data 
 
Supplementary Table  4-1. Patient plasma inflammatory marker concentrations. 
Patient 
characteristics 
Type 2 diabetes 
(n = 10) 
IGT 
(n = 10) 
Control 
(n = 10) 
CRP (mg/l) 2.2 ± 1.9 7.2 ± 11.8 1.3 ± 0.5 
IL-6 (ng/l) 2.4 ± 3.4 2.4 ± 4.8 1.0 ± 0.5 
IL-15 (ng/l) 1.5 ± 0.4 1.6 ± 0.4 1.8 ± 0.5 
IL-18 (ng/l) 306 ± 121 339 ± 196 232 ± 74 
TNFα (ng/l) 2.6 ± 0.5 2.2 ± 0.8 2.4 ± 0.6 
TNFR2 (ng/l) 203 ± 18 201 ± 42 171 ± 35 
Data are presented as mean ± SD. 
* P < 0.05 when compared with the control group. 
** P < 0.01 when compared with the control group. 
*** P < 0.0001 when compared with the control group. 
 
 
Supplementary Figure  4-1. RNU48 was stably expressed in Type 2 diabetes, IGT 
and controls.  RNU48 was used as the housekeeping gene to normalise mature 
microRNA expression levels. 
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Supplementary Figure  4-2. ∆Cycle thresholds for mature miR-133a, miR-206, 
miR-1 and miR-133b in the Type 2 diabetes, IGT and control group.  A lower 
microRNA abundance corresponds to a higher cycle threshold.  A higher 
microRNA abundance corresponds to a lower cycle threshold, miR-206 appeared 
to be less abundant than miR-1, miR-133a and miR-133b. ***  P < 0.001 * P < 0.05 
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Supplementary Figure  4-3. 18S was stably expressed in Type 2 diabetes, IGT and 
controls.  18S was used to normalise pri-microRNA expression.  Data shown as 
mean ± SE. 
 
 
Supplementary Figure  4-4. Quantification of miR-133a expression from Northern 
confirmed down-regulation of miR-133a in Type 2 diabetes.  Data shown as mean 
± SE, n = 3 per group *P < 0.05 
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Supplementary Figure  4-5. Residual plots from multiple regression predicting (A 
and B) fasting glucose, (C and D) glucose tolerance, (E and F) HbA1c and (G and 
H) HOMA[IR]. 
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Supplementary Figure  4-6.  Association between (A) miR-133a, (B) miR-206 and 
fasting glucose (mmol/L).  Association between (C) miR-133a, (D) miR-206 and 2 h 
glucose tolerance (mmol/L). 
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Supplementary Figure  4-7.  Association between (A) miR-133a, (B) miR-206 and 
basal insulin.  Association between (C) miR-133a, (D) miR-206 and HbA1c(%).  
Association between (E) miR-133a, (F) miR-206 and HOMA[IR]. 
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Supplementary Table  4-2. miR-1/206 and miR-133 family sequence homology 
microRNA miRbase 
Accession 
Sequence Homology 
Hsa-miR-206 
 
Hsa-miR-1 
MIMAT0000462 
 
MIMAT0000416 
 
Hsa-miR-133a 
 
Hsa-miR-133b 
MIMAT0000427 
 
MIMAT0000770 
 
 
 
Supplementary Figure  4-8. Example of micro-electrophoresis gel showing RNA 
quality from Type 2 diabetes patient RNA samples.  No evidence of RNA 
degradation and RIN scores were all >8.0 
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Supplementary Figure  4-9. Inter-laboratory RNA quantification reliability.  RNA 
was quantified using a Nanodrop spectrophometer.  The outlier is not included in 
the calculation of R2 
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Supplementary Table  4-3. Inter-laboratory reliability of RNA quantification using 
a Nanodrop spectrophotometer.  260/230 ratio of <1.5 indicates possible phenol 
contamination during RNA isolation. 
Sample 
ID 
RNA 
quantification 
A (µg/µl) 
RNA 
quantification 
B (µg/µl) 
A260 A280 Ratio 
260/280 
Ratio 
260/230 
16494 0.72 0.73 18.301 9.219 1.99 0.84 
16604 0.51 0.46 11.507 6.021 1.91 0.8 
17110 0.29 0.27 6.739 3.702 1.82 0.55 
17185 0.60 0.58 14.579 7.398 1.97 0.81 
16482 0.45 0.39 9.8 5.119 1.91 0.63 
17134 0.44 0.41 10.243 5.449 1.88 0.63 
16440 0.43 0.36 8.922 4.732 1.89 1.13 
15525 0.70 0.75 18.711 9.555 1.96 1.3 
16795 2.08 0.36 8.93 4.745 1.88 1.34 
15622 0.66 0.59 14.732 7.581 1.94 1.04 
16407 1.09 1.12 28.093 14.134 1.99 0.79 
15691 0.89 1.02 25.479 12.745 2 0.89 
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Supplementary Figure  4-10. Overexpression of miR-133a affects expression of 
miR-133a targets associated with diabetes. Data based on GEO8501 and curated 
literature citations linked to diabetes.  Data represent difference in log2 intensity 
between experiment and control cells. 
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Supplementary Figure  4-11. Efficiency of pri-microRNA primers. (A) Pri-miR-
133a-1, (B) Pri-miR-133a-2, (C) Pri-miR-1-1, (D) Pri-miR-1-2, (E) C20orf166 (host 
gene) and (F) ENSESTG00000007014 (host gene) across a range of cDNA 
dilutions. 
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Supplementary Table  4-4. SAM analysis of microRNA target expression 
signatures. 
microRNA d. 
value 
Raw 
p 
Q 
value 
microRNA d. 
value 
Raw 
p 
Q 
value 
hsa-let-7a 2.36 0.02 0.02 hsa-miR-1826 2.16 0.04 0.03 
hsa-let-7b 2.36 0.02 0.02 hsa-miR-186 2.21 0.03 0.03 
hsa-let-7c 2.36 0.02 0.02 hsa-miR-188-5p 2.26 0.03 0.03 
hsa-let-7d 2.36 0.02 0.02 hsa-miR-18a 3.41 0.00 0.01 
hsa-let-7e 2.36 0.02 0.02 hsa-miR-18b 3.41 0.00 0.01 
hsa-let-7f 2.36 0.02 0.02 hsa-miR-190 2.25 0.03 0.03 
hsa-let-7g 2.36 0.02 0.02 hsa-miR-190b 2.25 0.03 0.03 
hsa-let-7i 2.36 0.02 0.02 hsa-miR-195 2.92 0.00 0.01 
hsa-miR-1 2.48 0.02 0.02 hsa-miR-199a-3p 2.23 0.03 0.03 
hsa-miR-101 2.89 0.00 0.01 hsa-miR-199b-3p 2.23 0.03 0.03 
hsa-miR-106a 2.19 0.03 0.03 hsa-miR-19a 3.33 0.00 0.01 
hsa-miR-106b 2.19 0.03 0.03 hsa-miR-19b 3.33 0.00 0.01 
hsa-miR-1178 4.3 0.00 0.00 hsa-miR-202 3.59 0.00 0.00 
hsa-miR-1185 2.31 0.02 0.03 hsa-miR-204 2.36 0.02 0.02 
hsa-miR-1201 2.76 0.01 0.01 hsa-miR-206 2.48 0.02 0.02 
hsa-miR-1227 2.81 0.01 0.01 hsa-miR-20a 2.19 0.03 0.03 
hsa-miR-1231 2.56 0.01 0.02 hsa-miR-20b 2.19 0.03 0.03 
hsa-miR-1236 2.96 0.00 0.01 hsa-miR-21 2.1 0.04 0.03 
hsa-miR-124 3.86 0.00 0.00 hsa-miR-211 2.36 0.02 0.02 
hsa-miR-1244 2.35 0.02 0.02 hsa-miR-216b 2.51 0.01 0.02 
hsa-miR-1253 2.12 0.04 0.03 hsa-miR-221 2.69 0.01 0.02 
hsa-miR-1258 2.92 0.00 0.01 hsa-miR-222 2.69 0.01 0.02 
hsa-miR-1259 2.81 0.01 0.01 hsa-miR-223 3.33 0.00 0.01 
hsa-miR-125a-3p 2.94 0.00 0.01 hsa-miR-25 2.13 0.04 0.03 
hsa-miR-1264 2.55 0.01 0.02 hsa-miR-28-3p 2.5 0.01 0.02 
hsa-miR-1270 4.09 0.00 0.00 hsa-miR-297 3.22 0.00 0.01 
hsa-miR-1271 2.82 0.01 0.01 hsa-miR-301a 2.56 0.01 0.02 
hsa-miR-1274a 2.82 0.01 0.01 hsa-miR-301b 2.56 0.01 0.02 
hsa-miR-1274b 3.49 0.00 0.01 hsa-miR-302a 2.15 0.04 0.03 
hsa-miR-127-5p 2.89 0.00 0.01 hsa-miR-302b 2.15 0.04 0.03 
hsa-miR-1279 2.51 0.01 0.02 hsa-miR-302c 2.15 0.04 0.03 
hsa-miR-1283 3.05 0.00 0.01 hsa-miR-302d 2.15 0.04 0.03 
hsa-miR-1287 2.89 0.00 0.01 hsa-miR-302e 2.15 0.04 0.03 
hsa-miR-1301 2.4 0.02 0.02 hsa-miR-30a 2.9 0.00 0.01 
hsa-miR-1306 2.76 0.01 0.01 hsa-miR-30b 2.9 0.00 0.01 
hsa-miR-130a 2.56 0.01 0.02 hsa-miR-30c 2.9 0.00 0.01 
hsa-miR-130b 2.56 0.01 0.02 hsa-miR-30d 2.9 0.00 0.01 
hsa-miR-1321 2.19 0.03 0.03 hsa-miR-30e 2.9 0.00 0.01 
hsa-miR-1324 3.49 0.00 0.01 hsa-miR-31 2.28 0.03 0.03 
hsa-miR-140-3p 2.79 0.01 0.01 hsa-miR-32 2.13 0.04 0.03 
hsa-miR-143 2.59 0.01 0.02 hsa-miR-330-3p 2.55 0.01 0.02 
hsa-miR-144 2.66 0.01 0.02 hsa-miR-331-5p 2.18 0.03 0.03 
hsa-miR-148a 2.85 0.01 0.01 hsa-miR-338-5p 2.13 0.04 0.03 
hsa-miR-148b 2.85 0.01 0.01 hsa-miR-339-5p 2.62 0.01 0.02 
hsa-miR-150 2.49 0.02 0.02 hsa-miR-345 2.92 0.00 0.01 
hsa-miR-151-3p 2.51 0.01 0.02 hsa-miR-363 2.13 0.04 0.03 
hsa-miR-152 2.85 0.01 0.01 hsa-miR-367 2.13 0.04 0.03 
hsa-miR-15a 2.93 0.00 0.01 hsa-miR-369-3p 2.86 0.00 0.01 
hsa-miR-15b 2.93 0.00 0.01 hsa-miR-371-3p 2.22 0.03 0.03 
hsa-miR-16 2.92 0.00 0.01 hsa-miR-372 2.15 0.04 0.03 
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hsa-miR-17 2.19 0.03 0.03 hsa-miR-373 2.15 0.04 0.03 
hsa-miR-182 2.81 0.01 0.01 hsa-miR-374a 2.68 0.01 0.02 
hsa-miR-1825 2.37 0.02 0.02 hsa-miR-374b 2.68 0.01 0.02 
hsa-miR-520f 2.36 0.02 0.02 hsa-miR-585 2.19 0.03 0.03 
hsa-miR-520g 2.46 0.02 0.02 hsa-miR-587 2.49 0.02 0.02 
hsa-miR-520h 2.46 0.02 0.02 hsa-miR-590-5p 2.1 0.04 0.03 
hsa-miR-521 3.2 0.00 0.01 hsa-miR-597 3.35 0.00 0.01 
hsa-miR-522 2.2 0.03 0.03 hsa-miR-601 2.18 0.03 0.03 
hsa-miR-524-3p 3.05 0.00 0.01 hsa-miR-603 2.43 0.02 0.02 
hsa-miR-524-5p 2.92 0.00 0.01 hsa-miR-604 2.32 0.02 0.03 
hsa-miR-525-3p 3.05 0.00 0.01 hsa-miR-605 2.68 0.01 0.02 
hsa-miR-526a 3.06 0.00 0.01 hsa-miR-606 2.18 0.03 0.03 
hsa-miR-526b 3.49 0.00 0.01 hsa-miR-610 2.67 0.01 0.02 
hsa-miR-527 2.64 0.01 0.02 hsa-miR-620 4.09 0.00 0.00 
hsa-miR-545 2.65 0.01 0.02 hsa-miR-622 2.35 0.02 0.02 
hsa-miR-548a-3p 2.95 0.00 0.01 hsa-miR-628-3p 2.84 0.01 0.01 
hsa-miR-548a-5p 2.93 0.00 0.01 hsa-miR-631 2.86 0.00 0.01 
hsa-miR-548b-5p 2.93 0.00 0.01 hsa-miR-632 3.39 0.00 0.01 
hsa-miR-548c-3p 2.35 0.02 0.02 hsa-miR-633 2.75 0.01 0.01 
hsa-miR-548c-5p 2.93 0.00 0.01 hsa-miR-643 3.34 0.00 0.01 
hsa-miR-548d-3p 2.38 0.02 0.02 hsa-miR-645 2.7 0.01 0.01 
hsa-miR-548d-5p 2.93 0.00 0.01 hsa-miR-648 2.77 0.01 0.01 
hsa-miR-548e 2.95 0.00 0.01 hsa-miR-649 2.72 0.01 0.01 
hsa-miR-548f 2.95 0.00 0.01 hsa-miR-654-3p 2.23 0.03 0.03 
hsa-miR-548g 2.65 0.01 0.02 hsa-miR-655 2.61 0.01 0.02 
hsa-miR-548h 2.93 0.00 0.01 hsa-miR-720 2.55 0.01 0.02 
hsa-miR-548i 2.93 0.00 0.01 hsa-miR-758 2.15 0.04 0.03 
hsa-miR-548j 2.93 0.00 0.01 hsa-miR-765 2.83 0.01 0.01 
hsa-miR-548k 2.5 0.01 0.02 hsa-miR-768-5p 2.73 0.01 0.01 
hsa-miR-548l 2.8 0.01 0.01 hsa-miR-770-5p 2.98 0.00 0.01 
hsa-miR-548m 3.34 0.00 0.01 hsa-miR-875-3p 2.57 0.01 0.02 
hsa-miR-548n 2.38 0.02 0.02 hsa-miR-875-5p 2.76 0.01 0.01 
hsa-miR-549 3.77 0.00 0.00 hsa-miR-885-5p 2.64 0.01 0.02 
hsa-miR-550 2.76 0.01 0.01 hsa-miR-888 2.11 0.04 0.03 
hsa-miR-556-5p 2.85 0.01 0.01 hsa-miR-889 2.12 0.04 0.03 
hsa-miR-559 2.93 0.00 0.01 hsa-miR-891b 2.54 0.01 0.02 
hsa-miR-563 2.4 0.02 0.02 hsa-miR-892a 2.1 0.04 0.03 
hsa-miR-567 2.83 0.01 0.01 hsa-miR-922 2.73 0.01 0.01 
hsa-miR-568 3.24 0.00 0.01 hsa-miR-92a 2.13 0.04 0.03 
hsa-miR-570 2.4 0.02 0.02 hsa-miR-92b 2.13 0.04 0.03 
hsa-miR-574-5p 3.17 0.00 0.01 hsa-miR-93 2.19 0.03 0.03 
hsa-miR-575 2.18 0.03 0.03 hsa-miR-934 3.28 0.00 0.01 
hsa-miR-577 2.31 0.02 0.03 hsa-miR-935 2.28 0.03 0.03 
hsa-miR-580 2.66 0.01 0.02 hsa-miR-96 2.82 0.01 0.01 
hsa-miR-581 2.61 0.01 0.02 hsa-miR-98 2.36 0.02 0.02 
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Supplementary Table  4-5. Fold change in microRNA probe expression between 
Type 2 diabetes and control groups from microRNA arrays based on pooled 
patient RNA (I. Gallagher, personal communication). 
microRNA Fold Change 
hsa-miR-143/mmu-miR-143/rno-miR-143 1.31 
hsa-miR-27b/mmu-miR-27b/rno-miR-27b -1.30 
hsa-miR-29a/mmu-miR-29a/rno-miR-29a -1.20 
hsa-miR-29b/mmu-miR-29b/rno-miR-29b -1.10 
hsa-miR-424 -1.90 
Experimental validation was performed on these microRNAs using RT-qPCR and data 
is shown in  3.3.7. 
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Chapter 5 - MicroRNA knockdown and regulation in muscle cells 
5.1. Introduction 
MicroRNAs appear to change in skeletal muscle during the development of cancer 
cachexia and also Type 2 diabetes (Chapter 3 and 4), but the underlying mechanism and 
the functional consequences still need to be determined.  The mechanism underlying the 
microRNA changes in Type 2 diabetes and cancer cachexia patients was not clear from 
the previous studies in Chapter 3 and 4.  However, extracellular factors such as insulin 
or TNFα may play a role, as hormones and cytokines are known to activate or inhibit 
intracellular signaling pathways.  For example, insulin and TNFα are known to 
modulate protein synthesis, protein breakdown and glucose uptake (Tisdale, 2005; 
Muoio & Newgard, 2008), which are important processes in Type 2 diabetes and cancer 
cachexia.  From a functional viewpoint, there are many more predicted microRNA 
targets than experimentally validated microRNA targets (Bartel, 2009; Friedman et al. 
2009; Lewis et al. 2003).  Therefore it remains important to experimentally validate 
predicted targets of disease associated microRNAs, to establish a functional link 
between microRNAs and target proteins. 
5.1.1 MicroRNAs are regulated by insulin and glucose 
MicroRNAs are reported to respond to glucose and insulin in adipocytes and pancreatic 
β-cells (Poy et al. 2004; He et al. 2007; Ling et al. 2009; Tang et al. 2009).  In insulin-
resistant Type 2 diabetic rats with hyperglycaemia and hyperinsulineamia miR-29a was 
reported to be up-regulated in fat and skeletal muscle (He et al. 2007).  In addition, high 
glucose and high insulin treatment reportedly up-regulates miR-29a in adipocytes (He et 
al. 2007).  In Chapter 4, miR-29a was also found to be up-regulated in Type 2 diabetes 
patients, but miR-29a was not a strong predictor of fasting glucose, HbA1c, insulin 
resistance (HOMA[IR]) or glucose tolerance.  However, miR-133a was found to be the 
strongest predictor of fasting glucose, HbA1c, insulin resistance (HOMA[IR]) and 
glucose tolerance of the microRNAs examined in Type 2 diabetes patients (Chapter 4).  
To date there have been no studies on whether skeletal muscle miR-133a expression 
changes in response to high glucose or insulin which are characteristics of Type 2 
diabetes. 
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Recent findings from insulin-resistant adipocytes found miR-133a was among 29 down-
regulated microRNAs (Ling et al. 2009) following high glucose (25 mmol/L) and high 
insulin (1 µmol/L) treatment.  However, in another study in pancreatic β-cells, miR-
133a was not among the sixty microRNAs detected to be modulated by extracellular 
glucose (Tang et al. 2009), which highlights microRNAs are not regulated in the same 
manner across all tissues.  Therefore, the effects of extracellular factors on microRNA 
regulation in Type 2 diabetes should be examined primarily in muscle cells. 
5.1.2 MicroRNAs may be regulated by TNFα 
TNFα is known to trigger protein breakdown, thus has been implicated in the 
pathogenesis of cancer cachexia (Tisdale 2005; Stephens et al. 2008; Seruga et al. 2008).  
Micro-RNA-1, miR-133a and miR-206 were found to be down-regulated in pancreatic 
cancer cachexia patients (Chapter 3).  Therefore it would be useful to study the effects 
of TNFα on miR-1, miR-133a and miR-206 expression in skeletal muscle.  In addition, 
previously plasma TNFα has also been associated with Type 2 diabetes (Plomgaard et 
al. 2007).  Treatment of myotubes with TNFα is reported to trigger insulin resistance 
and decrease glucose uptake (del Aguila et al. 1999).  However, to date there have been 
no studies examining whether TNFα is a regulator of microRNA expression in skeletal 
muscle. 
5.1.3 Approaches to determine the functional consequences of microRNAs 
In Chapter 3 and Chapter 4 gene ontology enrichment analysis was used to identify 
functional gene groups, which may be coordinately targeted by microRNAs.  For miR-
133a, which was down-regulated in Type 2 diabetes patients, these functional gene 
groups included protein binding, intracellular organelles and protein amino acid 
dephosphorylation.  To date no studies have been able to experimentally validate the 
targeting of functional gene groups, possibly due to the difficulty in measuring global 
protein changes. 
 
Several studies have used both transcriptional and protein profiling in different tissues 
and identified potential microRNA targets based on discordant expression of gene and 
protein (Lu et al. 2008; Stentz & Kitabchi, 2007).  For example, in pancreatic β-cells 
protein expression may increase while gene expression remains unchanged, providing 
an indication that a post-transcriptional mechanism may be determining protein levels 
(Lu et al. 2008).  In skeletal muscle biopsies from Type 2 diabetes patients, mRNA and 
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protein levels have been measured simultaneously using 2D gels and microarrays 
(Stentz & Kitabchi, 2007).  Discordant changes in mRNA and protein levels were 
reported (Stentz & Kitabchi, 2007), but only 80 proteins were quantified in contrast to 
~40000 transcripts detectable by microarray and microRNAs were not measured.  
Nevertheless, changes in protein abundance in the absence of transcript changes suggest 
post-transcriptional regulation may be involved in Type 2 diabetes.  However, without 
the sensitivity to quantify all proteins in skeletal muscle, it is difficult to confirm the 
targeting of functional gene groups by microRNAs.  Thus functional microRNA studies 
tend to focus on one or two targets, using an in-vivo or in-vitro model to manipulate 
microRNA expression (Bartel, 2009). 
5.1.4 In-vivo microRNA knockdown and overexpression 
There is much interest in developing interventions to alter microRNA expression in-vivo 
(Mattes et al. 2008; Krützfeldt et al. 2005; Ren et al. 2009), but currently in-vivo 
manipulation of microRNA levels in patients has not been reported.  In-vivo mouse 
studies have shown it is possible to deliver antisense microRNA oligonucleotides 
(ASOs) to the liver with functional consequences.  ASOs conjugated with cholesterol 
and injected into mice were reported to significantly reduce miR-122 in liver 
(Krützfeldt et al. 2005).  Targets of miR-122 include critical components of the 
cholesterol pathway, and knockdown of miR-122 in-vivo improved liver cholesterol 
(Krützfeldt et al. 2005).  However, it remains to be seen whether microRNAs can be 
successfully delivered to other tissues such as skeletal muscle. 
 
In our laboratory there is no facility for in-vivo mouse studies.  Thus all data in this 
Chapter are based on in-vitro experiments using muscle cell cultures.  This has 
advantages as many studies have shown microRNA expression levels can be rapidly 
manipulated in-vitro, thus allowing functional microRNA targets to be determined at 
the protein level as tissue availability is not an issue for in-vitro experiments. 
5.1.5 In-vitro microRNA knockdown and overexpression 
In-vitro miR-1 and miR-133a overexpression in the HeLa cell-line with low endogenous 
miR-1 and miR-133a expression combined with microarray profiling revealed many 
targets can be down-regulated both directly and indirectly (Lewis et al. 2003; 
Sethupathy et al. 2006).  Subsequently, studies have often taken two approaches to 
determine microRNA function, studying loss of function or target protein expression 
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when a microRNA is over expressed, or gain of function or target protein expression 
when a microRNA is blocked. 
 
Overexpression of microRNAs within a cell culture system can be achieved in several 
ways.  The most commonly reported method is transfection of cells with microRNA 
duplexes, which are designed to mimic endogenous microRNAs following cleavage by 
DICER and results in suppression of targets with functional microRNA binding sites 
(Lim et al. 2005).  Other options include using interventions earlier in the microRNA 
biogenesis pathway (Kim et al. 2009).  Some studies have reported transfecting cells 
with microRNA precursor mimics.  These microRNA precursor mimics can be 
processed by DICER to produce functional mature microRNAs, which leads to a 
suppression of valid microRNA target proteins (Lee et al. 2005).  Another possibility is 
using a viral delivery system, by designing a vector containing the mature microRNA 
sequence of interest and infecting muscle cells (He et al. 2007).  The advantage of using 
a viral delivery system is the ability to over-express the microRNA of interest for a 
longer period of time.  Therefore, it would be possible to generate stable endogenous 
microRNA over-expressing cells, which would allow the longer-term consequences of 
elevated microRNA levels on cell phenotype to be observed. 
 
In Type 2 diabetes and cancer cachexia miR-133a and miR-206 expression was down-
regulated (Chapter 3 and 4).  Therefore a microRNA knockdown model would be most 
relevant to experimentally validate miR-133a and miR-206 targets.  For experimental 
validation of microRNA targets in skeletal muscle several cell-lines are available.  In 
previous studies attempting to validate skeletal muscle microRNA targets the murine 
C2C12 cell-line has been used (Boutz et al. 2007; Chen et al. 2006; Kim et al. 2006; 
Rosenberg et al. 2006; Brzeszczynska et al. under revision).  It is well known C2C12 
myoblasts proliferate in the presence of serum and glucose, whereas in the presence of 
low serum C2C12 myoblasts differentiate and fuse into myotubes after around four days. 
 
In the present study two approaches were attempted to knockdown mature miR-133a 
and miR-206 in myoblasts.  First, pri-microRNA ASOs were designed to target 
upstream of the pre-miR-133a and pre-miR-206 hairpins in an attempt to specifically 
knockdown pri-miR-133a and pri-miR-206 transcripts.  Second, mature microRNA 
ASOs designed to bind with perfect complementarity to their target mature microRNAs 
were used in an attempt to directly knockdown target mature microRNAs.  It is 
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currently unknown if targeting pri-microRNAs is effective for specific knockdown of 
mature microRNAs (Davis et al. 2006).  The latter approach is the most common, but 
the indirect effects on other microRNAs are rarely reported. 
5.1.6 MicroRNA target validation 
The targets chosen for experimental validation included PTBP1, CDC42, SMEK2 and 
TGIF2, which are predicted miR-133a and miR-206 targets.  PTBP1 is an alternative 
splicing factor, which regulates the inclusion of exons in muscle development genes and 
suppression of PTBP1 leads to increased inclusion of target exons during muscle 
differentiation (Boutz et al. 2007).  In cancer cachexia PTBP1 is potentially a relevant 
target of miR-133a, as in-vitro PTBP1 inhibits skeletal muscle differentiation.  
Therefore, the down-regulation of miR-133a with muscle-loss reported in Chapter 3 
could be partly causing dedifferentiation via de-repression of PTBP1 protein levels.  
 
CDC42 is a signal transduction kinase, which has been previously linked to insulin 
resistance and glucose uptake (Nevins and Thurmond, 2005; Cheatham et al. 1996).  A 
direct interaction between VAMP2 and CDC42 has been reported which regulates 
SNARE-dependent vesicle movement (Cheatham et al. 1996; Nevins and Thurmond, 
2005), which suggests both are potentially important for muscle glucose uptake.  In 
addition, CDC42 is required for the activation of JNK signaling which is a negative 
regulator of insulin signaling (Coso et al. 1995).  JNK protein is reportedly increased in 
skeletal muscle from obese Type 2 diabetes patients (Bandyopadhyay et al. 2005). 
CDC42 is a miR-133a target, which has been experimentally validated in cardiac 
muscle (Carè et al. 2007), but CDC42 has yet to be demonstrated as a miR-133a target 
in skeletal muscle. 
 
SMEK2 and TGIF2 were the other predicted miR-133a targets selected for experimental 
validation.  SMEK2 is a suppressor of MEK in the MAPK pathway, which is associated 
with multiple cellular functions including insulin signaling and muscle growth.  
However there are no studies on the function of SMEK2 in skeletal muscle.  TGIF2 is a 
transcriptional repressor, which is reported to suppress genes regulated by the TGF-β 
transcription factors (Melhuish et al. 2001).  Neither, SMEK2 nor TGIF2 has been 
previously associated with either Type 2 diabetes or cancer cachexia pathogenesis, thus 
validation of SMEK2 or TGIF2 as miR-133a targets would reveal a novel mechanism 
may contribute to Type 2 diabetes or cancer cachexia process. 
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5.1.7 Determination of microRNA function in skeletal muscle 
When dysregulated in-vivo muscle specific microRNA expression appears to be altered 
in human diseases associated with insulin resistance.  In Type 2 diabetes and pancreatic 
cancer cachexia patients the expression of mature miR-133a and miR-206 were both 
significantly reduced.  Expression of these two microRNAs was also correlated with 
different stages of insulin resistance and the impairment of glucose tolerance potentially 
leading to Type 2 diabetes in the presence of pancreatic β-cell dysfunction.  While miR-
133a was reduced in patients with impaired glucose tolerance, it was reduced further in 
Type 2 diabetes patients.  To determine the functional role of microRNAs within human 
Type 2 diabetes and cancer cachexia requires a model where microRNA expression can 
be manipulated and functional consequences determined. 
5.1.8 Aims 
• Determine the response of miR-133a and miR-206 in muscle cells to extracellular 
signals including insulin and TNFα. 
• Evaluate the effectiveness of primary microRNA knockdown and mature 
microRNA knockdown in muscle cells. 
• Determine the effects of miR-133a and miR-206 knockdown in muscle cells on 
predicted targets including CDC42, PTBP1, SMEK2 and TGIF. 
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5.2. Methods 
5.2.1 Approach 
Mature miR-1, miR-133a and miR-206 expression and primary microRNA transcription 
was determined in myotubes following insulin or TNFα treatment.  Then to knockdown 
mature miR-133a and miR-206 two approaches were employed.  Firstly, primary miR-
133a and miR-206 transcripts were targeted by anti-sense LNA oligonucleotides (pri-
microRNA ASOs) to determine their effectiveness.  If primary knockdown of miR-133a 
and miR-206 transcripts is effective then this should also specifically reduce mature 
miR-133a and miR-206.  Secondly, knockdown of mature miR-133a and miR-206 was 
attempted using ASOs designed to bind to mature microRNA.  Mature microRNA 
ASOs were used for experimental validation of miR-133a and miR-206 targets.  
CDC42, PTBP1, TGIF2 and SMEK2 protein level was determined using Western blot 
in response to miR-133a and miR-206 knockdown. 
5.2.2 Extracellular insulin, glucose and TNFα treatment 
C2C12 myoblasts were seeded at low density in DMEM supplemented with 10% FBS 
and 1% Streptomycin and then grown until 70-80% confluence.  Myogenic 
differentiation was induced when cells reached 70-80% confluence by changing cell 
media to high (25 mmol/L) or low glucose (5 mmol/L) DMEM supplemented with 10% 
horse serum.  Day 4 differentiated myotubes were used to determine the affects of 
insulin on miR-133a, miR-206 and miR-1 expression.  Immediately prior to 
experiments, cells were washed in 1 x PBS.  Then myotubes were treated with 100 nM 
or 0.1 nM insulin (Sigma, UK) for 0, 10, 30 and 60 min in the presence of high (25 
mmol/L) or low glucose (5 mmol/L), the experiment was performed in triplicate.  To 
recover RNA, cells were lysed in TRIZOL as previously described in  5.2.4 then stored 
at -80°C prior to RNA isolation and quantification. 
 
Mature miR-133a, miR-206 and miR-1 were measured in the cells using RT-qPCR as 
described in section  3.2.5 and  3.2.6  Unfortunately, RNA degradation occurred in the 
low glucose treated myotube samples and therefore RT-qPCR results from the 
myotubes treated with low glucose are not presented.  To assess the effect of insulin 
(100 nM or 0.1 nM) on primary microRNA transcription, RT-qPCR was used to 
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measure expression of pri-miR-1-1, pri-miR-1-2, pri-miR-133a-1, pri-miR-133a-2, pri-
miR-133b and pri-miR-206. 
 
To determine the effect of TNFα on mature miR-1, miR-133a and miR-206 in skeletal 
muscle cells, C2C12 myoblasts were differentiated for 4 days as described and 
incubated in 10 ng/ml TNFα (Invitrogen, UK) for 0, 1 and 24 h.  To recover RNA, cells 
were lysed in TRIZOL and stored at -80°C prior to analysis.  These experiments were 
performed in triplicate but to reduce costs the microRNA analysis was conducted on 
duplicate samples in some cases, this is indicated in the results. 
5.2.3 RNA isolation and quantification from muscle cells 
The procedure for RNA isolation was similar to section  3.2.3 with the following 
modifications.  Cell samples were defrosted at room temperature, 100 µl chloroform 
was added, samples were vortexed for 15 s and incubated for 10 min at 25°C.  Then 
samples were centrifuged at 13000g for 15 min at 4°C.  The aqueous phase was 
extracted and 250 µl isopropanol added.  Samples were incubated for 10 min at 25°C 
then centrifuged at 13000g for 10 min at 4°C.  The suspension was discarded and 1.5 ml 
70% EtOH added, followed by centrifugation at 7500g for 15 min at 4°C.  The 
suspension was again discarded and the pellet air-dried for 2 min.  The RNA pellet was 
dissolved in 15 µl DEPC water.  RNA concentrations were determined using a 
Nanodrop spectrophotometer as previously described (see section  4.2.5).  Samples were 
stored at -80°C prior to further analysis. 
5.2.4 Pri-microRNA knockdown 
C2C12 mouse skeletal myoblasts were maintained in DMEM supplemented with 10% 
Fetal Bovine Serum and 1% penicillin/Streptomycin. C2C12 myoblast cells were 
seeded at 1 x 105 in 6 well plates 24 h prior to transfections.  Immediately prior to 
transfections cells were washed in 1 x PBS and incubated in antibiotic free DMEM.  
Lipofectamine 2000 (Invitrogen, UK) and Optimem were used for all transfections.  Pri-
microRNA ASOs were designed to target 500 bp upstream and downstream of miR-
133a-1, miR-133a-2 and miR-206.  The microRNA ASO sequences are shown in Table 
 5-1.  Two individual pri-microRNA ASOs were designed to target each pri-microRNA.  
The locked nucleic acids (LNA) modifications were used to increase stability of the pri-
microRNA ASOs in the cell. 
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Table  5-1. Pri-microRNA ASO knockdown probe sequences  
microRNA pri-microRNA ASO sequence 
Pri-miR-133a-1   A 5’- CACAgacagataCACA – 3’ 
Pri-miR-133a-1   B 5’- CCTGcctctgccTCCC –3’ 
Pri-miR-133a-2   A 5’- AAGGggaaatcaGAGG – 3’ 
Pri-miR-133a-2   B 5’- GGAAggggaaaaGCAG –3’ 
Pri-miR-206   A 5’- GAAAatgtagccAAGG –3’ 
Pri-miR-206   B 5’- AGGGtgcaggttgcAGGG –3’ 
pri-microRNA ASO knockdown probes were obtained from Exiqon, Denmark 
 
Pri-microRNA ASO transfection in myoblasts 
For transfections, pri-microRNA ASOs were mixed in 250 µl Optimem and seperately 5 
µl Lipofectamine 2000 was mixed with 245 µl Optimem, then incubated for 5 min at 
25°C.  Pri-microRNA ASOs were then combined with Lipofectamine 2000 complexes 
and incubated for 25 min at 25°C.  Transfections were initially performed three times in 
duplicate (n = 6) using pri-microRNA ASOs at 100 nM.  For each transfection 500 µl 
transfection solution containing the pri-microRNA ASO/Lipofectamine/Optimem 
complexes was added dropwise to each well.  Cells were harvested 48 h later for RNA 
and protein.  Cells required for RNA were harvested in 500 µl TRIZOL and stored at -
80°C until RNA isolation. 
 
Knockdown of pri-microRNAs was measured using RT-qPCR as previously described 
(see section  4.2.8 -  4.2.9).  Primers were designed to target the sequence within 500 
base pairs of the pre-microRNA hairpin, primer sequences are listed in Table  5-2. 
Primer efficiency was determined by running RT-qPCR on five serial cDNA dilutions 
and plotting a standard curve to check linearity and slope >3.0 as described in section 
 4.2.7.  Primer efficiency and linearity are shown in Supplementary Figure  5-1. 
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Table  5-2. Primers designed to amplify mouse pri-microRNA transcripts  
Target Primers, sequences or probes 
Pri-mmu-miR-133a1 5’-tgtatatgcaagacattcttcaactg-3’  (forward) 
5’-gagggaaatatctctacaaacatcaa-3’  (reverse) 
Pri-mmu-miR-1-2 5’-cccaaatcttgaagtagcctttag-3’  (forward) 
5’-cgctcctctagtaaacctgcat-3’  (reverse) 
Pri-mmu-miR-1-1 5’-cactggtgagttggatcctg-3’  (forward) 
5’-ggttctgtcctgtaccacagc-3’  (reverse) 
Pri-mmu-miR-133a-2 5’-ttgtctcctcaacaggcaag-3’  (forward) 
5’-gggtcagtcacagcttaggg-3’  (reverse) 
Pri-mmu-miR-206 5’-ccctgaactcctcccttgt-3’  (forward) 
5’-gagagagagagcatgaaattgga-3’  (reverse) 
Pri-mmu-miR-133b 5’-agctgccagtgtccattcat-3’  (forward) 
5’-atcacctgcgtcacaatctg-3’  (reverse) 
Pri-mmu-miR-21 5’-ctttcttgctagtgtcctctgattt-3’  (forward) 
5’-tcacctagagtgggaatctcttactt-3’  (reverse) 
Primers were obtained from Invitrogen UK 
 
Following the initial transfections using 100 nM pri-microRNA ASOs, some resulted in 
cell death.  Therefore, these pri-microRNA ASOs were transfected later at different 
concentrations, 10 nM, 30 nM, 50 nM and 100 nM.  When pri-microRNA knockdown 
was evident, the downstream affects on mature microRNA expression were measured 
using RT-qPCR as described in section  3.2.5 and  3.2.6. 
 
Pri-microRNA ASO transfection in myotubes 
Additional experiments were conducted to determine whether pri-microRNAs could be 
knocked down effectively in myotubes, as typically myotubes are difficult to transfect, 
thus other methods such as electroporation have been used to deliver microRNA ASOs 
to myotubes (Chen et al. 2006), but indirect effects may occur during electroporation.  
Myoblasts were grown until 70-80% confluent in 6-well plates and myogenic 
differentiation was induced by changing cell media to DMEM supplemented with 10% 
horse serum.  Cells were transfected with pri-microRNA ASOs at 100 nM after 4 days 
differentiation.  Pri-microRNA ASOs were diluted in 250 µl Optimum and mixed 
gently.  Separately, 4 µl Lipofectamine 2000 was mixed in 245 µl Optimum.  After 5 
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min incubation at 25°C, pri-microRNA ASOs were combined with Lipofectamie 2000 
and incubated for a further 25 min at 25°C.  Cells were washed in 2 x PBS and 1 ml 
antibiotic-free DMEM was added to each well.  The pri-microRNA ASOs were 
transfected dropwise to each plate.  Cells were incubated at 37°C, after 12 h, cells were 
washed with PBS and new differentiation media added.  Cells were harvested 48 h later 
and stored at -80°C until RNA isolation.  
 
The results showed the pri-microRNA ASOs targeting pri-miR-133a-2 and pri-miR-206 
did not appear to be as effective at achieving mature miR-133a and miR-206 
knockdown compared to the mature microRNA ASOs described in the following 
section.  Therefore validation of predicted miR-133a and miR-206 targets was carried 
out following transfection of the mature microRNA ASOs only. 
5.2.5 Mature microRNA knockdown 
C2C12 myoblast cells were seeded at 50% confluence and transfected with mature 
microRNA ASO targeting miR-133a and/or miR-206 (Exiqon, Denmark) at 100 nM 
with Oligofectamine (Invitrogen, UK) following the manufacturer's protocol.  The 
mature microRNA ASO sequences are shown in Table  5-3.  Prior to transfection, 
myoblast cells were incubated in antibiotic free DMEM.  Mature microRNA ASOs 
were mixed with Optimem and then incubated with Oligofectamine for 25 min at 25°C.  
Transfections were performed in duplicate and myoblasts were not differentiated.  Four 
hours after transfections, DMEM with Fetal Calf Serum was added to cells and after 48 
h the cells were harvested. 
 
To recover protein, cells were scraped in 1 x PBS and spun down.  To recover RNA, 
cells were lysed in TRIZOL as previously described in section  5.2.3 then stored at -
80°C prior to analysis.  MicroRNA knockdown was confirmed using RT-qPCR as 
described previously in section  3.2.5 and  3.2.6.  In addition, the affects of microRNA 
knockdown on mature miR-1, miR-133a, miR-206, pri-miR-1-1, pri-miR-1-2, pri-miR-
133a-1 and pri-miR-133a-2 were quantified using RT-qPCR. 
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Table  5-3. Mature microRNA ASO probe sequences and product numbers 
microRNA Mature microRNA ASO probe Product No. 
mmu-miR-133a CAGCTGGTTGAAGGGGACCAAA 139460-00 
mmu-miR-206 CCACACACTTCCTTACATTCCA 139100-00 
Scrambled control GTGTAACACGTCTATACGCCCA 199002-00 
Probes were obtained from Exiqon, Denmark 
5.2.6 Western blot for detection of miR-133a and miR-206 targets 
Western blot was performed to detect evidence of reduced suppression of target proteins 
CDC42, PTBP1, TGIF2 and SMEK2 in myoblasts cells following microRNA 
knockdown with mature microRNA ASOs.   Cells were lysed at 100°C in Laemmli 
buffer for 5 minutes.  Cells were centrifuged to remove insoluble material.  BCA 
reagent was used to determine protein concentration.  Proteins were heat-denatured and 
size fractionated using SDS-polyacrylamide gel electrophoresis.  Proteins were loaded 
on a 4-12% gradient bis-Tris NuPage gel (Invitrogen, UK) and transferred onto a 
nitrocellulose membrane.  The nitrocellulose membrane was stained with Ponceau Red 
to check the protein transfer (Supplementary Figure  5-5).  The membrane was blocked 
using 5% skimmed milk in TBS, 0.2% Tween, 0.05% Triton X100 (TBST) at 25°C.  
Then membranes were incubated overnight at 4°C with primary antibodies diluted 
1:1000 mixed with 5% BSA /TBST.  Membranes were washed and incubated for 1 h at 
25°C with an anti-rabbit IgG HRP conjugated antibody diluted 1:5000 (Cell Signaling 
Technology).  Then blots were incubated in ECL reagent (GE Healthcare) and exposed 
to Kodak BioLight film.  The protein signal on the blot was analysed using ImageJ 
software (NIH).  The protein signal was corrected for protein loading based on the area 
under the curve from the Ponceau Red staining (Supplementary Table  5-1; 
Supplementary Figure  5-5).  Loading corrected protein signals were then scaled to cells 
transfected with scrambled ASO. 
5.2.7 Statistical Analysis 
Statistical analysis was conducted in Prism v5.0 (GraphPad).  To determine whether 
insulin and TNFα treatment of myotubes significantly decreased mature miR-1, miR-
133a and miR-206 expression t-tests were conducted.  Similarly, t-tests were used to 
determine whether the effect of miR-133a and miR-206 knockdown on protein targets 
was significant.  Significance was accepted at P < 0.05. 
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5.3. Results 
The response of miR-1, miR-133a and miR-206 expression in myotubes to insulin and 
TNFα treatment is presented in sections  5.3.1- 5.3.3.  To experimentally validate miR-
133a and miR-206 targets potentially post-transcriptionally regulated in Type 2 diabetes 
and/or cancer cachexia at the protein level two approaches were used.  In the first 
approach, pri-microRNA ASOs were designed in an attempt to knockdown mature 
miR-133a and mature miR-206, six pri-microRNA ASOs were tested for effectiveness 
and the results are presented in section  5.3.4.  In the second approach two ASOs 
designed to target mature miR-133a and miR-206 were tested for effectiveness, the 
results are presented in section  5.3.7.  The second approach proved most effective and 
was used to validate selected protein targets using Western blot in section  5.3.8. 
5.3.1 Insulin affects mature miR-1 and miR-133a expression  
Initially, the response of mature miR-133a was measured in myotubes in response to 
insulin resistance inducing high glucose and high insulin (100 nM) compared to control 
cells differentiated in low glucose media and treated with low insulin (0.1 nM), but 
RNA degradation occurred in the low glucose treated myotube samples (data not 
shown).  Therefore, the results presented examine the response of microRNAs to high 
insulin (100 nM) only compared to untreated myotubes. 
 
In response to 100 nM insulin miR-1 expression increased 40% after 30 min compared 
to untreated cells (P < 0.05) and this increase was also sustained at 60 min (Figure  5-1).  
There were no clear changes in miR-206 abundance in response to 100 nM insulin 
compared to untreated cells (Figure  5-1).  There was a trend for insulin to decrease 
miR-133a expression around 20% after 60 min compared to untreated cells, but the 
decrease was not found to be significant (Figure  5-1). 
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Figure  5-1. (A) Time-course of miR-1 (B) miR-133a and (C) miR-206 expression in 
response to 100 nM insulin treatment in myotubes (n = 3).  Data shown as mean ± 
SE. * P < 0.05 
5.3.2 Insulin stimulates primary microRNA transcription 
The observed changes in mature microRNA abundance in C2C12 myotubes following 
insulin treatment led to the hypothesis that insulin may stimulate an increase in 
transcription of pri-microRNAs.  MicroRNA-1 and miR-133a are transcribed from two 
genomic loci in human and mouse (Figure  5-2).  Pri-miR-1-1 and pri-miR-1-2 are both 
processed to form mature miR-1, while pri-miR-133a-1 and pri-miR-133a-2 are 
processed to form mature miR-133a.  
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Figure  5-2. Genomic loci encoding miR-1/206 and miR-133 family.  Arrows 
indicate location of primers designed to amplify the pri-microRNA transcript. 
 
Figure  5-3. (A) Fold change in pri-miR-1-1 and (B) pri-miR-1-2 expression in 
response to 100 nM insulin treatment in myotubes.  Data shown as mean ± SE. *P 
< 0.05 
 
When myotubes were treated with 100 nM insulin, transcription of pri-miR-1-1 was 
significantly increased after 10 min (P < 0.05), and appeared to continue to increase up 
to 125% of basal after 30 min, while no significant changes were detected in pri-miR-1-
2 transcription (Figure  5-3).  To determine whether insulin concentration may influence 
pri-microRNA expression, myotubes were treated with a lower concentration of insulin 
(0.1 nM), transcription of pri-miR-1-1 and pri-miR-1-2 appeared to increase around 
100% and 50% respectively after 60 min (Supplementary Figure  5-2). 
 
In the previous section mature miR-133a expression appeared to decrease in response to 
insulin treatment, so if this change was linked to transcription one would hypothesize 
pri-miR-133a transcripts would be decreased as well.  However, pri-miR-133a-1 
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transcript abundance was increased over 50% in response to 100 nM insulin after 10 
min (P < 0.05) compared to untreated myotubes (Figure  5-4).  There were no clear 
changes in pri-miR-133a-2 transcript abundance in response to 100 nM insulin.  The 
changes observed in expression of pri-miR-133a transcripts did not appear to be 
influenced at lower insulin concentrations (Supplementary Figure  5-2). 
 
Following the observation that mature miR-206 remained largely unchanged in 
myotubes in response to insulin treatment it would be expected that transcription of pri-
miR-206 would also remain unchanged.  On the contrary, pri-miR-206 expression 
followed a similar time course to pri-miR-1-2 in response to insulin (Figure  5-5).  Pri-
miR-206 transcription was increased over 100% after 60 min (P < 0.05) in response to 
100 nM insulin treatment (Figure  5-5) and to a similar extent in response to 0.1 nM 
insulin treatment (Supplementary Figure  5-2). 
 
Figure  5-4. (A) Fold change in pri-miR-133a-1 and (B) pri-miR-133a-2 in response 
to 100 nM insulin treatment in myotubes.  Data shown as mean ± SE. *P < 0.05 
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Figure  5-5. Fold change in (A) pri-miR-206 and (B) pri-miR-133b expression in 
response to 100 nM insulin treatment in myotubes. Data shown as mean ± SE. **P 
< 0.01 *P < 0.05 
 
5.3.3 TNFα down-regulates mature miR-1, miR-133a and miR-206 expression 
Cachexia and Type 2 diabetes are associated with elevated circulating TNFα levels.  
Therefore, differentiated myotubes were incubated in TNFα (10 ng/ml) for 1 h or 24 h.  
Myotubes were still visible following incubation with TNFα.  It appeared miR-1, miR-
206 and miR-133a levels responded to TNFα treatment (Figure  5-6).  After 1 h a 20% 
decrease in miR-1 was observed, after 24 h miR-1 was reduced by 60% (P < 0.01) 
compared to control myotubes (Figure  5-6).  A 50% reduction in miR-206 was clear 
after 1 h of TNFα treatment, following 24 h TNFα treatment miR-206 abundance was 
reduced by 70% (P < 0.05) compared to control myotubes (Figure  5-6).  Finally, miR-
133a was reduced by 40% after 1 h and 70% following 24 h TNFα treatment compared 
to untreated myotubes (Figure  5-6). 
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Figure  5-6. (A) Fold change in miR-1 (B) miR-133a and (C) miR-206 expression in 
response to TNFα treatment in myotubes. Data shown as mean ± SE. **P < 0.01 *P 
< 0.05 
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5.3.4 Effectiveness of pri-microRNA knockdown 
Effective knockdown of pri-microRNA should lead to a decrease in mature-microRNA 
abundance.  Two ASOs were designed to target upstream and downstream of the pri-
miR-133a-1, pri-miR-133a-2 and pri-miR-206 respectively.  Initially, the pri-
microRNA ASOs were tested for effectiveness at 100 nM in myoblasts.  Table  5-4 
shows pri-miR-133a-1 ASO A and B proved to be ineffective at 100 nM as ∆Ct and 
control ∆Ct were similar and no significant changes were dectectable (see 
Supplementary Figure  5-3).  Both pri-miR-133a-2 ASO A and B resulted in cell death 
(Table  5-4).  Finally, pri-miR-206 ASO A resulted in a 1∆Ct change in pri-miR-206 
expression, but pri-miR-206 ASO B resulted in cell death (Table  5-4). 
 
Table  5-4. Initial screening of pri-microRNA ASO effectiveness in myoblasts 
Pri-microRNA ASO N Concentration ∆Ct Control ∆Ct 
Pri-miR-133a-1 ASO A 6 100 nM -8.9 -8.7 
Pri-miR-133a-1 ASO B 6 100 nM -8.6 -8.7 
Pri-miR-133a-2 ASO A 6 100 nM Cells died 
Pri-miR-133a-2 ASO B 6 100 nM Cells died 
Pri-miR-206 ASO A 6 100 nM -6.7 -7.6 
Pri-miR-206 ASO B 6 100 nM Cells died 
 
Following the initial screening of pri-microRNA ASOs, three pri-microRNA ASOs 
were examined further at different concentrations.  Pri-miR-133a-2 ASO A, pri-miR-
133a-2 ASO B and pri-miR-206 B were transfected in myoblasts at 10 nM, 30 nM, 50 
nM and 100 nM.  Cell death was observed in myoblasts transfected with 100 nM pri-
miR-133a-2 ASOs.  Transfecting pri-miR-133a-2 ASO B at 10 nM, 30 nM and 50 nM 
reduced pri-miR-133a-2 expression by up to 80% (P < 0.05) although there appeared 
not to be directly corresponding effects on mature miR-133a expression (Figure  5-7).  
However, transfection of myoblasts with 30 nM or 50 nM pri-miR-133a-2 ASO B 
resulted in decreases in mature miR-133a of 40% (P < 0.05) and 80% (P < 0.01) 
respectively (Figure  5-7).  Myoblasts transfected with 100 nM and 50 nM of pri-miR-
206 ASO B resulted in cell death.  Transfecting pri-miR-206 ASO B at lower 
concentrations reduced pri-miR-206 expression by 60-80% (Figure  5-8).  Furthermore, 
mature miR-206 was reduced 70-75% when myoblasts were transfected with 10 nM or 
30 nM respectively (Figure  5-8). 
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Figure  5-7.  Pri-miR-133a-2 ASO transfection in C2C12 myoblasts at different 
concentrations.  (A) Fold change in pri-miR-133a-2 in response to pri-miR-133a-2 
ASO transfection at 10 nM, 30 nM, 50 nM compared to a scrambled ASO. (B) Fold 
change in mature miR-133a in response to pri-miR-133a-2 ASO transfection at 10 
nM, 30 nM, 50 nM compared to a scrambled ASO.  Data from triplicate 
transfections and shown as mean ± SE. **P  < 0.01 *P  < 0.05  
 
 
Figure  5-8. Pri-miR-206 ASO transfection in C2C12 myoblasts at different 
concentrations.  (A) Fold change in pri-miR-206 in response to pri-miR-206 ASO 
transfection at 10 nM and 30 nM compared to a scrambled ASO. (B) Fold change 
in mature miR-206 in response to pri-miR-206 ASO transfection at 10 nM and 30 
nM compared to a scrambled ASO.  Data from triplicate transfections and shown 
as mean ± SE. 
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5.3.5 Effectiveness of mature miR-133a and miR-206 knockdown 
Myoblasts transfected with mature microRNA ASOs targeting miR-133a resulted in 
knockdown of miR-133a to undetectable levels (P < 0.05, Figure  5-9), while there was 
no effect on miR-206 expression.  In miR-206 ASO transfected myoblasts there was a 
20% knockdown of miR-206 (P < 0.05, Figure  5-9).  When miR-133a and miR-206 
ASOs were transfected together, there was an 80% knockdown of miR-133a and miR-
206 (P < 0.05, Figure  5-9).  The housekeeping gene sno142 was stably expressed in 
myoblasts after transfection with miR-133a and miR-206 ASOs (Supplementary Figure 
 5-4).  Mature miR-133a and miR-133b differ by a single nucleotide at their 3’ end, so to 
check for specificity of miR-133a knockdown miR-133b expression was also measured.  
In miR-133a ASO transfected myoblasts there was also a 70% knockdown of miR-133b 
(P < 0.05, Figure  5-12).  Both miR-133a and miR-133b share almost identical predicted 
mRNA targets so despite the lack of specificity of the miR-133a knockdown, target 
protein levels should still reflect functional consequences of miR-133 family 
knockdown. 
 
Figure  5-9. Fold change in mature (A) miR-133a and (B) miR-206 expression in 
response to mature miR-133a and miR-206 knockdown.  Data based on duplicate 
transfections shown as mean ± SE. *P < 0.05 
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5.3.6 Knockdown of mature miR-133a and miR-206 regulates target proteins 
Gene targets of miR-133a and miR-206 were selected for experimental validation by 
Western blot following knockdown using mature microRNA ASOs.  The protein signal 
was normalized to total protein based on Ponceau Red staining of the nitrocellulose 
membrane rather than a housekeeping gene (Supplementary Table  5-1; Supplementary 
Figure  5-5).  One-tailed t-tests were performed on duplicate cell samples to determine 
whether microRNA knockdown resulted in significant increases in target protein. 
 
PTBP1 protein was increased around 20% following miR-133a knockdown (P < 0.05), 
while miR-206 knockdown resulted in a 20% decrease protein levels (Figure  5-10).  
There are four known PTBP1 isoforms, which the Western blot detects between 60-65 
kDa.  However, all share identical 3’UTRs and thus the same miR-133a and miR-206 
binding sites.  CDC42 was increased 125% following miR-133a knockdown (P < 0.05), 
while miR-206 resulted in 90% increase (P < 0.05) when compared to protein level in 
myoblasts transfected with a scrambled ASO (Figure  5-10).  
 
SMEK2 was decreased around 50% following miR-133a knockdown (P < 0.01), miR-
206 knockdown resulted in a 45% decrease (P < 0.01) in protein level (Figure  5-11).   
There was no additive effect evident following both miR-133a and miR-206 knockdown.  
Finally, TGIF2 results were less clear, miR-133a and miR-206 knockdown resulted in 
non-significant decreases around 40% compared to TGIF2 protein level in myotubes 
transfected with a scrambled ASO (Figure  5-11). 
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Figure  5-10. PTBP1 and CDC42 protein in response to miR-133a and miR-206 
knockdown. Data from Western blot on duplicate transfected myoblasts. *P < 0.05 
compared to scrambled ASO transfected myoblasts. 
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Figure  5-11. SMEK2 and TGIF2 protein in response to miR-133a and miR-206 
knockdown. Data from Western blot on duplicate transfected myoblasts. *P <  0.05 
compared to scrambled ASO transfected myoblasts. 
Chapter 5 – MicroRNA knockdown and regulation in muscle cells 
174 
5.3.7 Indirect affects of microRNA ASOs 
Rarely are the effects of microRNA knockdown on other microRNAs reported.  As 
miR-133a and miR-206 are both normally highly expressed in muscle and are predicted 
to target genes associated with transcriptional activation/suppression, it is possible that 
other microRNAs may be affected. Figure  5-12 shows miR-1 expression is suppressed 
around 30% following knockdown with miR-133a (P < 0.05) and miR-206.  
Remarkably, when both miR-133a and miR-206 were transfected together there was an 
80% decrease in miR-1 expression (P < 0.05, Figure  5-12).  Expression of miR-206 was 
affected by both miR-206 and miR-133a knockdown, again this effect appeared to be 
additive.  When both miR-133a and miR-206 were transfected together this resulted in 
around an 80% decrease in miR-206 expression (P < 0.05, Figure  5-9).  As described in 
section  5.3.5 miR-133a knockdown was very effective as miR-133a levels were found 
to be undetectable.  Knockdown of miR-206 had no effect on miR-133a levels (Figure 
 5-9).  Finally, miR-133b levels were reduced by around 70% following miR-133a 
knockdown, indicating the mature microRNA ASOs appeared to have unspecific affects 
on other muscle specific microRNAs (P < 0.05, Figure  5-12). 
 
Figure  5-12. Fold change in mature (A) miR-1 and (B) miR-133b expression in 
response to mature miR-133a and miR-206 knockdown.  Data shown as mean ± SE 
based on duplicate transfections.  *P < 0.05 
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5.3.8 Effects of microRNA ASOs on pri-microRNA transcription 
The observation that miR-1 and miR-206 expression appeared to be reduced following 
miR-133a or miR-206 knockdown raises the questions whether this change was 
occurring at the level of transcription.  Using RT-qPCR the expression of pri-
microRNA encoding miR-1, 206 and miR-133 families was examined in myoblasts 
following miR-133a or miR-206 ASO knockdown.  Transcription of pri-miR-133a-1 
and pri-miR-133a-2 was not significantly affected by miR-133a or miR-206 knockdown 
(Figure  5-13).  Transcription of pri-miR-1-2 (P < 0.05) was increased after miR-206 
knockdown, but pri-miR-1-1 and pri-miR-133b were not significantly affected 
(Supplementary Figure  5-6).  The housekeeping gene 18S was stably expressed 
following mature ASO transfections (Supplementary Figure  5-4) 
 
Figure  5-13. Effect of miR-133a and miR-206 knockdown on transcription of (A) 
pri-miR-133a-1, (B) pri-miR-133a-2 and (C) pri-miR-206.  Data from duplicate 
transfections shown as mean ± SE. 
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5.4. Discussion 
MicroRNA-1, miR-133a and miR-206 expression in myotubes responds to insulin and 
TNFα, which may partly explain the microRNA changes observed in Type 2 diabetes 
and pancreatic cancer cachexia patients (Chapter 3 and Chapter 4).  However, insulin 
appeared to stimulate primary miR-1, miR-133a and miR-206 expression and these 
changes were not consistent with changes in mature microRNA levels.  In order to 
experimentally validate targets microRNA knockdown was attempted using two 
approaches knockdown of primary miR-133a/206 and knockdown of mature miR-
133a/206.  CDC42 and PTBP1 were confirmed as miR-133a targets in skeletal muscle 
myoblasts, but TGIF2 and SMEK2 appeared not to be miR-133a or miR-206 targets.  
However, there were indirect effects of mature miR-133a and miR-206 knockdown 
using mature microRNA ASOs on primary and mature miR-1, miR-133a and miR-206 
expression.  More specific knockdown of mature miR-133a and miR-206 was achieved 
by targeting pri-miR-133a-2 and pri-miR-206, but requires further optimisation. 
5.4.1 Insulin affects primary and mature microRNA expression in myotubes 
Type 2 diabetes is characterised by hyperinsulinaemia and hyperglycaemia.  In this 
study myotubes were incubated in 100 nM insulin in the presence of 25 nM glucose and 
the effects on miR-1, miR-133a and miR-206 expression measured at 0, 10, 30 and 60 
min.  Despite the relatively short time frame miR-1 increased, there was a non-
significant decrease in miR-133a, while miR-206 remained stable, but the mechanism 
could not be determined in the present study.  The results support the idea that the 
down-regulation of miR-133a observed in Type 2 diabetes patients may in part be due 
to the effects of hyperinsulinaemia.  However, it would be worthwhile to repeat the cell 
experiments for different time points to determine whether chronic insulin treatment 
over 24-48 h down-regulates miR-133a. 
 
No transcriptional changes in pri-miR-133a-1 or pri-miR-133a-2 were observed in the 
Type 2 diabetes patients (Chapter 4).  Therefore it was important to establish whether 
hyperinsulinaemia had any effect on primary miR-133a transcription in the myotubes.  
Expression of pri-miR-133a-1 increased after 10 min in response to 100 nM insulin, but 
100 nM insulin had no effect on pri-miR-133a-2.  Expression of pri-miR-206 also 
increased in response to 100 nM insulin but had no effect on its neighbouring transcript 
pri-miR-133b.  Expression of pri-miR-1-1 increased in response to 100 nM insulin, but 
expression of pri-miR-1-2 was unchanged.  There appeared to be discordant expression 
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of primary and mature miR-133a and miR-206.  While mature miR-133a was decreased, 
primary miR-133a-1 expression appeared to be increased.  Likewise, pri-miR-206 
expression was increased, but mature miR-206 was unchanged. 
 
Past studies that have examined the effect of insulin on microRNA expression have 
been restricted to pancreatic β-cell-lines or adipocytes (Poy et al. 2004; He et al. 2007; 
Ling et al. 2009; Tang et al. 2009) and have not considered the effect of insulin on 
primary microRNA transcription.  The present data suggest further regulation occurs in 
the microRNA biogenesis and processing pathway, which determines functional mature 
microRNA expression.  However, it was not possible in the present study to examine 
the mechanism by which insulin influences primary and mature miR-1, miR-133a and 
miR-206 expression. 
5.4.2 TNFα decreases muscle-specific microRNA expression in myotubes 
In Type 2 diabetes patients TNFα has been reported to be elevated, and is a factor 
which may impair insulin signaling and hence muscle glucose uptake (Plomgaard et al. 
2007; Ruge et al. 2009).  In addition, TNFα is known to trigger protein breakdown in 
skeletal muscle, thus has been implicated in the pathogenesis of cancer cachexia 
(Tisdale 2005; Stephens et al. 2008; Seruga et al. 2008).  In the present study, the effect 
of TNFα on miR-1, miR-133a and miR-206 expression was examined to determine 
whether TNFα may explain some of the changes in miR-1, miR-133a and miR-206 
expression observed in human skeletal muscle in Chapter 3 and Chapter 4.  Treatment 
of myotubes with TNFα led to a decrease in miR-1, miR-133a and miR-206 expression 
after 1 h.  TNFα treatment for 24 h resulted in a 60-70% decrease in miR-1, miR-133a 
and miR-206 expression.  These findings suggest TNFα may be a regulator of muscle 
specific microRNA expression, but the mechanism could not be determined in the 
present study.  Further data would be useful from an in-vivo human TNFα infusion 
study to verify muscle specific microRNA expression responds to TNFα in-vivo.  A 
practical approach would be to examine the effects of blocking TNFα on microRNA 
expression in sepsis patients with chronic inflammation. 
5.4.3 Effectiveness of pri-microRNA and mature microRNA knockdown 
Mature microRNA sequences are contained within structured hairpins in pri- and pre-
microRNA (Lau et al. 2001).  It has been reported ASOs tend to have reduced 
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effectiveness when targeting structured hairpins (Davis et al. 2006).  Nevertheless, 
targeting of pre-microRNA using siRNA has been reported in cancer cell lines, but high 
concentrations were required for effective knockdown of mature miR-125b (Lee et al. 
2005).  Targeting pre-microRNA for knockdown of mature miR-133a was not an ideal 
approach in this study as Chapter 4 showed pre-miR-133a appeared to be rapidly 
processed in skeletal muscle from Type 2 diabetes patients, thus would be difficult to 
target effectively.  Therefore the approach taken in the present study was to target pri-
microRNA transcripts outside of the pre-microRNA hairpin structure (Davis et al. 2006).  
It must be borne in mind however, that the effectiveness of targeting pri-microRNA 
using ASOs has not been previously reported in skeletal muscle. 
 
In this study, ASOs targeting pri-miR-133a-1, pri-miR-133a-2 and pri-miR-206 were 
transfected into myoblasts to determine their effectiveness to knockdown pri-miR-133a-
1, pri-miR-133a-2 and pri-miR-206.  Both ASOs designed to target pri-miR-133a-1 
were ineffective at 100 nM for reducing pri-miR-133a-1 expression after 48 h.  This 
may be because pri-miR-133a-1 has a long half life in skeletal muscle, although the 
half-life of pri-microRNAs has not been reported in muscle or indeed any other tissue.  
If miR-133a-1 does have a long half-life then 48 h may have been too early to detect 
knockdown.  The pri-microRNA ASOs targeting pri-miR-133a-2 and pri-miR-206 
appeared to be effective at reducing pri-microRNA expression and thus mature 
microRNA expression when transfected at lower concentrations. 
 
In myoblasts pri-miR-133a-2 expression was effectively reduced by 80% by 
transfection of pri-miR-133a-2 ASOs at 10 nM, 30 nM and 50 nM.  Interestingly, 
mature miR-133a was not significantly reduced by pri-miR-133a-2 ASO transfections at 
10 nM despite the 80% knockdown of pri-miR-133a-2.  Pri-miR-133a-2 ASO 
transfections at 30 nM resulted in 40% knockdown of mature miR-133a.  While pri-
miR-133a-2 ASO transfections at 50 nM resulted in a comparable 80% knockdown of 
mature miR-133a.  Transfection of pri-miR-206 ASOs at 10 nM and 30 nM resulted in 
60-80% knockdown in pri-miR-206 and 60-80% knockdown of mature miR-206 at 30 
nM after 48 h.  However, transfection of pri-miR-206 ASOs at 50 nM resulted in cell 
death.  
 
In the present study the mechanism by which the pri-microRNA ASOs were acting was 
not determined, but it has been suggested that ASOs may act via an RNase H-based 
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mechanism causing degradation of the target transcript (Davis et al. 2006).  Together 
these findings suggest targeting of pri-miR-133a-2 and pri-miR-206 can be effective for 
specifically reducing mature miR-133a and mature miR-206.  This could be useful for 
further experiments to validate miR-133a and miR-206 targets.  Preliminary 
experiments suggest it may be possible to knockdown pri-miR-133a-2 and pri-miR-206 
in myotubes using ASOs (data not shown).  In addition, the knockdown effects of pri-
miR-206 in myoblasts appear to be retained upto 48 h during differentiation.  Therefore, 
targeting of pri-miR-133a-2 and pri-miR-206 could be useful for determining the 
contribution of these transcripts to myogenic differentiation (Brzeszczynska et al. under 
revision).  Furthermore, pri-microRNA ASOs could be useful for specific knockdown 
of mature microRNAs from the same family, but derived from different primary 
transcripts. 
 
The most common approach reported to knockdown microRNAs in muscle is by 
transfection of ASOs directly targeting mature microRNAs.  Therefore the effectiveness 
of mature microRNA ASOs targeting mature miR-133a and mature miR-206 was 
determined in myoblasts.  Mature miR-133a ASO transfection at 100 nM resulted in 
undetectable levels of miR-133a in myoblasts after 48 h.  Transfection of a miR-206 
ASO at 100 nM was less effective and resulted in a 20% knockdown of miR-206 in 
myoblasts after 48 h. 
5.4.4 CDC42 protein is up-regulated in response to miR-133a knockdown 
Western analysis showed CDC42 was up-regulated in response to miR-133a and miR-
206 knockdown providing evidence that CDC42 is a valid miR-133a and miR-206 
target.  CDC42 is a positive regulator of insulin signaling and cellular glucose uptake.  
CDC42 mediates insulin-stimulated GLUT4 translocation and glucose transport in a 
PI3-kinase dependent manner and acts upstream of PKC (Usui et al. 2003).  CDC42 
associates with p85 in response to insulin.  Therefore, down-regulation of miR-133a and 
miR-206 in Type 2 diabetes skeletal muscle may be associated with compensatory 
actions on targets such as CDC42 to increase glucose uptake post-transcriptionally.  
However, it is unknown whether CDC42 protein levels are altered in the skeletal muscle 
of Type 2 diabetes patients in-vivo (Sundsten & Ortsäter, 2009) and muscle glucose 
uptake measurement was not possible in the present study. 
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CDC42 has not been previously associated with cancer cachexia pathogenesis, but it has 
been linked to muscle wasting.  In a rat disuse model CDC42 protein was decreased 
60% after 3 days of hind limb suspension and increased 172% following 12 h reload 
(Chockalingam et al. 2002).  In addition, administration of a retroviral dominant-
negative CDC42 vector caused skeletal muscle fibre atrophy in rats (Chockalingam et 
al. 2002).  Activation of CDC42 in adult mice has been reported to significantly shorten 
life span, resulting in premature aging and muscle atrophy (Wang et al. 2007).  In 
embryonic fibroblasts activation of CDC42 was linked to increased basal apoptosis 
through elevated c-JNK signaling (Wang et al. 2005).  Apoptosis has been shown in 
skeletal muscle from gastro-intestinal cancer patients, indicated by increased DNA 
fragmentation (Busquets et al. 2007).  Taken together these studies suggest decreased 
miR-133a suppression of CDC42 may cause increased apoptosis, which has been 
reported in cancer cachexia, but CDC42 has not yet been measured in skeletal muscle 
from cancer cachexia patients. 
5.4.5 PTBP1 protein is up-regulated by miR-133a knockdown 
In agreement with a previous study (Boutz et al. 2007) western analysis of PTBP1 
following miR-133a knockdown showed PTBP1 protein was increased in skeletal 
muscle myoblasts.  PTBP1 is a polypyrimidine tract binding protein, which belongs to 
the subfamily of ubiquitously expressed heterogeneous ribonucleoproteins (hnRNPs).  
PTBP1 is reportedly repressed during myoblast differentiation by miR-133 and miR-
206 (Boutz et al. 2007).  A luciferase reporter with the 3’UTR of PTB was repressed by 
miR-133 (Boutz et al. 2007).  Transfection of ASOs to block miR-133 and miR-206 in 
myoblasts decreased expression of PTB dependent exons (Boutz et al. 2007) as PTBP1 
contains an RNA recognition motif, which binds RNA and modulates pre-mRNA 
splicing via the ubiquitin-proteosome pathway.  A recent proteomics study suggests 
mRNA-binding proteins in insulinoma cells respond to changes in glucose and proteins 
with PTBP1 bindings are modulated in response to glucose (Süss et al. 2009).  Type 2 
diabetes is associated with hyperglycaemia, but it is unknown whether mRNA-binding 
proteins change in skeletal muscle in response to glucose.  PTBP1 has not been 
previously associated with changes in skeletal muscle from Type 2 diabetes or cancer 
cachexia patients. 
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5.4.6 No evidence of miR-133a or miR-206 regulation of SMEK2 or TGIF2 
SMEK2 and TGIF2 appear not to be miR-133a or miR-206 targets in skeletal muscle 
myoblasts.  In response to miR-133a and miR-206 knockdown SMEK2 and TGIF2 
protein expression both appeared to be decreased or unchanged.  Past research indicates 
microRNAs usually suppress targets, but more recently microRNAs have been reported 
to activate target proteins (Bartel, 2009; Vasudevan et al. 2007).  SMEK2 is a 
suppressor of MEK, which has not been previously linked to Type 2 diabetes or cancer 
cachexia.  However, it may have powerful functions via suppression of MEK, which is 
an important MAPK protein associated with multiple cellular pathways including 
insulin signaling.  TGIF2 is a transcriptional repressor, which can directly bind DNA or 
interact with SMAD proteins leading to repression of TGF-β responsive transcription 
(Melhuish et al. 2001).  Alternatively, the fluctuations in SMEK2 and TGIF2 protein 
levels after miR-133a and miR-206 knockdown may have been indirect.  It was not 
possible in the present study to establish a direct interaction between miR-133a/206 and 
target 3’UTRs, as luciferase reporter assays were not possible in the present study. 
5.4.7 Knockdown of miR-133a and miR-206 impacts other microRNAs 
A problem with using mature microRNA ASOs to knockdown endogenous microRNAs 
is that close family members can also be affected.  Both miR-133a and miR-206 have 
close family members in miR-133b and miR-1.  The knockdown of miR-133a using the 
mature microRNA ASO approach resulted in ~40% knockdown of mature miR-206, 
~30% knockdown of mature miR-1 and 70% knockdown of mature miR-133b.  
Knockdown of miR-206 using the mature microRNA ASO approach resulted in no 
effect on mature miR-133a, while mature miR-133b was increased ~30% and miR-1 
was reduced ~30%. However, when miR-133a and miR-206 were transfected together, 
mature miR-1 and miR-206 was reduced by ~80%, while miR-133b was reduced by 
50%.  The effects of transfecting miR-133a ASOs on miR-133b in myoblasts could be 
explained by imperfect base pairing to the miR-133a ASO as mature miR-133a and 
miR-133b differ by only one nucleotide.  Indeed, the effects of transfecting miR-206 
ASOs on miR-1 could also be due to sequence complementarity in agreement with 
reports of widespread off-target effects of siRNAs mediated by sequence 
complementarity (Jackson et al. 2006).  However, this cannot explain why miR-206 and 
miR-1 are knocked down by transfection of the miR-133a ASO in myoblasts.  The 
current data suggests there must be some feedback from knockdown of mature miR-
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133a on miR-206 and miR-1 therefore the effect of transfecting miR-133a and miR-206 
ASOs into myoblasts on pri-microRNA transcription was examined. 
5.4.8 Knockdown of miR-133a and miR-206 impacts microRNA transcription 
Transfection of the miR-133a ASOs into myoblasts did not significantly affect pri-
microRNA expression.  In contrast, transfection of the miR-206 ASOs in myoblasts 
resulted in an >100% increase in pri-miR-1-2.  Taken together these findings indicate 
there was surprisingly an effect of miR-206 knockdown on primary transcription of 
miR-1. 
 
The mechanism regulating the effect of miR-206 on primary transcription of miR-1 was 
not established in this study.  Previously, a feedback loop regulating miR-1 expression 
has been reported, as miR-1 targets MEF2 in myoblasts and MEF2 binding sites have 
been found on pri-miR-1-1 and pri-miR-1-2 (Liu et al. 2007; Rao et al. 2006).  
Furthermore, miR-206 inhibits MyoD expression and MyoD binding sites have been 
found in pri-miR-1-1, pri-miR-1-2, pri-miR-133a-1 and pri-miR-133a-2 (Rao et al. 
2006).   Therefore, down-regulation of miR-206 either directly or indirectly using the 
mature microRNA ASO approach may influence the transcription of miR-1 and miR-
133a via de-repression of MyoD inhibitor (Kim et al. 2006).  Nevertheless, the mature 
microRNA ASO approach remains the most commonly used method for knockdown of 
microRNAs in cell culture for experimental validation of targets (Horwich & Zamore, 
2008; Carè et al. 2007). 
5.4.9 Limitations 
The experimental validation of targets is important when determining the function of 
microRNAs.  Western blot is most often used for measuring protein abundance of 
targets.  However, it is only practical to validate 1-2 targets using this method.  
Therefore it is not possible to confirm the actual number of genes targeted by one 
microRNA.  The microRNA predictions used in this Chapter were based on the 
TargetScan algorithm.  Estimates of false positive target predictions are around 40%, 
which is lower than other microRNA target prediction algorithms.  However, even 
determining a false positive target prediction percentage is difficult as the complete set 
of microRNA targets is unknown.  In the present study CDC42 and PTBP1 were up-
regulated in response to miR-133a knockdown in murine skeletal muscle myoblasts.  
Previous studies often provide additional evidence of binding of microRNA to target 
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based on a 3’UTR luciferase assay.  This would have been useful to check whether the 
predicted miR-133a binding sites in the 3’UTRs of SMEK2 and TGIF2 were functional, 
as SMEK2 and TGIF2 were not found to be up-regulated in response to miR-133a or 
miR-206 knockdown.   A more general limitation of using a murine myoblast cell line is 
that it does not represent mature human skeletal muscle.  Although there is ~90% 
homology between the mouse and human genomes the murine myoblasts may lack 
unknown contextual determinants that are present in adult muscle.  For example, C2C12 
myotubes appear not to require GLUT4 for cellular glucose uptake, whilst GLUT4 has 
been identified as the primary skeletal muscle glucose transporter in humans. 
 
The knockdown of mature microRNA was attempted using two methods.  The most 
widely used method involves transfection of mature microRNA ASOs into cells.  
However, in the present study the specificity of the ASO targeting miR-133a was not 
ideal.  There were clearly effects on miR-1, miR-133b, miR-206 and potentially an 
unknown number of other microRNAs.  Primary miR-133a and miR-1 transcripts were 
almost universally increased in response to mature miR-133 and miR-206 knockdown.  
Therefore caution is needed when interpreting the results of any microRNA knockdown 
experiments. 
 
The experiments determining the effect of insulin on miR-1, miR-133a and miR-206 
expression would have benefited from additional experiments being performed to 
increase power for statistical analysis.  The use of a high insulin dose may be criticised 
for being unphysiological and results from these experiments should be treated with 
caution.  Further experiments were conducted using a lower insulin dose, but the results 
were far from clear.  In future it would be worthwhile to manipulate glucose 
independently of insulin to determine the effects of hypoglycemia on microRNA 
expression in myotubes.  Further experiments using different concentrations of TNFα 
would be useful to determine whether miR-1, miR-133a and miR-206 changes are dose-
dependent. 
5.4.10 Future research directions 
The experimental validation of all predicted miR-133a and miR-206 targets in-vitro 
would be useful to indicate how effective current microRNA target prediction 
algorithms are.  Furthermore, in addition to validating microRNA targets it would be 
useful to establish whether miR-133a or miR-206 knockdown has functional 
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consequences on muscle glucose uptake or muscle protein degradation pathways, which 
are associated with Type 2 diabetes and cancer cachexia pathogenesis respectively. 
 
It would be advantageous to conduct microRNA knockdown experiments on human 
primary skeletal muscle cultures rather than mouse myoblasts.  Knockdown of 
microRNAs in human primary skeletal muscle cultures to validate targets would include 
contextual features, which may not be present in mouse myoblasts.  The pri-microRNA 
and mature microRNA knockdown approaches appear to be effective in myoblasts and 
could be further optimised for knockdown of miR-133a and miR-206 in human primary 
skeletal muscle cell cultures.  It will be important to establish that the miR-133a and 
miR-206 targets validated in-vitro in myoblasts are also up-regulated in-vivo in skeletal 
muscle of Type 2 diabetes and pancreatic cancer cachexia patients. 
5.4.11 Conclusions 
• CDC42 and PTBP1 protein levels in skeletal muscle myoblasts were elevated in 
response to miR-133a knockdown.  However, SMEK2 and TGIF2 appeared not to 
be regulated by miR-133a or miR-206. 
• Transfection of miR-133a and miR-206 ASOs in skeletal muscle myoblasts may 
lead to indirect effects on primary and mature miR-1, miR-133a and miR-206 
expression. 
• Specific knockdown of mature miR-133a and miR-206 is possible with ASOs 
targeting pri-microRNA transcripts in skeletal muscle myoblasts and could be useful 
to specifically target microRNAs with close family members. 
• Mature miR-1, miR-133a and miR-206 expression in skeletal muscle myotubes may 
be regulated by insulin and TNFα, although the mechanism is unknown. 
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5.5. Supplementary data 
 
Supplementary Figure  5-1. Efficiency of pri-microRNA primers.  (A) Pri-miR-
133a-1, (B) Pri-miR-1-2, (C) Pri-miR-133a-2, (D) Pri-miR-1-1, (E) Pri-miR-206 
and (F) Pri-miR-133b cycle thresholds across a range of cDNA dilutions. 
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Supplementary Figure  5-2 Fold change in (A) pri-miR-1-1, (B) pri-miR-1-2, (C) 
pri-miR-133a-1, (D) pri-miR-133a-2 and (E) pri-miR-206 in myotubes in response 
to 0.1 nM insulin treatment (n = 3).  Data shown as mean ± SE. 
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Supplementary Figure  5-3. Pri-microRNA ASOs designed to target pri-miR-133a-
1 were ineffective when transfected at 100 nM in myoblasts (n = 6).  Data shown as 
mean ± SE. 
 
 
Supplementary Figure  5-4. (A) Stable 18S and (B) sno142 expression in myoblasts 
following mature microRNA ASO transfections. Data shown as mean ± SE. 
 
 
 
Chapter 5 – MicroRNA knockdown and regulation in muscle cells 
188 
Supplementary Table  5-1. Total protein intensity for normalisation of Western 
blots determined from Ponceau Red stained nitrocellulose membrane  
Sample Lane Total protein intensity* 
miR-133a ASO 1 45344 
miR-133a ASO 2 38228 
miR-206 ASO 3 40988 
miR-206 ASO 4 31861 
miR-133a + 206 ASO 5 36324 
miR-133a + 206 ASO 6 39089 
Scrambled ASO 7 33432 
Scrambled ASO 8 43065 
Non-transfected 9 42900 
* Determined using ImageJ software (NIH). 
 
 
Supplementary Figure  5-5. Total protein from Ponceau Red stained nitrocellulose 
membrane.  
 
 
 Lane   1     2      3      4       5       6      7      8       9 
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Supplementary Figure  5-6. Effect of miR-133a and miR-206 knockdown on 
transcription of (A) pri-miR-1-1, (B) pri-miR-1-2 and (C) pri-miR-133b.  Data 
from duplicate transfections shown as mean ± SE. * P < 0.05 
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Chapter 6 - Final Conclusions 
In recent years evidence that microRNAs are important global regulators of gene 
expression and biomarkers of disease has been accumulating.  This thesis focused on 
identifying microRNA biomarkers of cancer cachexia and Type 2 diabetes in skeletal 
muscle.  There has been no previous research on microRNA expression in skeletal 
muscle from Type 2 diabetes or cancer cachexia patients, thus this thesis presents some 
very novel data. 
6.1. Novel microRNA biomarkers in cancer cachexia patients  
In Chapter 3, muscle specific miR-1, miR-133a, miR-133b and miR-206 expression 
were shown to be negatively related to weight loss in pancreatic cancer cachexia 
patients.  Weight loss in cancer cachexia patients is a commonly used indicator of 
cancer cachexia severity.  Therefore, muscle specific miR-1, miR-133a, miR-133b and 
miR-206 may be potential biomarkers of cancer cachexia severity in pancreatic cancer 
patients.  Past studies have established the importance of these muscle specific 
microRNAs in myogenesis and muscle growth (Kim et al. 2006; Nakajima et al. 2006; 
Chen et al. 2006; Boutz et al. 2007; van Rooij et al. 2008), thus the down-regulation of 
these microRNAs in pancreatic cancer cachexia patients observed in Chapter 3 is 
consistent with the role of these microRNAs in muscle growth and differentiation. 
 
However, an important caveat to bear in mind is miR-1, miR-133a, miR-133b and miR-
206 expression was not significantly related to weight loss when the cancer patients 
with different tumour types were considered.  The prevalence of cachexia has been 
reported to be higher among pancreatic cancer patients compared to other cancer 
patients but the mechanism remains unexplained (Fearon, 1992).  No universal cause 
for cachexia has been identified, which suggests for some cancer patients these 
microRNAs may be biomarkers of cachexia pathogenesis, but for others these 
microRNAs may be less important.  Gene ontology enrichment analysis suggests miR-1, 
miR-133a, miR-133b and miR-206 may regulate transcriptional regulators thus may 
have widespread indirect effects on gene expression, but the possible functional role of 
these microRNAs in cancer cachexia was not clear. 
 
During skeletal muscle differentiation miR-1, miR-133a and miR-206 are strongly 
induced.  Therefore down-regulation of these microRNAs may indicate proliferation 
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and stem-cell renewal is occurring (Boutz et al. 2007; Rao et al. 2006).  Previously, it 
has been suggested cachexia may stimulate an increase in stem cells populations in an 
attempt to maintain muscle mass (Berardi et al. 2008).  For example, increases in 
hematopoietic stem cells have been reported in skeletal muscle of C-26 tumour bearing 
mice, thus supporting the idea that muscle regeneration may be occurring during 
cachexia (Berardi et al. 2008). 
 
It was not possible to determine whether miR-1, miR-133a, miR-133b and miR-206 
were directly involved in cachexia pathogenesis or were only biomarkers of cancer 
cachexia severity due to the cross-sectional study design.  In future, a longitudinal study 
of microRNA changes in cancer cachexia patients would help establish whether these 
microRNAs contribute to cancer cachexia pathogenesis.  There was no evidence of 
differences in microRNA processing genes between control, pre-cachexia and cachexia 
patients, in agreement with an earlier study on muscle atrophy in mice (McCarthy et al. 
2007).  However this does not preclude that post-transcriptional changes may influence 
microRNA processing genes in cancer cachexia patients (Wiesen & Tomasi, 2009). 
 
A major limitation of the present cancer cachexia cohort was that cachexia severity was 
based on patients estimated body mass prior to cancer diagnosis compared to measured 
body mass during clinical examination before tumour resection.  Patients may have 
over- or under-estimated initial body mass, which would have affected the 
determination of weight loss and cachexia severity.  It is unknown how reliable patient 
estimates of body mass were and it was not possible to check medical records. 
 
In addition, miR-21 was measured in cancer cachexia patients as a potential biomarker 
of cancer cachexia severity because miR-21 was found to be dysregulated in ICU 
patients characterised by severe inflammation and muscle wasting (Fredriksson et al. 
2008).  There was an indication miR-21 may be elevated in cancer cachexia patients 
similar to previous findings in patients with various muscular dystrophies, but these 
results were not significant (Eisenberg et al. 2007).  Nevertheless, the predicted targets 
of miR-21 include genes involved in the ubiquitin-proteolysis pathway, which has been 
implicated in cancer cachexia (Williams et al. 1999).  Further studies would be 
necessary in a larger cross-sectional cancer cachexia cohort to establish whether miR-21 
may be a useful biomarker of cancer cachexia severity. 
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6.2. Down-regulated miR-133a and miR-206 in Type 2 diabetes patients 
In skeletal muscle from Type 2 diabetes patients, miR-133a and miR-206 were found to 
be significantly down-regulated compared to age, BMI and VO2max matched controls 
with normal glucose tolerance.  In addition, miR-133a expression alone could explain 
30-40% variance in glucose tolerance and fasting glucose both part of the WHO criteria 
for diagnosis of impaired glucose tolerance and Type 2 diabetes (WHO, 2006).  
Furthermore, miR-133a and miR-206 expression could predict 30% of the variance in 
HbA1c which indicates prolonged hyperglycaemia and HOMA[IR] which indicates 
insulin resistance.  Therefore, miR-133a may be a potential biomarker for the 
development of insulin resistance and Type 2 diabetes.  However, it was not possible to 
determine whether miR-133a expression changes were a cause or effect of 
pathophysiological changes leading to Type 2 diabetes. 
 
Discovery of new biomarkers is important as earlier diagnosis of Type 2 diabetes would 
help to significantly improve morbidity and mortality rates (Roglic et al. 2005; Shaw et 
al. 2000; Wild et al. 2004; WHO, 2006; Zimmet et al. 2001).  MicroRNA analysis 
requires only small amounts of RNA using RT-qPCR (Cissell & Deo, 2009; Chen et al. 
2005), but muscle biopsies are not useful for routine clinical testing.  Thus it would be 
useful to determine whether similar changes in microRNA expression occur in blood.  
In the future it will be important to establish in a larger population sample how sensitive 
microRNA expression is to early changes in glucose tolerance indicators and 
furthermore whether microRNA expression can predict the development of Type 2 
diabetes. 
 
Transcription of miR-133a appeared to be unaltered in Type 2 diabetes patients and 
there was no change in the expression of the primary microRNA processing genes 
DROSHA and DGCR8.  These findings suggest a factor downstream of primary 
microRNA transcription appears to be responsible for the down-regulation of mature 
miR-133a and miR-206 expression in Type 2 diabetes.  Pre-miR-133a appeared to be 
rapidly processed into mature miR-133a in agreement with previous findings (Lee et al. 
2008) and the pre-microRNA processing genes DICER and AGO2 were unaltered in 
Type 2 diabetes.  Taken together these findings suggest there must be other regulatory 
steps after initial microRNA transcription that determines mature microRNA levels.  
Recent studies suggest an important role of RNA-binding proteins in regulating 
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microRNA processing (Guil & Cáceres, 2007; Kim et al. 2009; Michlewski et al. 2008) 
or alternatively perhaps microRNA degradation is regulated in Type 2 diabetes.  Further 
studies would be useful to identify the factors which cause post-transcriptional down-
regulation of miR-133a in Type 2 diabetes.  No studies have yet considered when or 
how microRNAs are degraded and this would be worthwhile to establish as this may 
explain why mature miR-133a is lower in skeletal muscle from Type 2 diabetes patients. 
 
In Chapter 4, analysis of existing microarray data after miR-133a overexpression in 
HeLa cells (Grimson et al. 2007) revealed multiple down-regulated miR-133a targets 
have been previously linked to diabetes, including CDC42.  However, in Type 2 
diabetes patients there was evidence of increased miR-206 target expression, but not 
miR-133a target expression.  Therefore, miR-133a may act primarily via translational 
repression of targets.  In the present study it was not possible to determine whether 
miR-133a or miR-206 target proteins were increased in-vivo in skeletal muscle from 
Type 2 diabetes patients.  Gene ontology enrichment analysis (Sherman et al. 2007) 
revealed the functional consequences of miR-133a in adult skeletal muscle may be 
partly through repression of intracellular transport proteins and protein phosphatases.  
Insulin signaling and hence glucose uptake are known to be inhibited by protein 
phosphatases (Muoio & Newgard, 2008; Youngren et al. 2007), but these were not 
measured in Type 2 diabetes patients in the present study.  In future, in-vivo 
measurement of microRNA target proteins in skeletal muscle from Type 2 diabetes 
patients may help to reveal the importance of post-transcriptional regulation by 
microRNAs. 
 
In agreement with published microarray data from diabetic rats (He et al. 2007), miR-
29a was found to be up-regulated in skeletal muscle from Type 2 diabetes patients.  
Furthermore, overexpression of miR-29a is reported to suppress insulin-stimulated 
glucose uptake in adipocytes (He et al. 2007).  Hyperglycaemia and hyperinsulinaemia 
were both reported to mimic miR-29 suppression of insulin-stimulated glucose uptake 
(He et al. 2007).  However, recent microRNA array data from diabetic GK rats failed to 
show miR-29a was up-regulated (Huang et al. 2009).  The lack of concordance between 
two microRNA array studies conducted in diabetic GK rats may have been due to the 
use of different custom microarray platforms (Huang et al. 2009; He et al. 2007).  A 
recent study compared five commercial microRNA array platforms for agreement and 
reported a lack of agreement between some platforms (Sato et al. 2009).  Despite the 
Chapter 6 – Final Conclusions 
194 
limitations in previous studies on microRNAs in diabetic GK rats, most importantly in 
human skeletal muscle miR-29a is up-regulated in-vivo in Type 2 diabetes patients.  
Therefore, miR-29a appears to be another potential microRNA biomarker of human 
Type 2 diabetes.  In future studies, it would be worthwhile determining whether miR-
29a transcription or processing is altered in human Type 2 diabetes. 
 
The potential importance of post-transcriptional regulation in skeletal muscle in Type 2 
diabetes has been supported by recent genome-wide transcriptome studies which found 
no evidence of transcriptional changes in skeletal muscle from Type 2 diabetes patients 
when compared to BMI and physical activity matched controls (J. Timmons, personal 
communication).  Importantly, in the present study Type 2 diabetes patients and 
controls were matched for BMI and physical activity as these factors are known to 
influence gene expression (Krämer et al. 2006; Ling et al. 2004; Mathai et al. 2008; 
Sriwijitkamol et al. 2007; Timmons et al. 2006).  In Chapter 2, studies demonstrating 
microRNAs target insulin signaling proteins were reviewed (Gauthier & Wollheim, 
2006; Hennessy & O'Driscoll, 2008; Poy et al. 2007; Tang et al. 2008), but most of 
these studies were not performed in human skeletal muscle.  Nevertheless it does 
highlight there are many more microRNAs which may be involved in the development 
of Type 2 diabetes which remain to be verified in human skeletal muscle.  Taken 
together the present findings and past studies provide strong evidence to suggest 
microRNAs are not only novel biomarkers of insulin resistance and Type 2 diabetes, but 
may also play a role in Type 2 diabetes pathogenesis.  However, a larger longitudinal 
study would be needed to establish whether microRNAs are down-regulated in skeletal 
muscle as individuals develop Type 2 diabetes.  Alternatively, microRNA changes in 
Type 2 diabetes could be secondary effects of hyperglycaemia and hyperinsulinaemia 
due to insulin resistance and pancreatic β-cell dysfunction. 
6.3. MicroRNAs respond to extracellular factors in myotubes 
In Chapter 5, to determine possible regulators of microRNA expression in Type 2 
diabetes and cancer cachexia the effects of extracellular factors on microRNA 
expression in myotubes was determined.  Hyperglycaemia and hyperinsulinaemia are 
characteristics of Type 2 diabetes and develop with insulin resistance and pancreatic β-
cell dysfunction.  Here it was only possible to examine the response of miR-1, miR-
133a and miR-206 to hyperinsulinaemia, due to RNA degradation occurring in cell 
samples subjected to high or low glucose.  Nevertheless, in response to insulin miR-1 
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appeared to increase, miR-133a appeared to decrease, while miR-206 remained stable in 
myotubes.  These findings support the idea that the down-regulation of miR-133a 
observed in Type 2 diabetes patients may in part be due to the effects of 
hyperinsulinaemia, although it would be worthwhile repeating this experiment over a 
longer time period. There were also transcriptional changes associated with insulin 
treatment in myotubes.  Insulin treatment increased expression of pri-miR-1-1, pri-miR-
133a-1 and pri-miR-206 but had no affect on pri-miR-1-2, pri-miR-133a-2 or pri-miR-
133b.  The lack of concordance between primary and mature microRNA expression in 
response to insulin suggests further regulation occurs in the microRNA biogenesis and 
processing pathway, which determines functional mature microRNA expression.  
However, it was not possible in the present study to examine the mechanism by which 
insulin influences primary and mature miR-1, miR-133a and miR-206 expression.  In 
future studies, it would be worthwhile to determine whether skeletal muscle microRNA 
expression changes in response to experimental hyperglycaemia or hyperinsulinaemia in 
humans. 
 
In Type 2 diabetes patients elevated plasma TNFα is reported, which may impair 
insulin signaling and hence muscle glucose uptake (Lindmark et al. 2006; Plomgaard et 
al. 2007).  In addition, TNFα is known to trigger protein breakdown in skeletal muscle, 
thus has been implicated in the pathogenesis of cancer cachexia (Tisdale 2005; Stephens 
et al. 2008; Seruga et al. 2008).  Treatment of myotubes with TNFα led to a decrease in 
miR-1, miR-133a and miR-206 expression after 1 h and after 24 h.  These findings 
suggest TNFα may be a regulator of muscle specific microRNA expression; this is 
plausible as TNFα has recently been reported to modulate microRNA expression in 
adipocytes (Xie et al. 2009).  Further studies would be useful to verify muscle specific 
microRNA expression responds to TNFα, for example by reducing TNFα levels in 
sepsis patients using TNFα antibodies. 
6.4. MicroRNA targets regulated in myoblasts 
Knockdown of miR-133a and miR-206 showed CDC42 protein was up-regulated 
confirming CDC42 is regulated by miR-133a and miR-206 in skeletal muscle 
myoblasts.  CDC42 mediates insulin-stimulated GLUT4 translocation and glucose 
transport in a PI3-kinase dependent manner (Usui et al. 2003).  Therefore, down-
regulation of miR-133a and miR-206 in Type 2 diabetes skeletal muscle may be 
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associated with compensatory actions on targets such as CDC42 to increase glucose 
uptake.  However, it is unknown whether CDC42 protein levels are altered in the 
skeletal muscle of Type 2 diabetes patient’s in-vivo (Sundsten & Ortsäter, 2009).  
 
CDC42 has not been previously associated with cancer cachexia pathogenesis, but it has 
been linked to muscle wasting.  For example, in a rat disuse model CDC42 protein was 
decreased 60% after 3 days of hind limb suspension, in addition administration of a 
retroviral dominant-negative CDC42 vector caused skeletal muscle fibre atrophy in rats 
(Chockalingam et al. 2002).  Therefore, miR-133a and miR-206 regulation of CDC42 
may be relevant in cancer cachexia, although it was not possible to measure CDC42 
protein levels in cancer cachexia patients in the present study.   
 
In agreement with a previous study western analysis of PTBP1 protein following miR-
133a knockdown increased PTBP1 protein levels (Boutz et al. 2007).  PTBP1 is a 
polypyrimidine tract binding protein, which belongs to the subfamily of ubiquitously 
expressed heterogeneous ribonucleoproteins (hnRNPs). A recent proteomics study 
suggests mRNA-binding proteins such as PTBP1 respond to changes in glucose in 
insulinoma cells (Süss et al. 2009).  Type 2 diabetes is associated with hyperglycaemia, 
but it is unknown whether mRNA-binding proteins change in skeletal muscle in 
response to glucose.  Findings from the present study establish miR-133a targets 
PTBP1, but it remains to be determined whether PTBP1 protein is elevated in-vivo in 
cancer cachexia or Type 2 diabetes patients. 
6.5. Primary microRNA knockdown is possible in myoblasts 
Typically, microRNA knockdown with anti-sense oligonucleotides (ASOs) is used to 
help experimentally validate predicted microRNA targets (Horwich & Zamore, 2008; 
Carè et al. 2007).  In Chapter 5, there appeared to be indirect effects on other highly 
expressed muscle specific microRNAs when transfecting myoblasts with ASOs 
targeting mature microRNAs.  Improved specificity to knockdown microRNAs can be 
achieved by transfecting myoblasts with ASOs targeting pri-microRNA transcripts.  For 
example, in Chapter 5 knockdown of mature miR-133a was demonstrated in response to 
knockdown of pri-miR-133a-2 using ASOs.  In addition, pri-miR-206 knockdown 
decreased mature miR-206 levels in myoblasts.  In the present study the mechanism by 
which the pri-microRNA ASO was acting was not determined, but it has been suggested 
ASOs may act via an RNase H-based mechanism causing degradation of the target 
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transcript (Davis et al. 2006).  Nevertheless, it appears targeting pri-microRNAs may be 
an effective strategy to knockdown mature microRNAs and may be useful to 
experimentally validate microRNA targets in the future. 
6.6. Future research directions 
Longitudinal studies are needed to determine whether microRNAs are sensitive to the 
early changes in skeletal muscle occurring in the pre-cachexia state (Bozzetti & Mariani, 
2008) and pre-diabetes state (Edelstein et al. 1997; WHO, 2006) compared to other 
biomarkers such as fasting glucose, glucose tolerance, CRP and TNFα.  It would be 
advantageous to use more sensitive indicators of cancer cachexia severity, for example 
muscle-mass loss determined by MRI or DEXA scanning.  In addition, the 
hyperinsulinaemic euroglycaemic clamp would provide a more sensitive indicator of 
insulin resistance in Type 2 diabetes rather than the oral glucose tolerance test used here. 
 
Furthermore, in addition to validating microRNA targets it would be useful to establish 
whether miR-133a or miR-206 knockdown has functional consequences on muscle 
glucose uptake or muscle protein degradation pathways, which are associated with Type 
2 diabetes and cancer cachexia pathogenesis respectively.  It would be advantageous to 
conduct microRNA knockdown experiments on human primary skeletal muscle cultures 
rather than mouse C2C12 myoblasts. 
 
It will be important to establish that the miR-133a and miR-206 targets validated in-
vitro in myoblasts are also up-regulated in-vivo in skeletal muscle of Type 2 diabetes 
and pancreatic cancer cachexia patients.  From the perspective of microRNA function in 
cancer cachexia and Type 2 diabetes, new studies measuring global changes in 
microRNA targets at the mRNA and protein level in patient skeletal muscle would 
provide more robust evidence of the magnitude of microRNA regulation in disease 
pathogenesis. 
6.7. Final word 
There is now huge interest in the role of microRNAs in chronic human diseases 
including cancer, Type 2 diabetes, cardiovascular disease and muscular dystrophies 
(van Rooij et al. 2008; Chen et al. 2009; Yang & Wu, 2007; Couzin, 2008; Hennessy & 
O'Driscoll, 2008).   MicroRNA target predictions suggest over 60% of protein coding 
genes have been under evolutionary pressure to maintain microRNA target sites 
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(Friedman et al. 2009).  Furthermore, over 45,000 conserved microRNA target sites 
have now been identified in human 3’UTRs (Friedman et al. 2009).  Therefore 
microRNAs have significant potential to influence diease pathogenesis. 
 
This thesis demonstrates that skeletal muscle microRNAs may be involved in the 
pathogenesis of Type 2 diabetes and cancer cachexia.  Furthermore microRNAs may 
provide early biomarkers of Type 2 diabetes and cancer cachexia thus facilitating earlier 
intervention.  MicroRNA-133a was the strongest predictor of existing diagnostic criteria.  
However, this thesis is based on cross-sectional microRNA expression data, therefore 
further longitudinal studies would be required to determine whether microRNA 
expression in human skeletal muscle can predict Type 2 diabetes and cancer cachexia 
development. 
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Appendix  7-1. GO Molecular function terms enriched among miR-1/206 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
NUCLEIC ACID BINDING 72 217 1974 9167 0.000 0.0% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
43 217 1002 9167 0.000 0.0% 
BINDING 184 217 6819 9167 0.000 0.0% 
PROTEIN BINDING 105 217 3398 9167 0.000 0.0% 
DNA BINDING 54 217 1482 9167 0.001 0.0% 
TRANSCRIPTION FACTOR 
ACTIVITY 
30 217 734 9167 0.004 0.0% 
PHOSPHOPROTEIN 
PHOSPHATASE ACTIVITY 
6 217 128 9167 0.184 144.0% 
UBIQUITIN-PROTEIN LIGASE 
ACTIVITY 
7 217 157 9167 0.166 147.0% 
 
Appendix  7-2. GO Cellular component terms enriched among miR-1/206 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
MEMBRANE-BOUND 
ORGANELLE 
126 202 3740 8448 0.000 0.0% 
NUCLEUS 94 202 2482 8448 0.000 0.0% 
INTRACELLULAR ORGANELLE 137 202 4330 8448 0.000 0.0% 
CELL 195 202 7620 8448 0.001 0.0% 
ENDOMEMBRANE SYSTEM 16 202 240 8448 0.001 0.0% 
GOLGI STACK 15 202 260 8448 0.004 0.0% 
GOLGI APPARATUS 17 202 332 8448 0.006 0.0% 
ORGANELLE MEMBRANE 15 202 302 8448 0.013 9.1% 
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Appendix  7-3. GO Biological process terms enriched among miR-1/206 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
REGULATION OF CELLULAR 
PHYSIOLOGICAL PROCESS 
86 214 2246 8892 0.000 0.0% 
REGULATION OF CELLULAR 
METABOLISM 
63 214 1551 8892 0.000 0.0% 
REGULATION OF 
TRANSCRIPTION 
57 214 1424 8892 0.000 0.0% 
CELL ORGANIZATION AND 
BIOGENESIS 
45 214 1120 8892 0.001 0.0% 
VESICLE-MEDIATED 
TRANSPORT 
17 214 263 8892 0.001 0.0% 
PROTEIN LOCALIZATION 19 214 412 8892 0.010 0.0% 
SECRETORY PATHWAY 9 214 132 8892 0.014 3.0% 
ENZYME LINKED RECEPTOR 
PROTEIN SIGNALING PATHWAY 
10 214 155 8892 0.012 3.3% 
ESTABLISHMENT OF 
LOCALIZATION 
64 214 2015 8892 0.011 3.6% 
METABOLISM 137 214 5050 8892 0.020 5.6% 
MUSCLE DEVELOPMENT 7 214 94 8892 0.025 7.5% 
TRANSMEMBRANE RECEPTOR 
PROTEIN TYROSINE KINASE 
SIGNALING PATHWAY 
8 214 117 8892 0.022 8.1% 
NEGATIVE REGULATION OF 
CELLULAR PHYSIOLOGICAL 
PROCESS 
21 214 529 8892 0.028 9.3% 
 
Appendix  7-4. GO Molecular function terms enriched among miR-21 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
TRANSCRIPTION REGULATOR 
ACTIVITY 
26 111 1033 9743 0.000 0.0% 
DNA BINDING 31 111 1539 9743 0.001 0.0% 
RNA BINDING 11 111 380 9743 0.011 0.0% 
UBIQUITIN-PROTEIN LIGASE 
ACTIVITY 
7 111 165 9743 0.011 0.0% 
STRUCTURE-SPECIFIC DNA 
BINDING 
4 111 41 9743 0.011 0.0% 
LIGASE ACTIVITY, FORMING 
CARBON-NITROGEN BONDS 
7 111 198 9743 0.024 11.1% 
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Appendix  7-5. GO Cellular component terms enriched among miR-21 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
NUCLEUS 50 102 2557 8941 0.000 0.0% 
INTRACELLULAR MEMBRANE-
BOUND ORGANELLE 
58 102 3848 8941 0.004 0.0% 
MEMBRANE-BOUND ORGANELLE 58 102 3850 8941 0.004 0.0% 
INTRACELLULAR 74 102 5326 8941 0.005 0.0% 
PROTEIN COMPLEX 25 102 1430 8941 0.027 14.3% 
ORGANELLE 62 102 4463 8941 0.022 16.7% 
INTRACELLULAR ORGANELLE 62 102 4461 8941 0.021 20.0% 
UBIQUITIN LIGASE COMPLEX 5 102 120 8941 0.047 50.0% 
 
Appendix  7-6. GO Biological process terms enriched among miR-21 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
REGULATION OF CELLULAR 
PROCESS 
48 108 2425 9408 0.000 0.0% 
REGULATION OF 
TRANSCRIPTION, DNA-
DEPENDENT 
32 108 1391 9408 0.000 0.0% 
REGULATION OF 
PHYSIOLOGICAL PROCESS 
46 108 2398 9408 0.000 0.0% 
NUCLEOBASE, NUCLEOSIDE, 
NUCLEOTIDE AND NUCLEIC 
ACID METABOLISM 
40 108 2317 9408 0.004 0.0% 
DNA PACKAGING 7 108 213 9408 0.034 11.8% 
PROTEIN UBIQUITINATION 5 108 120 9408 0.048 19.0% 
 
Appendix  7-7. GO Molecular function terms enriched among miR-23a targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
TRANSCRIPTION FACTOR 
ACTIVITY 
54 355 764 9743 0.000 0.0% 
DNA BINDING 89 355 1539 9743 0.000 0.0% 
NUCLEIC ACID BINDING 111 355 2056 9743 0.000 0.0% 
RNA POLYMERASE II 
TRANSCRIPTION FACTOR 
ACTIVITY 
18 355 186 9743 0.000 0.0% 
PROTEIN SERINE/THREONINE 
KINASE ACTIVITY 
22 355 306 9743 0.004 0.0% 
PROTEIN KINASE ACTIVITY 28 355 430 9743 0.004 0.0% 
ION BINDING 110 355 2479 9743 0.012 7.1% 
CALMODULIN BINDING 11 355 119 9743 0.011 8.3% 
 
Chapter 7 - Appendices 
202 
Appendix  7-8. GO Cellular component terms enriched among miR-23a targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
NUCLEUS 148 333 2557 8941 0.000 0.0% 
MEMBRANE-BOUND 
ORGANELLE 
184 333 3850 8941 0.000 0.0% 
INTRACELLULAR ORGANELLE 205 333 4461 8941 0.000 0.0% 
NUCLEAR ENVELOPE 8 333 74 8941 0.020 37.5% 
GOLGI APPARATUS 21 333 350 8941 0.036 70.0% 
MUSCLE MYOSIN 3 333 14 8941 0.093 193.0% 
 
Appendix  7-9. GO Biological process terms enriched among miR-23a targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
REGULATION OF TRANSCRIPTION 89 344 1472 9408 0.00 0.0% 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
32 344 423 9408 0.00 0.0% 
POSITIVE REGULATION OF 
BIOLOGICAL PROCESS 
34 344 501 9408 0.00 0.0% 
NEGATIVE REGULATION OF 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
9 344 62 9408 0.00 0.0% 
CELL ADHESION 34 344 548 9408 0.00 0.0% 
WNT RECEPTOR SIGNALING 
PATHWAY 
10 344 85 9408 0.00 0.0% 
CELL PROLIFERATION 29 344 473 9408 0.01 0.0% 
PROTEIN AMINO ACID 
PHOSPHORYLATION 
26 344 427 9408 0.01 2.9% 
REGULATION OF CELL CYCLE 24 344 376 9408 0.01 2.9% 
NEGATIVE REGULATION OF 
PROGRESSION THROUGH CELL 
CYCLE 
11 344 126 9408 0.02 5.4% 
PROTEIN MODIFICATION 51 344 1036 9408 0.02 7.1% 
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Appendix  7-10. GO Molecular function terms enriched among miR-27b targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
PROTEIN SERINE/THREONINE 
KINASE ACTIVITY 
39 435 306 9743 0.000 0.0% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
80 435 1033 9743 0.000 0.0% 
PROTEIN-TYROSINE KINASE 
ACTIVITY 
23 435 168 9743 0.000 0.0% 
CAMP-DEPENDENT PROTEIN 
KINASE ACTIVITY 
23 435 172 9743 0.000 0.0% 
PROTEIN KINASE CK2 ACTIVITY 22 435 168 9743 0.000 0.0% 
TRANSFERASE ACTIVITY, 
TRANSFERRING PHOSPHORUS-
CONTAINING GROUPS 
55 435 688 9743 0.000 0.0% 
ATP BINDING 66 435 916 9743 0.000 0.0% 
ADENYL NUCLEOTIDE BINDING 67 435 945 9743 0.000 0.0% 
PROTEIN BINDING 189 435 3453 9743 0.000 0.0% 
PHOSPHOPROTEIN PHOSPHATASE 
ACTIVITY 
16 435 131 9743 0.001 0.0% 
PHOSPHORIC ESTER HYDROLASE 
ACTIVITY 
22 435 243 9743 0.003 0.0% 
STEROID HORMONE RECEPTOR 
ACTIVITY 
8 435 50 9743 0.006 0.0% 
STRUCTURAL CONSTITUENT OF 
CYTOSKELETON 
10 435 81 9743 0.010 3.1% 
LIGAND-DEPENDENT NUCLEAR 
RECEPTOR ACTIVITY 
8 435 53 9743 0.009 3.2% 
PROTEIN BINDING, BRIDGING 8 435 60 9743 0.017 5.9% 
RNA POLYMERASE II 
TRANSCRIPTION FACTOR 
ACTIVITY 
16 435 186 9743 0.019 8.1% 
TRANSCRIPTION COFACTOR 
ACTIVITY 
18 435 219 9743 0.018 8.3% 
 
Appendix  7-11. GO Cellular component terms enriched among miR-27b targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
NUCLEUS 164 397 2557 8941 0.000 0.0% 
MEMBRANE-BOUND 
ORGANELLE 
206 397 3850 8941 0.000 0.0% 
INTRACELLULAR 268 397 5326 8941 0.001 0.0% 
INTRACELLULAR ORGANELLE 229 397 4461 8941 0.001 0.0% 
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Appendix  7-12. GO Biological process terms enriched among miR-27b targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
DEVELOPMENT 117 426 1598 9408 0.000 0.0% 
PROTEIN MODIFICATION 82 426 1036 9408 0.000 0.0% 
PROTEIN AMINO ACID 
PHOSPHORYLATION 
44 426 427 9408 0.000 0.0% 
REGULATION OF 
TRANSCRIPTION 
101 426 1472 9408 0.000 0.0% 
PHOSPHORYLATION 46 426 522 9408 0.000 0.0% 
METABOLISM 273 426 5213 9408 0.000 0.0% 
LOCALIZATION OF CELL 23 426 213 9408 0.000 0.0% 
CELL DIFFERENTIATION 35 426 431 9408 0.001 0.0% 
POSITIVE REGULATION OF 
TRANSCRIPTION, DNA-
DEPENDENT 
9 426 67 9408 0.010 2.3% 
ENZYME LINKED RECEPTOR 
PROTEIN SIGNALING PATHWAY 
15 426 156 9408 0.011 2.2% 
INTRACELLULAR SIGNALING 
CASCADE 
52 426 824 9408 0.012 2.1% 
WNT RECEPTOR SIGNALING 
PATHWAY 
10 426 85 9408 0.014 4.1% 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
30 426 423 9408 0.016 3.9% 
SMALL GTPASE MEDIATED 
SIGNAL TRANSDUCTION 
15 426 177 9408 0.029 10.2% 
TRANSMEMBRANE RECEPTOR 
PROTEIN TYROSINE KINASE 
SIGNALING PATHWAY 
11 426 117 9408 0.039 14.8% 
UBIQUITIN CYCLE 19 426 256 9408 0.042 14.5% 
 
Appendix  7-13. GO Molecular function terms enriched among miR-29 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
EXTRACELLULAR MATRIX 
STRUCTURAL CONSTITUENT 
21 372 88 9743 0.000 0.0% 
BINDING 306 372 7066 9743 0.000 0.0% 
PROTEIN BINDING 168 372 3453 9743 0.000 0.0% 
CATION BINDING 116 372 2282 9743 0.000 0.0% 
STRUCTURAL MOLECULE 
ACTIVITY 
41 372 605 9743 0.000 0.0% 
CALCIUM ION BINDING 45 372 696 9743 0.001 0.0% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
59 372 1033 9743 0.001 0.0% 
ION BINDING 120 372 2479 9743 0.002 0.0% 
METALLOENDOPEPTIDASE 
ACTIVITY 
11 372 93 9743 0.003 0.0% 
DNA BINDING 79 372 1539 9743 0.004 0.0% 
TRANSCRIPTION FACTOR 
ACTIVITY 
44 372 764 9743 0.006 0.0% 
PROTEIN SERINE/THREONINE 
PHOSPHATASE ACTIVITY 
7 372 56 9743 0.019 15.4% 
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Appendix  7-14. GO Cellular component terms enriched among miR-29 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
COLLAGEN 19 342 33 8941 0.000 0.0% 
EXTRACELLULAR MATRIX 38 342 241 8941 0.000 0.0% 
FIBRILLAR COLLAGEN 8 342 10 8941 0.000 0.0% 
COLLAGEN TYPE IV 5 342 6 8941 0.000 0.0% 
SHEET-FORMING COLLAGEN 5 342 7 8941 0.000 0.0% 
BASEMENT MEMBRANE 10 342 49 8941 0.000 0.0% 
NUCLEUS 125 342 2557 8941 0.001 0.0% 
ANCHORING COLLAGEN 4 342 9 8941 0.004 0.0% 
INTRACELLULAR 228 342 5326 8941 0.004 0.0% 
COLLAGEN TYPE V 3 342 3 8941 0.004 0.0% 
COLLAGEN TYPE I 3 342 3 8941 0.004 0.0% 
EXTRACELLULAR REGION 54 342 973 8941 0.004 0.0% 
 
Appendix  7-15. GO Biological process terms enriched among miR-29 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
PHOSPHATE TRANSPORT 20 355 68 9408 0.000 0.0% 
DEVELOPMENT 104 355 1598 9408 0.000 0.0% 
ANION TRANSPORT 23 355 151 9408 0.000 0.0% 
CELL ADHESION 43 355 548 9408 0.000 0.0% 
REGULATION OF CELLULAR 
METABOLISM 
88 355 1599 9408 0.000 0.0% 
REGULATION OF TRANSCRIPTION 82 355 1472 9408 0.000 0.0% 
REGULATION OF NUCLEIC ACID 
METABOLISM 
83 355 1495 9408 0.000 0.0% 
ION TRANSPORT 39 355 597 9408 0.001 0.0% 
TRANSCRIPTION, DNA-DEPENDENT 76 355 1435 9408 0.001 0.0% 
TRANSMEMBRANE RECEPTOR 
PROTEIN TYROSINE KINASE 
SIGNALING PATHWAY 
12 355 117 9408 0.004 0.0% 
ENZYME LINKED RECEPTOR PROTEIN 
SIGNALING PATHWAY 
14 355 156 9408 0.006 0.0% 
SKELETAL DEVELOPMENT 12 355 122 9408 0.006 0.0% 
DNA MODIFICATION 4 355 15 9408 0.017 6.5% 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
26 355 423 9408 0.017 6.7% 
INSULIN RECEPTOR SIGNALING 4 355 18 9408 0.028 10.5% 
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Appendix  7-16. GO Molecular function terms enriched among miR-133 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
PHOSPHOPROTEIN PHOSPHATASE 
ACTIVITY 
9 132 128 9167 0.000 0.0% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
27 132 1002 9167 0.002 0.0% 
PROTEIN BINDING 66 132 3398 9167 0.002 0.0% 
PHOSPHORIC ESTER HYDROLASE 
ACTIVITY 
11 132 238 9167 0.002 0.0% 
PRENYLATED PROTEIN 
TYROSINE PHOSPHATASE 
ACTIVITY 
5 132 61 9167 0.011 0.0% 
CALCIUM-DEPENDENT PROTEIN 
SERINE/THREONINE 
PHOSPHATASE ACTIVITY 
4 132 41 9167 0.020 7.1% 
PROTEIN PHOSPHATASE TYPE 1 
ACTIVITY 
4 132 40 9167 0.019 7.7% 
PROTEIN PHOSPHATASE TYPE 2B 
ACTIVITY 
4 132 39 9167 0.018 11.1% 
 
Appendix  7-17. GO Cellular component terms enriched among miR-133 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
INTRACELLULAR ORGANELLE 83 121 4330 8448 0.000 0.0% 
MEMBRANE-BOUND 
ORGANELLE 
74 121 3740 8448 0.000 0.0% 
NUCLEUS 54 121 2482 8448 0.000 0.0% 
INTRACELLULAR 92 121 5164 8448 0.000 0.0% 
ORGANELLE ENVELOPE 9 121 191 8448 0.006 0.0% 
ENVELOPE 9 121 194 8448 0.006 0.0% 
PROTEIN PHOSPHATASE TYPE 
2A COMPLEX 
3 121 15 8448 0.019 10.0% 
 
Appendix  7-18. GO Biological process terms enriched among miR-133 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
REGULATION OF 
PHYSIOLOGICAL PROCESS 
53 130 2337 8892 0.000 0.0% 
PROTEIN AMINO ACID 
DEPHOSPHORYLATION 
8 130 110 8892 0.001 0.0% 
REGULATION OF NUCLEOBASE, 
NUCLEOSIDE, NUCLEOTIDE AND 
NUCLEIC ACID METABOLISM 
36 130 1447 8892 0.001 0.0% 
DEPHOSPHORYLATION 8 130 114 8892 0.001 0.0% 
REGULATION OF 
TRANSCRIPTION 
35 130 1424 8892 0.002 0.0% 
REGULATION OF CELLULAR 
METABOLISM 
37 130 1551 8892 0.002 0.0% 
PROTEIN LOCALIZATION 15 130 412 8892 0.003 0.0% 
PROTEIN TRANSPORT 14 130 388 8892 0.004 0.0% 
 
Chapter 7 - Appendices 
207 
Appendix  7-19. GO Molecular function terms enriched among miR-143 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
TRANSFERASE ACTIVITY, 
TRANSFERRING PHOSPHORUS-
CONTAINING GROUPS 
19 126 688 9743 0.003 0.0% 
EPIDERMAL GROWTH FACTOR 
RECEPTOR ACTIVITY 
3 126 7 9743 0.003 0.0% 
KINASE ACTIVITY 17 126 592 9743 0.004 0.0% 
TRANSFERASE ACTIVITY 26 126 1120 9743 0.004 0.0% 
BINDING 104 126 7066 9743 0.007 0.0% 
PROTEIN KINASE ACTIVITY 13 126 430 9743 0.009 0.0% 
TRANSCRIPTIONAL ACTIVATOR 
ACTIVITY 
8 126 191 9743 0.011 0.0% 
PHOSPHOTRANSFERASE 
ACTIVITY, ALCOHOL GROUP AS 
ACCEPTOR 
14 126 503 9743 0.012 0.0% 
INSULIN-LIKE GROWTH FACTOR 
BINDING 
3 126 19 9743 0.024 6.7% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
22 126 1033 9743 0.022 7.1% 
PROTEIN-TYROSINE KINASE 
ACTIVITY 
7 126 168 9743 0.021 7.7% 
 
Appendix  7-20. GO Cellular component terms enriched among miR-143 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
INTRINSIC TO PLASMA 
MEMBRANE 
20 116 1124 8941 0.128 210% 
NON-MEMBRANE-BOUND 
ORGANELLE 
19 116 1078 8941 0.148 217% 
PLASMA MEMBRANE 26 116 1545 8941 0.127 233% 
 
Appendix  7-21. GO Biological process terms enriched among miR-143 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
DEVELOPMENT 36 121 1598 9408 0.001 0.0% 
MORPHOGENESIS 16 121 517 9408 0.002 0.0% 
TRANSCRIPTION 31 121 1534 9408 0.009 0.0% 
POSITIVE REGULATION OF 
TRANSCRIPTION, DNA-
DEPENDENT 
5 121 67 9408 0.010 0.0% 
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Appendix  7-22. GO Molecular function terms enriched among miR-195/424 
targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
BINDING 335 397 7066 9743 0.000 0.0% 
PROTEIN BINDING 195 397 3453 9743 0.000 0.0% 
PROTEIN KINASE ACTIVITY 43 397 430 9743 0.000 0.0% 
PROTEIN SERINE/THREONINE 
KINASE ACTIVITY 
31 397 306 9743 0.000 0.0% 
TRANSFERASE ACTIVITY, 
TRANSFERRING PHOSPHORUS-
CONTAINING GROUPS 
51 397 688 9743 0.000 0.0% 
CAMP-DEPENDENT PROTEIN 
KINASE ACTIVITY 
19 397 172 9743 0.000 0.0% 
PROTEIN-TYROSINE KINASE 
ACTIVITY 
17 397 168 9743 0.001 0.0% 
THIOLESTER HYDROLASE 
ACTIVITY 
7 397 39 9743 0.005 0.0% 
TRANSCRIPTION REGULATOR 
ACTIVITY 
59 397 1033 9743 0.006 0.0% 
CAMP-DEPENDENT PROTEIN 
KINASE REGULATOR ACTIVITY 
4 397 10 9743 0.006 0.0% 
MICROTUBULE MOTOR 
ACTIVITY 
8 397 56 9743 0.007 0.0% 
PROTEIN KINASE REGULATOR 
ACTIVITY 
7 397 48 9743 0.013 0.0% 
INSULIN RECEPTOR SUBSTRATE 
BINDING 
3 397 4 9743 0.009 0.0% 
PROTEIN DOMAIN SPECIFIC 
BINDING 
7 397 45 9743 0.009 3.9% 
UBIQUITIN-SPECIFIC PROTEASE 
ACTIVITY 
6 397 32 9743 0.009 4.4% 
PHOSPHOPROTEIN 
PHOSPHATASE ACTIVITY 
12 397 131 9743 0.018 4.6% 
 
Appendix  7-23. GO Cellular component terms enriched among miR-195/424 
targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
GOLGI-ASSOCIATED VESICLE 8 373 41 8941 0.001 0.0% 
CYTOPLASMIC MEMBRANE-
BOUND VESICLE 
14 373 126 8941 0.002 0.0% 
CAMP-DEPENDENT PROTEIN 
KINASE COMPLEX 
4 373 8 8941 0.003 0.0% 
MICROTUBULE ASSOCIATED 
COMPLEX 
10 373 78 8941 0.005 0.0% 
TRANSPORT VESICLE 6 373 28 8941 0.005 0.0% 
INTEGRAL TO PLASMA 
MEMBRANE 
64 373 1120 8941 0.007 0.0% 
COATED VESICLE 10 373 89 8941 0.011 8.3% 
TRANS-GOLGI NETWORK 
TRANSPORT VESICLE 
5 373 20 8941 0.008 9.1% 
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Appendix  7-24. GO Biological process terms enriched among miR-195/424 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
PROTEIN MODIFICATION 80 395 1036 9408 0.000 0.0% 
PROTEIN AMINO ACID 
PHOSPHORYLATION 
40 395 427 9408 0.000 0.0% 
CELL ADHESION 46 395 548 9408 0.000 0.0% 
CELL CYCLE 45 395 559 9408 0.000 0.0% 
VESICLE-MEDIATED 
TRANSPORT 
27 395 267 9408 0.000 0.0% 
CELL ORGANIZATION AND 
BIOGENESIS 
69 395 1146 9408 0.002 0.0% 
CELLULAR PROTEIN 
METABOLISM 
105 395 1910 9408 0.002 0.0% 
ENZYME LINKED RECEPTOR 
PROTEIN SIGNALING PATHWAY 
16 395 156 9408 0.002 0.0% 
REGULATION OF PROTEIN 
KINASE ACTIVITY 
13 395 113 9408 0.003 0.0% 
WNT RECEPTOR SIGNALING 
PATHWAY 
11 395 85 9408 0.003 0.0% 
UBIQUITIN CYCLE 21 395 256 9408 0.005 0.0% 
UBIQUITIN-DEPENDENT 
PROTEIN CATABOLISM 
10 395 83 9408 0.008 0.0% 
MODIFICATION-DEPENDENT 
PROTEIN CATABOLISM 
10 395 83 9408 0.008 0.0% 
TRANSMEMBRANE RECEPTOR 
PROTEIN TYROSINE KINASE 
SIGNALING PATHWAY 
12 395 117 9408 0.010 1.8% 
ENDOCYTOSIS 12 395 116 9408 0.009 1.9% 
INTRACELLULAR RECEPTOR-
MEDIATED SIGNALING 
PATHWAY 
6 395 31 9408 0.009 1.9% 
DEPHOSPHORYLATION 12 395 115 9408 0.009 2.0% 
MAPKKK CASCADE 9 395 78 9408 0.016 3.3% 
CELL DIFFERENTIATION 29 395 431 9408 0.014 3.5% 
CELLULAR PROTEIN 
CATABOLISM 
11 395 112 9408 0.019 4.6% 
PROTEOLYSIS DURING 
CELLULAR PROTEIN 
CATABOLISM 
11 395 111 9408 0.018 4.8% 
INSULIN RECEPTOR SIGNALING 
PATHWAY 
4 395 18 9408 0.037 9.4% 
REGULATION OF 
TRANSCRIPTION 
76 395 1472 9408 0.037 9.5% 
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Appendix  7-25. GO Molecular function terms enriched among miR-208 targets. 
GO Molecular function term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
BINDING 85 96 7066 9743 0.000 0.0% 
NUCLEIC ACID BINDING 36 96 2056 9743 0.000 0.0% 
RNA BINDING 11 96 380 9743 0.004 0.0% 
TRANSCRIPTION FACTOR 
ACTIVITY 
16 96 764 9743 0.007 0.0% 
PROTEIN KINASE ACTIVITY 11 96 430 9743 0.009 0.0% 
PHOSPHOPROTEIN 
PHOSPHATASE ACTIVITY 
6 96 131 9743 0.009 0.0% 
DNA BINDING 25 96 1539 9743 0.011 0.0% 
PROTEIN SERINE/THREONINE 
PHOSPHATASE ACTIVITY 
4 96 56 9743 0.017 0.0% 
PROTEIN SERINE/THREONINE 
KINASE ACTIVITY 
8 96 306 9743 0.030 5.9% 
CALMODULIN BINDING 5 96 119 9743 0.029 6.3% 
 
Appendix  7-26. GO Cellular component terms enriched among miR-208 targets. 
GO Cellular component term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
NUCLEUS 47 83 2557 8941 0.000 0.0% 
MEMBRANE-BOUND 
ORGANELLE 
50 83 3850 8941 0.002 0.0% 
INTRACELLULAR 60 83 5326 8941 0.013 0.0% 
INTRACELLULAR ORGANELLE 52 83 4461 8941 0.016 0.0% 
CALCINEURIN COMPLEX 2 83 4 8941 0.036 28.6% 
 
Appendix  7-27. GO Biological process terms enriched among miR-208 targets. 
GO Biological process term List 
hits 
List 
total 
Pop 
hits 
Pop 
total 
EASE  
score 
FDR 
DEVELOPMENT 32 94 1598 9408 0.000 0.0% 
TRANSCRIPTION 28 94 1534 9408 0.001 0.0% 
REGULATION OF 
TRANSLATIONAL INITIATION 
4 94 27 9408 0.002 0.0% 
RNA PROCESSING 9 94 237 9408 0.002 0.0% 
CELLULAR METABOLISM 62 94 4903 9408 0.006 0.0% 
REGULATION OF 
TRANSCRIPTION 
25 94 1472 9408 0.008 0.0% 
RNA METABOLISM 9 94 291 9408 0.008 0.0% 
TRANSLATIONAL INITIATION 4 94 42 9408 0.008 0.0% 
WNT RECEPTOR SIGNALING 
PATHWAY 
5 94 85 9408 0.010 0.0% 
SKELETAL MUSCLE 
DEVELOPMENT 
3 94 18 9408 0.013 0.0% 
MUSCLE DEVELOPMENT 5 94 95 9408 0.014 0.0% 
PROTEIN POLYUBIQUITINATION 2 94 3 9408 0.029 2.7% 
RNA SPLICING 5 94 116 9408 0.028 2.8% 
PROTEIN AMINO ACID 
DEPHOSPHORYLATION 
5 94 111 9408 0.024 3.0% 
CELL PROLIFERATION 10 94 473 9408 0.044 7.9% 
CELL DIFFERENTIATION 9 94 431 9408 0.063 10.9% 
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Appendix  7-28. RNA concentrations from myotubes treated with 100 nM or 0.1 
nM insulin used in Chapter 5. RNA quantification conducted using the Nanodrop 
spectrophotometer.  A 260/230 ratio of <1.5 indicates possible phenol 
contamination during RNA isolation. 
Sample ID Insulin Time RNA 
ng/µl  
260/280  260/230  
HGDM41 0 nM 0 min 559.33 1.96 2.06 
HGDM42 0 nM 0 min 868.95 2.12 2.17 
HGDM43 0 nM 0 min 860.9 1.99 2.13 
HGI1 100 nM 10 min 630.19 1.9 2.39 
HGI2 100 nM 10 min 620.02 1.9 2.28 
HGI3 100 nM 10 min 548.1 1.92 2.23 
HGI4 0.1 nM 10 min 510.81 1.96 2.19 
HGI5 0.1 nM 10 min 633.08 1.9 2.45 
HGI6 0.1 nM 10 min 377.92 1.79 2.11 
HGI7 100 nM 30 min 680.09 1.87 2.19 
HGI8 100 nM 30 min 697.42 1.87 2.15 
HGI9 100 nM 30 min 519.25 1.89 2.34 
HGI10 0.1 nM 30 min 660.83 1.89 2.22 
HGI11 0.1 nM 30 min 579.96 1.86 2.37 
HGI12 0.1 nM 30 min 909.59 1.97 2.18 
HGI13 100 nM 60 min 386.6 1.92 2.4 
HGI14 100 nM 60 min 420.51 1.89 2.44 
HGI15 100 nM 60 min 338.9 1.94 2.56 
HGI16 0.1 nM 60 min 512.31 1.94 2.53 
HGI17 0.1 nM 60 min 370.1 1.9 2.46 
HGI18 0.1 nM 60 min 389.22 1.88 2.46 
HGI19 0 nM 60 min 302.44 1.96 2.66 
HGI20 0 nM 60 min 252.69 1.91 2.65 
HGI21 0 nM 60 min 536.44 1.93 2.47 
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